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Abstract 
Three DNA DSB repair pathways have been identified to date in human somatic 
cells: HR (homologous recombination), C-NHEJ (classic non-homologous end joining) 
and A-NHEJ (alternative-NHEJ).  Which repair pathway gets used appears to be a 
function of several parameters although cell type and cell cycle phase are chief amongst 
them.  For example, B- and T-lymphocytes carry out site-specific recombination {V(D)J 
and class switch} reactions that are required for the proper development of the human 
immune system.  Since V(D)J and class switch recombination reaction rely heavily on C-
NHEJ to produce functional immune molecules, the C-NHEJ repair process dominates in 
B-and T-lymphocytes.  Similarly, cells that reside in the G1/G0 phase of the cell cycle 
use C-NHEJ almost exclusively and since ~75% of the cells in a human’s body are, at 
any given time, in G1/G0, the C-NHEJ repair pathway is again chiefly used. 
Seven core proteins; Ku70, Ku86, DNA-PKcs, Artemis, LIGIV, XRCC4 and XLF are 
known to be required for C-NHEJ.  Mutations of most of these genes result in cells or 
animals with profound deficits in DNA DSB repair, hypersensitivity to DNA damaging 
agent exposure and severe immune deficiencies.  The phenotypes resulting from loss of 
function of LIGIV, were, however rather variable depending upon what model organism 
was being study.  Consequently, it was unclear whether LIGIV is essential for human cell 
survival or not.  To experimentally address this issue, we functionally inactivated the 
LIGIV gene and showed that LIGIV (and presumably C-NHEJ) is not essential for 
human somatic cell survival. 
LIGIV is but one of three mammalian ligases, the other two being LIGI and LIGIII.  
LIGI is thought to be involved in HR and DNA replication.  LIGIII was recently 
implicated as possibly being involved in A-NHEJ pathway.  There are, however, to date 
very few model systems available to study A-NHEJ.  Recent studies carried out in mice 
indicated that LIGIII had an essential function in mitochondria and was likely involved in 
chromosomal translocations in nucleus.  To study similar phenotypes in human somatic 
cells we generated a conditionally viable LIGIII-null cell line.  We then demonstrated 
that human LIGIII is also essential for mitochondria function but then went on to show 
that absence of nuclear LIGIII is tolerated with almost no pathological phenotypes.  
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Finally, we have observed that cells lacking the key C-NHEJ factor, Ku86, succumb 
because of telomere dysfunction, including telomere loss, sister chromatid fusion and t-
circle formation.  Several laboratories have postulated that the t-circle formation is due to 
the aberrant activity of HR on telomeric DNA.  To experimentally test this model, we 
functionally inactivated the Rad54B gene — a major HR component — in Ku86 
conditional null cells.  Impressively, a Rad54B deficiency partially rescues the defects of 
Ku86-null cells: it significantly delays the death of Ku86-null cells and significantly 
reduces t-circle formation.  These results indicate that the telomere dysfunction observed 
in Ku86-null cell is, at least in part, mediated by HR.  
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Living organisms store and transmit their genetic information in the form of DNA, so 
the reliable replication and sustainment of DNA’s integrity is important.  Among the 
various types of DNA damage that a cell can sustain, DNA double-strand breaks (DSBs) 
are the most deleterious because even a single un-repaired DSB can cause cell death (1).  
Not surprisingly, therefore, the number of DSBs that a cell suffers is thought to be quite 
small, in the range of only ~10 DSB per day.  It is wrong, however to view all DSBs as 
pathological (2).  In mammals, for example, the generation of site-specific DSBs is a 
critical step during antigen receptor gene rearrangement in the course of lymphocyte 
maturation process, which includes V(D)J recombination and class-switch recombination 
(CSR) (3-5).  In addition, DSB formation is an absolute prerequisite for proper generation 
of human gametes during meiosis (6).  Nonetheless, it is probably fair to describe the 
majority of DSBs as harmful.  Some pathological DSBs can be generated as the by-
product of natural processes.  First, DNA replication across a nick can convert that 
single-strand lesion into a DSB (7).  Second, as a by-product of oxidation within 
mitochondria, cells generate high-energy, reactive oxygen species (ROS). ROS cause 
damage to mitochondrial genes and once it is leaked into the nucleus, ROS can generate 
DSBs in chromosomal DNA (2).  In addition to the internal generation of DSBs, 
however, DSBs can also be produced from exogenous sources.  The most common of 
these is due to ionizing radiation (IR) or chemotherapeutic exposure during a course of 
clinical cancer therapy (2). Additionally, DNA damage likely accrues due to exposure to 
common environmental toxins (e.g., automobile exhaust, cigarette smoke, sunlight, etc.).  
Importantly, no matter whether the DSBs occur endogenously or exogenously, their 
impact is almost always deleterious to the well-being of the cell. 
Unrepaired DSB can lead to the accumulation of mutations, cancer and cell death.  To 
protect individuals and their progeny from the detrimental results of DSBs, all cells have 
evolved several different ways to repair DSBs. 
 
DNA DSB repair pathways 
There are two major DNA DSB repair pathways; homologous recombination (HR) 
and classic non-homologous end joining (C-NHEJ) (2, 8-12). They are evolutionarily 
conserved from bacteria to man but their usage varies depending on the organism at-hand  
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and the cell cycle. HR, as the name implies, requires extensive sequence homology to 
template.  In lower eukaryotes like yeast, HR is the predominant repair mechanism (10, 
11, 13-16).  In the higher eukaryotes, however, HR is the major repair mechanism only 
during the late S/G2 phases of the cell cycle, when proximal homology donors are 
present as sister chromatids or homologous chromosome.  Because HR uses homologous 
sequences as a repair template, the repaired products are generally regarded as “error-
free”.  This descriptor is essentially accurate for most HR-mediated repair events 
although it should be kept in mind that HR is likely the cause of rarer mutagenic loss-of-
heterozygousity events (17).  The other major DNA DSB repair pathway is C-NHEJ, 
which — again as the name implies — does not require a long homologous sequence 
donor, but instead simply re-joins the ends together in a process that often results in the 
loss or addition of multiple nucleotides (11, 15, 18, 19).  Consequently, C-NHEJ is often 
(correctly) referred to as an error-prone process (20).  Despite this mutagenic attribute, 
however, C-NHEJ is nonetheless the main DSB repair pathway in higher organisms, — 
especially in humans — and is most active during the G1/G0 phases of the cell cycle (16, 
21, 22).  The fact that the vast majority of the human genome is littered with non-coding 
DNA probably explains why C-NHEJ is tolerated so well, since minor alterations to non-
coding regions likely have little or no evolutionary impact.  Recently, a third, minor DSB 
repair pathway has been reported.  This novel pathway, alternatively named either 
alternative non-homologous end joining (A-NHEJ) or backup non-homologous end 
joining (B-NHEJ), is detectable only under C-NHEJ-deficient conditions (23-27).  A-
NHEJ requires 5 to 25 nucleotides of micro-homology, and its repair products always 
contain deletions.  Conceptually, A-NHEJ can be thought of as a hybrid of the HR and C-
NHEJ pathways since it requires (micro) homology (i.e., ~HR) to mediate direct end-
joining in a mutagenic fashion (i.e., ~NHEJ).  The details of the A-NHEJ pathway, 
however, are still vague and its detailed mechanism is under active investigation. 
 
DSB signaling 
The first step in DNA DSB repair, regardless of which DNA DSB repair is ultimately 
utilized, is likely to be the upstream recognition of the DSB and the signaling that ensues 
to activate the downstream repair pathways.  Like many biological processes, DSB 
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signaling is mediated by a kinase-mediated phosphorylation cascade (28, 29).  There are 
two related kinases required for the DNA DSB damage response: ATM (ataxia-
telangiectasia mutated) and ATR (ATM- and Rad3- related).  They are members of the 
PIKK (phosphatidyl inositol 3-kinase-like kinase) family (30, 31).  Both ATM and ATR 
are the principle DNA damage signal transducers but they deal with different types of 
substrates; ATM mostly functions in DSB repair whereas ATR responds more to ssDNA 
and consequently more to the DSBs introduced at stalled DNA replication forks (29, 32-
34).  ATM and ATR are recruited to damage sites through the interaction with Nbs1 (part 
of the MRN complex; see below) and ATR-interacting protein (ATRIP), respectively 
(35).  Damage sensing subsequently proceeds via a checkpoint signaling cascade, which 
includes phosphorylation of downstream effectors, chromatin remodeling, recruitment 
and retention of additional proteins required for repair process (36). 
ATM is activated via a two-step mechanism (37).  ATM is normally present as an 
inactive dimer, but following the introduction of DNA damage, ATM is recruited to the 
damaged sites through the interaction with Nbs1. This step results in MRN-dependent 
DNA-tethering, which increases the local concentration of dsDNA ends and enhances the 
monomer formation (37).  Second, the ATM monomer undergoes trans auto-
phosphorylation on Ser1981, which happens in a DNA-independent manner and fully 
activates ATM (38, 39). Fully-activated ATM subsequently phosphorylates (and thus 
activates) many downstream cellular targets such as Chk2 (checkpoint kinase 2), p53, 
H2AX and BRCA1 (breast cancer allele 1) to complete the signaling process (8). 
ATM signaling is required for the bulk of DSB signaling.  The DSBs associated with 
replication fork collapse, however, are a special case where ATR is the most relevant 
kinase.  During normal DNA replication, the single-stranded DNA that accumulates 
behind a replication fork on the retrograde strand is normally coated with RPA 
(replication protein A), a trimeric ssDNA binding complex.  If the replication fork should 
collapse and generate a DSB, ATRIP (ATR-interacting protein) is recruited to the RPA-
bound ssDNA (35, 40, 41).  ATRIP, in turn, recruits ATR, which becomes activated and 
phosphorylates its targets, including RPA and Chk1 (checkpoint kinase 1), to initiate 
checkpoint response (38, 40). 
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Initially, it was thought that ATM and ATR work independently of each other.  
However, more recent evidence suggests that these two signaling pathways may actually 
overlap more than was previously appreciated.  For example, following exposure to IR in 
S/G2 phases, ATM activates the nuclease activity of the MRN complex, which generates 
RPA-coated ssDNA that becomes a substrate for ATR (34).  Similarly, after DNA 
replication fork stalling the phosphorylation and activation of ATM is ATR-dependent 
(42).  In summary, ATM and ATR, either independently or together, seem to regulate 
cellular responses to DSBs. 
 
MRN complex 
As detailed above, the recruitment of ATM to DSBs requires interaction with the 
protein Nbs1, which is one component of the hetero-hexameric MRN protein complex 
that is composed of two molecules of Mre11, Rad50, and Nbs1 (Xrs2 in yeast).  MRN is 
a key, but very complicated complex, that is required for both upstream regulatory and 
downstream processing steps.  In addition to the activation of ATM, the rapid recruitment 
of MRN to a DSB that will be repaired by HR ensures the protection of the broken ends 
from non-specific degradation and it keeps the broken ends in proximity to one another 
(43).  MRN, which has associated helicase and nuclease activities, also functions in the 
end-processing steps of A-NHEJ.  In contrast to HR and A-NHEJ, C-NHEJ confusingly 
appears to only utilize the MRN complex for damage signaling and not for end resection 
(44).  Interestingly, the MRN complex is also found at telomeres and seems to facilitate t-
loop formation by generating 3’ G-overhangs using its nuclease activity (discussed in 
more detail below) (43, 45-48).  Despite intense effort, it is still unclear how — 
depending on the particular repair pathway utilized — the end-processing activities of 
MRN complex are regulated (44).  At least some of these complicated attributes of MRN 
appear to be coordinated by different combinations of conformational changes, post-
translational modifications, and protein interactions (43, 49). 
Mre11 has both Rad50 and Nbs1 binding domains in addition to a DBD (DNA 
binding domain) (49-51).  Mre11 is thus likely through these three domains to be the 
linchpin that mediates the interactions of the individual subunits with each other and with 
DNA (51).  Mre11 also has both endonuclease and 3’ to 5’ exonuclease activities.  While 
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Mre11 is required for end processing, it is not clear whether MRN actually directly does 
this, because Mre11 does not have the 5’ to 3’ polarity exonuclease activity generally 
necessary for end resection (52-54).  Rad50 has globular heads containing ATPase 
domains at both ends and a coiled-coil helix with a zinc hook at the middle (50).  The 
ATPase and zinc hook domains are required for ATP-dependent DNA unwinding activity 
and DNA end tethering, respectively (55).  The third subunit, Nbs1, has two BRCT 
(breast cancer allele C-terminus) domains that can interact with ATM or ATR, when 
MRN complex is recruited to DSBs or stalled replication forks, respectively.  ATM 
directly interacts with Nbs1 and the MRN-dependent accumulation of ATM at DSBs 
occurs within seconds (39).  Nbs1 autoregulates the catalytic functions of the MRN 
complex by activating ATM, which ultimately results in ATM or ATR subsequently 
phosphorylating Nbs1.  Nbs1 is required for localization of MRN complex in the nucleus 
as well (56, 57). 
Defects in the MRN complex cause serious diseases. Nbs1-deficiency leads to a 
condition called Nijmegen breakage syndrome (NBS) (58).  Patients without functional 
Mre11 have ataxia-telangiectasia-like disorder (ATLD).  Only one Rad50 patient, who 
displayed NBS-like phenotypes, has been reported (59).  All MRN patients still express 
mutant forms of their respective protein, because complete loss of MRN does not appear 
to be tolerated in mammals (60). 
 
Homologous recombination (HR) 
HR is an evolutionarily well-conserved DSB repair pathway, which uses homologous 
regions of either a sister chromatid or a homologous chromosome as a template for repair 
(10, 13).  HR, while perhaps not the major DNA DSB repair pathway, is nonetheless 
essential.  HR is required for all the meiotic recombination that occurs during the 
generation of functional gametes (6, 61).  Moreover, HR plays a crucial role in the restart 
and repair of stalled or broken replication forks during S phase (62).  Lastly, HR also 
plays a role in the repair of spontaneous and environmentally-induced DNA damage that 
occurs to cells in late S/G2 phases of the cell cycle.  
Although some of the specifics of HR are still lacking, the general process has been 
described in reasonable detail.  A general overview of the process is as follows: a DSB is 
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recognized by damage sensors and processed by nucleases to yield 3’-ssDNA (single-
stranded DNA). Several HR proteins then bind to and stabilize the ssDNA.  The protein-
coated ssDNA is then used in a search for homology and forms a synapsis with a 
homology target through strand-invasion.  Replication starts from the synaptic point, 
where it uses the 3’-end of invading strand as a primer and an intact homologous 
sequence as a template.  This replication results in the recombination junction migrating 
outward from the initial break site.  This junction is ultimately resolved by resolvases and 
the remaining gaps are filled in by polymerases.  
A large number of proteins are involved in mammalian HR, including Rad51, Rad51 
paralogs (XRCC2, XRCC3, Rad51B, Rad51C, Rad51D), Rad52, the BRCA proteins, 
Rad54 & Rad54B, and the MRN complex.  Rad51 and the Rad51 paralogs mediate 
strand-exchange reactions during HR.  Rad51 paralogs, a family of five proteins, share 
only 20% to 30% amino acid homology with Rad51, but appear to have retained the 
strand transfer activity of the parent gene (63, 64).  Through evolution, the Rad51 
paralogs have presumably acquired novel functions, but the specific roles and tissue 
distributions of each member are not clear yet. 
Rad52 does not have demonstrable enzymatic activity of any kind and yet it is 
required to facilitate the RAD51-dependent strand transfers and to help displace RPA 
from ssDNA (65).  In yeast, Rad52 is arguably the most important HR protein and Rad52 
mutants are essentially incapable of performing just about any HR-related reaction (66, 
67).  Confusingly, this importance is not conserved as mutation of Rad52 in the mouse 
(68) or human somatic cells {Yinan Kan, personnel communication} are virtually 
aphenotypic.  It appears that in mammals Rad52 has evolved to work not in the canonical 
HR pathway but predominately in an HR subpathway termed single-strand annealing (69).  
This fact begs the question, however, about what is the cofactor for strand exchange in 
mammals if Rad52 has evolved different uses?  In this regard, BRCA1 and BRCA2 are 
attractive candidates.  Mutations in BRCA1 or BRCA2 increase the risk of developing 
breast, ovarian and other cancers and are thus true tumor suppressors (70).  BRCA1 has 
broad cellular roles including DNA repair, chromatin remodeling, cell cycle regulation, 
and transcriptional regulation (71).  Whether BRCA1 can stimulate Rad51 strand 
exchanges is currently unknown.  In contrast, BRCA2 is clearly involved in DNA 
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recombination and repair, and facilitates Rad51-nucleoprotein filament formation (72, 
73).  
Rad54 is a dsDNA-dependent ATPase, which translocates along chromosomes as a 
chromatin remodeling protein.  Rad54 is involved in several steps of HR (74).  At the 
early phase of HR, Rad54 interacts with Rad51 and stabilizes the Rad51-nucleoprotein 
filament (75-77).  Rad54 also promotes homology pairing and strand exchange steps (78-
80).  Later, Rad54 induces the dissociation of Rad51 from the repaired chromosome.  
Rad54B, a homolog of Rad54, shares many biochemical properties with Rad54 (81).  
Rad54B is also a chromatin-remodeling factor with DNA-dependent ATPase and helicase 
activities (82).  Thus, Rad54B also has the ability to translocate down DNA and promote 
DNA helix opening.  Moreover, Rad54B also interacts with Rad51 and facilitates 
homology pairing and D-loop formation (81).  Interestingly, Rad54B has longer N-
terminus, which has not yet been fully characterized, than RAD54 and this undoubtedly 
confers additional activities on to RAD54B that are not found in RAD54.  Rad54B 
knockout somatic human cell lines are viable and they contain reduced HR activity, as 
indicated by their inability to carry out any (subsequent) gene targeting (83).  
Accentuating the difference between murine and human cell models, Rad54B knockout 
MEF cell lines display different phenotypes: the gene targeting rate is not reduced but the 
cells are hypersensitive to IR and mitomycin C, a DNA cross-linking agent (74).  It is not 
understood why a Rad54B-deficiency in human and mouse cells results in different 
phenotypes, but this species difference is not that unusual (see, for more examples, 
below).  
The MRN complex was introduced earlier as a trimeric complex, which is required 
for upstream DNA damage signaling.  The exact role(s) of MRN, however, are 
complicated and it is clear that the complex also has direct roles in the downstream 
aspects of HR.  As detailed above, the MRN complex is one of the first components 
recruited to DSBs and the DNA-bound MRN complex recruits ATM to the break through 
a direct interaction with the Nbs1 subunit (35, 39, 51, 84-86). Phosphorylation of MRN 
by ATM enhances the nuclease activity of the MRN complex, which is necessary for the 
end processing that generates the 3’-hydroxyl overhang required for all subsequent 
homology search and strand invasions (34, 60). Confusingly, however, the actual 
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exonuclease involved in 3’ overhang generation is as yet unidentified, although it is 
almost certainly not MRN as Mre11 has 3’ to 5’ exonuclease activity, which is the 
opposite polarity required to generate a 3’ overhang.  The most likely candidate is CtIP 
(C-terminal interacting protein), which directly interacts with MRN complex through 
Nbs1 and seems to facilitate ssDNA formation at the site of DSB {there have been 3 or 4 
papers in the past month showing that these MRN and CtIP work together to mediate 
end-processing; you should cite them}.  It is possible that the interaction with CtIP 
mediates the transition of the MRN complex’s activity from end sensing to end 
processing by switching the direction of or altering the exonuclease activity (22, 49, 87-
89). Nonetheless, it is still not clear whether Mre11, CtIP, or both are required for end 
resection. Moreover, it has not even been demonstrated yet whether CtIP itself has an 
exonuclease activity or not.  What seems clear (even if the mechanism is obscure) is that 
MRN and CtIP together are responsible for removing the first few nucleotides (and 
probably no more than a hundred) around the break.  Subsequently, Exo1 (exonuclease 1) 
and Dna2 take over the end resection and generate upwards of kilobase-sized 3’ ssDNA 
overhang (54, 90).  Thus, the current model envisions resection as a two-step process (37): 
MRN/CtIP does the small initial resection, and Exo1/Dna2 performs the large subsequent 
resection.  The biochemical mechanism of end resection is one of the most intensely 
studied areas in HR.    
After end resection, the 3’ overhang is covered with single-stranded DNA binding 
protein, RPA, which protects the ssDNA from secondary structure formation and 
nuclease attacks (91).  Before RPA gets saturated on ssDNA (92, 93) and inhibits strand-
exchange, Rad52 replaces RPA with Rad51 and stabilizes the Rad51:nucleoprotein 
filament (65).  Rad52 also directly binds to ssDNA protecting it from nucleolytic 
degradation and facilitates strand-annealing (66).  Homology searches by the Rad51-
nucleoprotein filament are performed by random collision with duplex DNA (94).  Once 
a 3’ overhang finds a duplex homology target, strand invasion and joint molecule 
formation transpire followed by DNA replication, where the all-important 3’-hydroxyl 
end of invading strand is used as a replication primer.  When this end of the newly 
synthesized strand is linked to the other side of the broken end, a Holliday junction is 
formed (95).  A classic Holliday junction has four strands of DNA, which are derived 
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from two duplex DNA molecules and which are crossed, relative to each other.  Specific 
resolvases are then needed to resolve this topologically complicated structure back into 
two dsDNAs.  Holliday junction resolution appears to be carried out by at least 3 
complexes (96-99), that are genetically and biochemically redundant with one another.  
In mitotic cells, the resolution step is generally not associated with crossing-over (i.e., 
rather it is a gene conversion event) whereas during meiosis a large fraction of the events 
do trigger crossing-over, resulting in genetically recombinant chromosomes. 
In summary, HR is relatively well-understood at the mechanistic level and in late S 
phase cells it can lead to error-free repair of DNA DSBs. 
 
Classic non-homologous end joining (C-NHEJ) 
C-NHEJ is the major DNA DSB repair pathway in human somatic cells.  In addition 
to DSB repair, C-NHEJ components also function in V(D)J recombination, CSR (class 
switch recombination), and telomere maintenance.  V(D)J recombination is a site-specific 
DNA recombination process required for the maturation of antigen receptor genes in 
early B- and T-lymphocytes (100, 101).  Lymphocyte-specific endonucleases, RAG1 
(recombination activating gene 1) and RAG2, make breaks at specific recombination 
signal sequences (RSS) and generate two products: the signal joint and the (biologically 
important) coding joint.  The proper generation of both of these products absolutely 
requires C-NHEJ (2).  CSR is a temporally distinct recombination reaction following 
V(D)J recombination that replaces one antibody constant region with another, thus 
altering the antibody effector function (4).  CSR is initiated by AID (activation-induced 
cytidine deaminase), which introduces uracil:guanine mistmatches (102, 103).  These 
mismatches are recognized by mismatch repair proteins or UNG (uracil-DNA 
glycosylase) and eventually converted into a DSB that can be repaired by C-NHEJ (104).  
Unlike V(D)J recombination intermediates, which are exclusively processed by C-NHEJ, 
CSR intermediates can be repaired by either C-NHEJ or, less frequently, A-NHEJ 
(alternative-NHEJ), a somewhat obscure DSB repair pathway, described more fully 
below.  Lastly, telomeres are the nucleoprotein structures found at the end of linear 
chromosomes (47, 105).  A telomere generally consists of a 2 to 15 kb stretch of 
repetitive DNA complexed with a dedicated set of proteins, which in humans are 
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collectively called “Shelterin” (106-108).  Telomeres provide at least two functions for 
chromosomes: 1) they provide an elegant solution to the “End Replication Problem” 
(105, 109) and they stabilize the chromosomes from fusing with one another.  It is this 
latter activity — that of impeding chromosome end fusions — that makes telomeres one 
of the least likely places to find DNA DSB factors, whose biological goal is almost 
always to join DNA fragments together.  Paradoxically, however, many C-NHEJ factors 
actually play a positive role in telomere maintenance (110-119).  Some of these 
requirements will be explained later in this chapter (120).   
There are at least seven main C-NHEJ components: the Ku heterodimer (Ku70 and 
Ku86), DNA-PKcs (DNA dependent protein kinase catalytic subunit), Artemis, and a 
trimeric complex consisting of LIG4/XRCC4/XLF (ligase IV/X-ray cross complementing 
4/XRCC4-like factor). In addition, DNA damage sensors, signal transducers, and 
polymerases are also required to complete DSB repair via C-NHEJ. 
 
Ku70/86 
The Ku complex, a heterodimer composed of Ku70 and Ku86 proteins, was first 
identified in patients suffering from an autoimmune disease, polymyositis-scleroderma 
overlap syndrome (121).  This clinical red herring (i.e., a seeming autoimmune function) 
obscured for several decades Ku’s real role, which in reality turned out to be that of a 
critical DNA DSB repair factor.  The first direct evidence that Ku is involved in DNA 
DSB repair and V(D)J recombination came when Chinese hamster ovary cell lines 
defective in DNA DSB repair and V(D)J recombination could be functionally rescued by 
the expression of a human Ku86 cDNA (122, 123).  Ku is evolutionarily well conserved 
and homologs exist from bacteria to human.  Ku70 and Ku86 (the names relate to the 
approximate sizes of the proteins, which are 69 and 83 kDa, respectively) together form a 
donut- or ring-shaped protein.  Even when not bound to DNA, Ku70 and Ku86 form a 
heterodimer and stabilize each other.  Consequently, mutations of or deficiencies in one 
of the subunits results in depletion of the other (124).  Ku is a highly abundant (about 
500,000 molecules per cell in humans; (125)) cellular protein and because the ring 
formed by the heterodimer is precisely big enough to encircle a dsDNA end, it has a very 
high affinity for binding to free DNA ends in a sequence-independent manner (126).  In 
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addition to a sequence-independency, Ku complex can also bind to DSB ends with 
different structures such as blunt ends, ends with protrusions, or hairpin structures (127, 
128).  These features have been visualized by crystal structures of Ku complexed with 
dsDNA, where the interdigitated Ku70 and Ku86 form an opening that is precisely large 
enough to accompany only one DNA double strand (129).  Once Ku binds to DNA, it 
displays a higher affinity for the other C-NHEJ components and appears to function as an 
assembly platform for them. 
The central portion of the two Ku subunits forms the ring-shaped DNA end-binding 
domain (129).  It is this central domain that is conserved throughout evolution (2, 116, 
130).  In contrast, the N- and C-termini of each subunit appear to have grown as the 
proteins evolved.  Specifically, Ku interacts with a kinase (DNA-PKcs), a nuclease 
(Artemis), polymerases (pol µ and λ) and the ligase complex (LIGIV:XRCC4:XLF) and 
Ku makes these interactions using domains located within the extreme N- and C-termini 
of the two subunits.  In vertebrates, one of the most important contacts (mediated by the 
Ku86 C-terminus) is with DNA-PKcs (131).  This interaction is needed to recruit and 
activate the kinase at the DSB and is required for all of DNA-PKcs’s subsequent 
downstream signaling functions (131, 132).  Ku makes similar contacts with most of the 
other C-NHEJ factors.  Thus, polymerase µ and λ contribute to junctional additions, 
which facilitate incompatible ends joining, and this activity requires their BRCT domains 
and is dependent both physically and functionally on Ku (133, 134).  Similarly, several 
studies have demonstrated an interaction between Ku and LIGIV:XRCC4:XLF (135-
138), and the requirement of Ku for the recruitment of the LIGIV:XRCC4:XLF complex 
to DNA ends (135).  In summary, Ku is a multi-domain protein that uses its central 
domain to bind onto the ends of all ds DNA molecules and then uses its N- and C-
terminal domains to recruit a bevy of other DNA repair factors to the end(s) to facilitate 
repair.  
Quite surprisingly, Ku also has a role in telomere maintenance.  In yeast, yKu80 
directly interacts with telomeric DNA and this interaction is required for its telomere 
functions, such as telomere end protection, telomere length regulation, and sub-telomeric 
silencing (139).  This observation supports the “two-face” model of Ku (140), where the 
yKu70:yKu80 heterodimer can bind DNA in an asymmetric orientation; when yKu80 is 
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distal from the break site the function of Ku complex is different from when yKu70 is 
proximal to the end.  This model is further substantiated by a structure:function study 
showing that point mutations in yKu80 abrogate telomere functions, whereas yKu70 
mutations affect DSB repair (140).  Human Ku appears to have similar telomere 
functions as yeast Ku, but it is not clear yet whether human Ku interacts directly with 
telomeres or not.  In human cells, Ku can be co-immunoprecipitated with the telomeric 
Shelterin complex and it can also pull down telomere DNA sequences in chromatin 
immunoprecipitation (ChIP) experiments (113).  In these experiments, Ku seemed to 
interact with TRF1 (telomere recognition factor 1; a essential component of Shelterin), 
but not with the telomere directly (112).  Additional studies demonstrated that Ku and 
TRF2 also interact (141).  These studies support the belief that Ku is either a component 
of Shelterin or a critically-important associated factor.  It has been suggested that 
telomere-bound Ku suppresses the pathological action of HR on telomeres and that Ku’s 
interaction with the Shelterin complex prevents it from initiating C-NHEJ (142).  
Although Ku’s exact role at human telomeres is not yet resolved, it is clear that Ku is 
essential, because Ku-deficient human somatic cells are dead due to massive telomere 
dysfunction (117).  This essential requirement for Ku in telomere maintenance likely 
explains why not a single Ku-null patient has ever been reported. 
In addition to Ku’s well-documented role in DNA DSB repair and telomere 
maintenance, Ku has also been reported to function as a membrane protein in a subset of 
cells and contribute to adhesion and invasion processes (143-145).  Membrane-bound Ku 
also affects viral or bacterial entry into target cells (146-148) and a requirement for Ku in 
cell-matrix attachment (149), proteolytic processing (150), and migration of activated 
monocytes (151) have been reported as well.  In addition, cytoplasmic Ku70 also inhibits 
apoptosis by sequestering a pro-apoptotic protein, Bax, outside of mitochondria (152, 
153).  The biological significance of these non-nuclear roles for Ku is obscure since the 
loss-of-function of the nuclear activities of Ku are generally sufficient to explain all of 
the resultant phenotypes of Ku mutant cells. 
Perhaps most puzzlingly, even though Ku is evolutionarily conserved, its importance 
shows considerable species variability.  Humans, for example, are the only species where 
a Ku deficiency causes lethality.  In contrast to humans, a variety of Ku-null model 
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organisms have been reported, such as in bacteria (154, 155), yeast (137), worms (156), 
plants (111, 118, 157), chickens (158, 159), hamster (123)and the mouse (160, 161).  The 
less severe phenotypes observed in these “lower” organisms is probably linked to species 
differences in telomere maintenance mechanisms.  For example, viable knockout mice 
for Ku70 and Ku86 have been reported (160-162).  These mice have very severe deficits 
in DNA DSB repair and V(D)J recombination, but only mild telomere dysfunction.  
However, telomere maintenance in the mouse is fundamentally different than it is in 
humans.  Mice have telomeres that are about 10 times longer than the average human 
telomere (163, 164).  Moreover, all mouse somatic cells express the enzyme (telomerase) 
that can synthesize new telomeres, whereas human somatic cells do not (165).  Thus, 
human cells appear to be much more sensitive to mutations that cause telomere 
dysfunctions than other species and this fact probably explains the differences in loss-of-
function mutations for Ku reported in various species. 
 
DNA-PKcs and Artemis 
DNA-PKcs and Artemis are not evolutionarily conserved and are present only in 
vertebrates (15, 166).  The evolutionary introduction of two new proteins with the genesis 
of vertebrates clearly coincides with the development of V(D)J recombination (167).  
Importantly, V(D)J recombination, which is essential for establishing a functional 
immune system, results in the generation of an intermediate that requires unusual end 
processing.  DNA-PKcs and Artemis seem to have evolved to deal with this processing 
event.  
DNA-PKcs, a member of the PIKK family, is a serine/threonine kinase (30, 31).  
DNA-PKcs is a large protein with a molecular weight of 469 kDa, which is in itself 
perplexing since the only functionally identifiable domain (the kinase domain) is located 
in the C-terminal 20 kDa.  What the N-terminal 449 kDa of the protein is required for is 
still not clear despite decades of dedicated work on this issue.  In normal cells, DNA-
PKcs, unlike ATM, is present as a monomer.  DNA-PKcs is recruited to a DSB through its 
interaction with the C-terminal end of a DNA-bound Ku86 (131, 132).  DNA-PKcs 
recruitment is followed by the inward translocation of Ku complex, which promotes 
homodimerization of the DNA-PKcs molecules bound to separate ends of a DSB.  The 
	   15	  
end result is that the two ends of the DSB are held together by the DNA-PKcs homodimer 
(168).  The binding of each DNA-PKcs monomer to Ku and the DNA also results in 
DNA-PKcs acquiring a higher affinity for the DNA, which, in turn, stimulates the kinase 
activity of DNA-PKcs (169-171).  The initial phosphorylation target of DNA-PKcs 
appears to be itself, and this autophosphorylation is critical for productive C-NHEJ (172, 
173).  The autophosphorylation of DNA-PKcs happens both in trans and cis, but the 
biological significance of this distinction is unknown (174).  Regardless, 
autophosphorylation seems to induce a subsequent conformational change that permits 
downstream processing steps and simultaneously also induces dissociation of DNA-PKcs 
(175, 176).  The dissociation of DNA-PKcs is a mechanistically important step, because it 
allows the subsequent downstream processing events to proceed.  Mutants of DNA-PKcs 
that cannot be autophosphorylated, remain bound to DSB ends and actually result in a 
more severe IR-sensitive phenotype than the null mutants (177).  As importantly, the 
activation of DNA-PKcs also results in the phosphorylation (and activation) of 
downstream targets.  As an added complexity, however, it is still unclear if DNA-PKcs is 
directly or indirectly required for these phosphorylation events.  For example, Ku, 
XRCC4, XLF, and LIGIV are all phosphorylated robustly in vitro by DNA-PKcs, but 
phosphorylation of these proteins by DNA-PKcs seems to be non-essential in vivo and/or 
carried out by a different kinase (125, 176, 178-180).  The best example of this 
conundrum is Artemis.  Artemis is intensely phosphorylated by DNA-PKcs in vitro (181, 
182); in contrast the in vivo phosphorylation of Artemis seems more dependent on ATM 
(183-185). 
Artemis was first identified as the gene defective in rare subgroup of RS-SCID 
(radiosensitive severe combined immunodeficient) patients.  Artemis is a single-strand-
specific 5’ to 3’ exonuclease.  Importantly, after phosphorylation by ATM or DNA-PKcs, 
Artemis acquires an endonuclease activity specific for hairpin and overhang structures.  
This enzymatic activity is required for the hairpin opening and overhang processing of 
the coding ends generated by RAG1/RAG2 recombinase during V(D)J recombination 
(182).  Mechanistically, this explains why Artemis-deficient patients present with a 
profound immune deficiency — they are incapable of completing V(D)J recombination.  
The radiation sensitivity of Artemis patients is much less well understood, but is 
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presumably due to certain types of DNA ends that are generated by IR exposure, which 
can’t be religated without some sort of (Artemis-dependent) overhang processing event 
(186). 
In summary, DNA-PKcs and Artemis are critical components of the C-NHEJ pathway 
and together they generate a nuclease activity that is critical for V(D)J recombination and 
DNA DSB repair. 
 
LIGIV:XRCC4:XLF 
Ku, as noted above, is required for the recruitment and activation of DNA-PKcs to 
DNA DSBs.  Ku is also required for the recruitment of the C-NHEJ ligation complex 
(which is composed of LIGIV and its two accessory factors, XRCC4 and XLF), because 
the ligation complex by itself does not have particularly high affinity for DNA DSBs 
(135, 136).  The ligation complex is formed in a stoichiometry of 2:2:1 
(XRCC4:XLF:LIGIV) and the complex is well conserved throughout evolution (187, 
188).  Budding yeast, for example, have orthologs of all three components, named 
Lif1:Nej1:Dnl4, respectively (15, 189). 
LIGIV is one of three mammalian ligases (190).  Interestingly, the other two ligases, 
LIGI and LIGIII, do not appear to operate at all in C-NHEJ.  LIGI appears to have the 
most wide-spread usage with documented roles in DNA single-stranded break repair 
(191), Okazaki fragment processing during DNA replication (192) and HR (193).  
LIGIII, in contrast, is used exclusively in A-NHEJ ((194); see below).  Importantly, 
neither ligase appears capable of substituting for LIGIV during C-NHEJ (158).  LIGIV is 
a 911-amino acid protein and was first identified through a homology search using a C-
terminal conserved region of the known eukaryotic ligases at the time, LIGI and LIGIII 
(195).  A unique feature of LIGIV is a large C-terminal region containing two BRCT 
domains.  Interestingly, LIGIV interacts with the XRCC4 homodimer not through one of 
the BRCT (which are known protein:protein interaction modules) domains but through a 
inter-BRCT linker domain (196).  Structural studies have demonstrated that one molecule 
of LIGIV is asymmetrically bound to the same helical region of two polypeptides within 
the XRCC4 dimer (188).  The second BRCT domain, although dispensable for direct 
binding, is nonetheless important to stabilize LIGIV:XRCC4 complex (196).  The first 
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BRCT domain interacts with Ku (197), and this interaction, as noted above, increases the 
affinity of the ligation complex to DNA (135, 136). 
XRCC4 was first identified as the human cDNA that rescued the defects of the XR-1 
CHO (Chinese hamster ovary) cell line, which is defective for DSB repair and V(D)J 
recombination (198).  XRCC4 is a 334-amino acid protein with a globular N-terminal 
head domain followed by a long helical tail.  XRCC4 stabilizes LIGIV (199), and 
functions as a scaffold protein by recruiting LIGIV and XLF to the break site.  
Consequently, XRCC4-null mutations phenocopy LIGIV-null mutations and this 
mechanistically explains the attendant IR sensitivity and V(D)J recombination defects.  
XRCC4 can form a filamentous structure through head-to-head interactions in vitro, but 
the in vivo importance of this aggregation activity is unknown.  Interestingly, however, 
the interaction of LIGIV with the XRCC4 inter-BRCT linker domain weakens the 
XRCC4 filamentous structure and dissociates it into a dimer form (187, 200).  Finally, 
XRCC4 also shows a strong interaction with DNA-PKcs, albeit not with Ku (138, 201, 
202).  This interaction presumably also helps to anchor the ligation complex at the DSB 
site. 
Two different groups identified XLF (also called Cernunnos).  One group 
complemented cells from RS-SCID patients with a cDNA library and found that a XLF 
cDNA could rescue the IR sensitivity and V(D)J recombination defects of a XLF patient-
derived cell line (203).  The other group isolated XLF from yeast-two hybrid screens as a 
protein that interacted with XRCC4 (204).  XLF is a 299-amino acid protein and it has a 
high structural similarity with XRCC4 despite a low (13.7%) sequence identity (204).  
XLF consists of a globular head domain and an elongated coiled-coil region similar to 
XRCC4, but its coiled-coil tail is shorter than that of XRCC4.  XLF is not essential for C-
NHEJ but it greatly stimulates the ligation of non-compatible ends by promoting re-
adenylation of LIGIV (205, 206). 
Unlike the other C-NHEJ factors, the ligation complex components are essential in 
mice.  It seems likely that LIGIV is also essential for humans, because all the described 
LIGIV patients have hypomorphic mutations (see below).  Interestingly, however, LIGIV 
is not essential in either mouse (207) or human somatic cell lines (207), suggesting a 
developmental role for the gene.  Indeed, LIGIV-null mice are embryonic lethal due to 
	   18	  
the p53-mediated neuronal apoptosis (208-210).  Actively dividing neuronal cells 
apparently generate higher levels of ROS than most cells, and they seem to be unable to 
manage ROS-induced DNA breaks without functional LIGIV.  With a phenotype and 
timing very similar to LIGIV, XRCC4-null mice are also late embryonic lethal (211).  
Confusingly, XLF-null mice are viable (212) and this has led to suggestions that perhaps 
only LIGIV and XRCC4 constitute the ligation complex, whereas XLF performs some 
non-essential, ancillary role.  This issue is under active investigation from a number of 
laboratories. 
  
The polymerase X family 
There are six polymerase X family members and three of them are required for C-
NHEJ; pol µ, pol λ, and TdT (terminal deoxynucleotide transferase) (134).  All three 
enzymes share the polymerase X core catalytic homology domain as well as including an 
enzymatic activity that is capable of adding dNTPs to the 3’-end of DNA.  Pol µ and pol 
λ are capable of both DNA-template-dependent and DNA-template-independent modes 
of synthesis (213).  Impressively, they can even synthesize DNA across a gap (214).  In 
C-NHEJ, the lack of homology at the DNA ends to be joined probably generates gaps at a 
high frequency, which probably explains the requirement for polymerases like pol µ and 
λ.  TdT is a lymphoid-specific gene expressed only in pre-B and pre-T cells and it 
synthesizes DNA on the 3’-hydroxyl of a short overhang in a template-independent 
manner, which makes it useful for increasing the functional variability of V(D)J 
recombination products (215).  
 
Mechanism of C-NHEJ 
Although the exact mechanism of C-NHEJ is not fully elucidated, a reasonable model 
of the repair mechanism exists: 
 
1) Ku70/Ku86 binding 
The Ku70/Ku86 complex is first recruited to DNA DSB ends and serves as a damage 
sensor.  Ku70/86 is an abundant protein in cells and it has a very high affinity for DNA 
ends, which enables free DNA DSB ends to recruit Ku within 10 sec of a DSB forming 
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(216, 217).  The Ku heterodimer, which forms a ring-shaped structure, binds to dsDNA 
by encircling it such that the DNA passes through Ku like a thread through a bead (129). 
  
2) DNA-PKcs binding  
DNA-PKcs is recruited to a DSB through the interaction with the C-terminal end of 
DNA-bound Ku86 (131).  The DNA-bound Ku complex then translocates inward and 
allows DNA-PKcs to bind at the very end of the DSB (170).  DNA-PKcs makes direct 
contacts with DNA termini, occupying about a 10 nt region proximal to the free end, and 
this interaction with DNA stimulates a conformational change within DNA-PKcs, which 
subsequently activates the kinase activity of DNA-PKcs (169, 170, 218).  Importantly, 
DNA-PKcs forms a homodimeric synaptic complex with the other DNA-PKcs molecule 
bound to the opposite side of the break. This interaction stimulates trans-
autophosphorylation across the DSB and is also presumed to function in end bridging. 
 
3) DNA end processing 
The structure of DSB ends varies depending on many parameters and end processing 
is often required to generate ligatable ends.  For example, IR-induced DNA breaks can 
have blunt or staggered ends with 5’- or 3’-overhangs, and these ends may need to be 
processed by either the MRN complex, Artemis or both.  In V(D)J recombination, the 
RAG1/RAG2 recombinase makes DSBs with hairpinned ends and the processing of these 
ends requires Artemis and (directly or indirectly) DNA-PKcs.  Finally, in order to ligate 
DNA ends together, the LIGIV complex needs a 3’-phosphate group.  If the 3’-phosphate 
group is lost through DNA damage or end processing, polynucleotide kinase (PNK) 
phosphorylates the 3’-end and enables ligation (219, 220).  This latter event apparently 
happens infrequently, since the loss-of-function of PNK generates, at best, a mild C-
NHEJ defective phenotype (221).  
  
4) DNA end ligation 
The LIGIV:XRCC4:XLF complex is recruited to DSBs using interactions with either 
Ku or DNA-PKcs (135, 136, 197, 222).  Once the ligation complex is recruited to a DSB 
end, it induces an inward translocation of Ku, freeing the DNA end for ligation (223).  
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The active site lysine of LIGIV needs to be adenylated for ligation, and most of LIGIV in 
cells is present as an adenylated form. This adenylate group, adenosine 5’-
momohposphate (AMP), is transferred to the 5’-phosphate of the DNA substrate during 
ligation.  Adenylation of the DNA activates the 5’-phosphate for the nucleophilic attack 
by the 3’-hydroxyl group, which displaces the AMP and covalently joins the ends 
together (190).  The role of XRCC4 is to stabilize LIGIV and to help with the adenylation 
of LIGIV.  Lastly, XLF facilitates the re-adenylation of LIGIV and it promotes the 
ligation of non-compatible ends (205, 206, 224). 
 
Even though C-NHEJ has been extensively studied for the past two decades, there are 
still a few critical questions that have yet to be adequately answered.  First, how C-NHEJ 
components are dissociated from a repaired DSB is perhaps the least understood topic.  In 
particular, the Ku heterodimer is a donut-shaped protein that encircles the DNA.  Because 
DNA-PKcs and the ligation complex are recruited by Ku (223), it is highly unlikely that 
Ku is released before ligation.  This however, presents a large logistical problem, because 
the Ku subunits are topologically interdigitated (129) and cannot just disassemble like 
many other multi-subunit complexes.  Thus, following successful C-NHEJ-mediated 
DNA DSB repair the Ku heterodimer is presumably topologically trapped on the 
chromosome.  If this Ku is not removed, it would almost certainly subsequently interfere 
with dynamic chromosomal processes such as DNA replication and RNA transcription.  
One possible way to solve this problem would be to proteolytically degrade the Ku ring 
off of the DNA (225) — after DSB repair has been completed — in a manner analogous 
to the disassembly of the cohesion ring from sister chromatids following DNA 
replication.  Unfortunately, there is no clear evidence for the involvement of proteases in 
Ku dissociation yet. 
Another area in the C-NHEJ mechanism that still requires clarification is what factors 
are required to activate the repair process.  Thus, C-NHEJ is usually described (as I have 
done) as a sequential event, but it is not clear whether all the components need to be 
recruited first to initiate C-NHEJ or not.  For example, in yeast, Dnl4 and Lif1 are 
required to initiate NHEJ (226, 227).  Similarly, not only Ku and DNA-PKcs, but also 
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LIGIV and XRCC4 can suppress other repair pathways (228), implying that LIGIV and 
XRCC4 might be involved in very early step of C-NHEJ. 
 
Human diseases associated with C-NHEJ defects 
Work on C-NHEJ has flourished over the past two decades and it continues to be a 
vibrant and highly competitive area of research.  One of the reasons for this interest has 
been the realization that defects in C-NHEJ genes are directly responsible for a veritable 
bevy of serious human diseases.  In many cases the complete phenotypes are quite 
complex — too complex for an exhaustive discussion here — but a brief synopsis will be 
useful.  Ataxia-telangiectasia (A-T) is a rare, autosomal recessive syndrome caused by 
mutations in ATM and it displays multisystem defects such as telangiectasia (a condition 
characterized by the dilation of capillaries), cerebellar degeneration, immunodeficiency, 
genomic instability and cancer predisposition (229).  Mutations in the other major 
upstream signaling kinase, ATR, cause Seckel syndrome, which is characterized by 
microencephaly and developmental delay (230). 
The subunits of the MRN complex have also been identified as disease-causing 
alleles.  NBS1-mutations, which lead mostly to truncated Nbs1 variants, cause the 
Nijmegen chromosome breakage syndrome, which is an autosomal recessive 
chromosomal instability disorder characterized by premature aging, microcephaly, 
growth retardation, immunodeficiency, cancer predisposition and IR sensitivity (57, 58, 
231, 232).  The NBS1 gene is located on human chromosome 8q21 and it codes for a 
protein termed nibrin.  Over 90% of NBS1 patients are homozygous for a founder 
mutation: a deletion of five base pairs, which leads to a frame-shift and C-terminal 
protein truncation (233).  Given that MRN is required for the recruitment of ATM to a 
DSB end, it is perhaps not at all surprising that hypomorphic mutations in Mre11 cause a 
disease termed ataxia-telangiectasia-like disorder (ATLD).  ATLD patients display ataxia 
and neurodegeneration, similar to the symptoms of A-T patients (234, 235).  A single 
patient with a hypomorphic mutation in Rad50 has been reported and the patient, again 
not surprisingly, presented with phenotypes similar to NBS1 patients (59).  Thus, 
mutations to any of the subunits of MRN, ATM or ATR result in profound pathological 
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disorders in humans, highlighted by neurological and immunological dysfunction and 
cancer predisposition. 
Recently, the first DNA-PKcs human mutation was described in a T-B- RS-SCID 
patient (236).  This patient displays a classic SCID phenotype similar to RAG1-, RAG2- 
or Artemis-deficient patients.  Confusingly, however, the putative hypomorphic missense 
mutation identified in the DNA-PKcs patient affected neither protein expression nor 
(auto)phosphorylation, but rather appeared to cause a defect in Artemis activation (236).  
The presumption, therefore, is that this mutation disrupts a DNA-PKcs domain required 
for the DNA-PKcs:Artemis interaction.  Direct experimental evidence for this hypothesis, 
however, is lacking.  Mutations in Artemis also lead to a RS-SCID syndrome, which is 
characterized by a hypersensitivity to DNA DSBs and an absence of functional B- and T- 
lymphocytes (237). 
Patients resulting from defects in the C-NHEJ ligation complex components are 
extremely rare.  For example, to date, only seven LIGIV patients have been reported.  
One of these patients did not have any obvious developmental defects but subsequently 
developed a radiosensitive leukemia (238).  Tragically, this patient had an extreme (and 
fatal) reaction to the therapeutic radiation treatment.  A cell line derived from this patient, 
180BR, has a mutation within a highly-conserved motif encompassing the active site of 
LIGIV, and the resulting mutant protein is severely compromised in forming an enzyme-
adenylate complex in vitro (238).  Four other patients with mutations in LIGIV presented 
with phenotypes (e.g., chromosomal instability, developmental and growth delay, unusual 
facial features, pancytopenia and various skin abnormalities) similar to ATLD/NBS1 
patients (239).  Unlike NBS1-mutant cell lines, however, LIGIV-mutant cell lines show 
normal cell cycle checkpoint responses (240, 241).  These LIGIV syndrome patients 
appeared to have suffered sporadic mutations as each had a unique homozygous or 
compound heterozygous hypomorphic mutations, which did not completely abolish — 
but did significantly reduce — enzyme function (242).  A sixth LIGIV patient presented 
with an acute T-leukemia (240).  This radiosensitive leukemia patient was a 4.5-year-old 
boy with a facial shape (bird-like) strongly reminiscent of NBS1 patients.  Importantly, 
however, this patient had no mutations in their Nbs1 genes, but did have a homozygous 
truncating mutation in LIGIV (240).  The seventh LIGIV patient had a T-B-NK+ RS-
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SCID phenotype without developmental defects.  Somewhat surprisingly, a cell line 
derived from this patient, SC2, had no detectable LIGIV protein and no detectable DNA 
end joining activity (243), suggesting that it might be functionally null for LIGIV.  More 
extreme than LIGIV is XRCC4, for which no patients have been described, suggesting 
that, as in the mouse (211), the gene is essential.  In contrast, XLF patients have been 
described and they universally show growth retardation, microcephaly, and an 
immunodeficiency characterized by a profound B- and T-cell lymphocytopenia (203).  
The more frequent occurrence of XLF patients compared to LIGIV and XRCC4 patients 
is consistent with the hypothesis that LIGIV:XRCC4 is the core ligation complex and 
XLF only provides accessory activity. 
 
Alternative non-homologous end joining (A-NHEJ) 
A-NHEJ was first documented in chicken DT40 cells as a DSB repair pathway that 
overlapped with neither C-NHEJ nor HR (159).  DT40 cells repair IR-induced DSBs in a 
highly reproducible biphasic manner.  The half time of the fast component is 13 min and 
the half time of the slow component is 4.5 hr.  In DT40 cells lacking the expression of 
Ku, the fast component disappears but a significant proportion of DSB repair can still be 
performed using the slow repair pathway.  Co-inactivation of HR components, such as 
Rad51B, Rad52, and Rad54 did not change the activity of the slow repair pathway, 
suggesting that the slow repair pathway did not represent HR (159).  Importantly, this 
slow-kinetic repair pathway was also observed in the 180BR cell line, a primary human 
fibroblast cell line derived from a patient with an inactivating mutation in LIGIV (238, 
244).  Thus, the LIGIV deficiency of 180BR compromised the fast, but not the slow, 
repair pathway in a manner analogous to Ku-deficient DT40 chicken cells.  Finally, 
wortmannin, a DNA-PKcs inhibitor, treatment abolished the fast repair pathway in wild-
type human cells but not the slow repair pathway.  Together, these results implied the 
presence of a novel repair pathway, which is Ku-, DNA-PKcs- and LIGIV-independent 
(244).  The existence of this pathway was subsequently confirmed and it has been termed 
A-NHEJ. 
Following the identification of the A-NHEJ pathway, a large amount of work has 
gone into establishing what proteins/genes are involved in this process.  Using a classical 
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fractionation:complementation approach, LIGIII was identified as the first authentic A-
NHEJ factor (194).  By inference, XRCC1 was therefore implicated as well.  XRCC1 
forms a stable heterodimer with LIGIII in the nucleus and is known to stabilize LIGIII 
(245-247).  Subsequent experimentation confirmed the involvement of XRCC1 and 
extended them to PARP1 as well.  In DNA-PK-defective (i.e., C-NHEJ deficient) rodent 
cells, DNA DSB repair required the synaptic activity of PARP-1 and the ligation activity 
of LIGIII:XRCC1 (248).  Current models suggest that PARP1, which like Ku has a very 
high affinity for DNA double-stranded ends (27, 249), competes with Ku for a DNA DSB 
— if Ku wins, C-NHEJ ensues; if PARP-1 wins, A-NHEJ is utilized.  These three 
proteins (LIGIII, XRCC1 and PARP1) constitute the core A-NHEJ factors, but it is clear 
that more (perhaps many more) await identification.  For example, histone H1 has a 
stimulatory effect on the A-NHEJ pathway, presumably by facilitating the alignment of 
the DSB ends (250). In addition, the A-NHEJ pathway is assumed to require at least 
modest end-resection in a search for microhomology regions and this process is likely 
dependent on MRN and CtIP (44, 251, 252).  Finally, LIGIII interacts with polymerase γ 
and while this is only known to be required for mitochondrial DNA replication (253) it 
also suggests the possible role of polymerase γ in A-NHEJ. 
Unlike HR and C-NHEJ, LIGIII-dependent A-NHEJ is not evolutionarily conserved 
and is present only in mammals and Xenopus laevis (190).  This makes it difficult to use 
simple model organisms, such as yeast, for A-NHEJ study.  In addition, the physiological 
function of the A-NHEJ pathway is unclear.  That is, the loss of HR leads to profound 
meiotic defects and the loss of C-NHEJ leads to acute IR sensitivity and severe V(D)J 
recombination defects, but what pathological states the absence of A-NHEJ generates is 
not known.  Thus, there have been several attempts to establish systems where A-NHEJ 
activity is measurable.  Because A-NHEJ is suppressed by C-NHEJ (254), a C-NHEJ 
deficient condition is frequently used to measure A-NHEJ activity.  Moreover, the 
sequence of the repaired junctions has been used as an indicator of which pathway is 
being used, because HR, C-NHEJ, and A-NHEJ use micro-homology differently (89, 
254, 255).  Two assays that have gained popularity are a system in which the expression 
of a truncated RAG2 generates robust A-NHEJ activity during V(D)J recombination 
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(251) and a plasmid end-joining assay in which a substrate, designed to detect only 
microhomology-mediated end joining, is used (252). 
The mechanism of A-NHEJ is still unclear, but consideration of the few known A-
NHEJ components gives some hints.  First, the MRN complex and ATR signaling are 
required for end-resection (252, 256-259).  The end-resection process in A-NHEJ seems 
very similar to that in HR, with the exception that Rad51 appears not to be involved in A-
NHEJ (260).  It is unknown how the degree of resection is regulated and how/when the 
homology pairing that is required for repair happens.  The involvement of histone H1 
around the damage site may be required to keep the broken ends proximal to one another 
(250).  This is because histone H1 facilitates PARP-1 activity and PARP-1 is thought to 
be bound to the DSB ends and likely mediates their synapsis.  About the only thing 
known for sure is that the LIGIII:XRCC1 complex clearly covalently links the ends of the 
DSB back together and somewhat surprisingly this does not appear to be a function that 
can be assumed by either of the other two ligases.  Finally, it is clear that nucleases 
(perhaps MRN and CtIP) and polymerases (perhaps pol γ) will be needed, but their 
identity remains elusive. 
 
LIGIII 
Unlike other ligases, LIGIII shows molecular heterogeneity, implying that it may 
have diverse roles.  Alternative splicing generates two different LIGIII isoforms (α and 
β), which are expressed with or without a C-terminal BRCT domain, respectively.  The 
α-form has a C-terminal BRCT motif and is expressed ubiquitously.  The β-form of 
LIGIII, which does not have the BRCT domain, is expressed exclusively in germ cells.  
Because LIGIIIβ appears to have a very specialized and constrained role, the rest of this 
Introduction will be concerned only with LIGIIIα, hereafter referred to simply as LIGIII.  
LIGIII interacts with XRCC1 and this interaction occurs through LIGIII’s BRCT domain.  
Additional heterogeneity comes from alternative translational initiation of LIGIII, which 
results in mitochondrial- and nuclear-specific forms based on the presence and absence of 
an N-terminal mitochondrial leader sequence (MLS), respectively (246, 261, 262). 
The nuclear LIGIII isoform forms a heterodimeric complex with XRCC1 (245), and 
this LIGIII:XRCC1 complex also functions in single-strand break repair (SSB), short 
	   26	  
patch base excision repair (BER) and nucleotide excision repair (NER) (190) in addition 
to A-NHEJ.  LIGIII and XRCC1 interact through BRCT domains (263) and this 
interaction seems to result in mutual stabilization (247, 264).  XRCC1- and LIGIII-
deficient mice are early embryonic lethal at 6.5-7.5 days postcoitum (dpc) and 8.5 dpc, 
respectively (265, 266).  The similarities in the phenotypes of these knockout mice 
suggest strongly that the two genes always work together.  This belief, however, is likely 
to be true only in the nucleus.  Thus, unlike LIGIII, XRCC1 is not present in 
mitochondria, implying that LIGIII has a XRCC1-independent function in mitochondria 
(267, 268).  How mitochondrial LIGIII remains stable in the absence of XRCC1 is not 
well understood. 
Recently, Maria Jasin’s group generated a LIGIII-null mouse model (269).  LIGIII-
null mice were early embryonic lethal (266), so a conditionally-null LIGIII mouse strain 
was generated (269).  Surprisingly, LIGIII-null MEF cell lines complemented with a 
mitochondrial-only expressed LIGIII cDNA were alive and neither showed any growth 
defect nor sensitivity against DNA damaging agents.  This observation conclusively 
demonstrated that the essential function of LIGIII resides in the mitochondria and is 
presumably related to mitochondrial DNA replication.  Perhaps even more surprisingly, 
the expression of a LIGI or Chlorella virus DNA ligase (the latter constitutes the minimal 
eukaryal nick-sealing enzyme (270)), cDNA in mitochondria was also sufficient to 
suppress the lethality of LIGIII loss-of-function. The essential role of LIGIII in 
mitochondria is further supported by the recent discovery that LIGIII is required for 
mitochondrial Okazaki fragment maturation (271).  All of these studies, however, beg the 
pressing question of what role — if any — LIGIII plays in the nucleus.  Recent studies 
have suggested that one of the main physiological functions of nuclear LIGIII may be in 
regulating chromosomal translocations (228, 272).  This result had actually been 
anticipated since the sequencing of human cancer genomes demonstrated that many of 
the chromosomal translocations observed in cancer cells exhibited the preferential use of 
microhomology (273), which, of course, is the salient feature of A-NHEJ.  To measure 
the contribution of C-NHEJ and A-NHEJ on chromosomal translocation formation, two 
different fluorescent markers were incorporated into different chromosomal locations 
with adjacent I-SceI sites in LIGIV- or XRCC4-deficient mammalian cells.  After I-SceI 
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expression, the cleavage and translocation frequency was scored by identifying derivative 
chromosomes that contained both markers.  These studies demonstrated that LIGIV and 
XRCC4 were not only NOT required for the translocations, but that they actually 
normally suppressed the translocations because their deficiency increased the 
translocation frequency and did not change the sequence characteristics of the 
translocation junctions (272).  These data compelling suggest that A-NHEJ, and not C-
NHEJ, is involved in mediating chromosomal translocations (228).  The utility of the 
conditionally-null LIGIII cell line was evident in another study where specific 
chromosomal breaks were induced using a zinc-finger nuclease, and — expectedly — the 
translocation efficiency in cells not expressing LIGIII was dropped (272). 
Finally, it should be emphasized that although the field now readily accepts the 
existence of a Ku-, DNA-PKcs- and LIGIV-independent and LIGIII-dependent A-NHEJ 
pathway, it is very unclear how many microhomology-mediated end-joining (MMEJ) 
pathways actually exist (274).  In addition to the A-NHEJ pathway described above, there 
are indications of other variations of MMEJ based on the requirements for different 
protein factors (274, 275). 
 
The relationship between DNA DSB repair pathways 
The mechanism of pathway choice is currently perhaps the most actively researched 
issue in the field of DSB repair.  That competition between HR and C-NHEJ for DSB 
ends can occur is widely accepted.  This competition is perhaps best illustrated by studies 
investigating gene targeting, which is an exclusively HR-mediated process (83, 276-278).  
In mammalian cells, the gene targeting frequency increases 5- to 20-fold in Ku-depleted 
cells, indicating that C-NHEJ normally suppresses HR (254, 276).  The binding affinity 
and the abundance of end-binding factors (e.g., Ku or MRN) at DSB ends seems to play 
an important role in deciding what repair pathway (e.g., C-NHEJ or HR, respectively) is 
utilized for a particular DSB.  However, it is not clear whether a single end-binding factor 
is enough to commit a broken end to a specific pathway or not.  For example, in yeast, 
the Dnl4:Lif1 complex is required to stabilize DNA-bound yKu and thus is also likely to 
be required for pathway choice in that organism (227).  In an analogous fashion, studies 
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with human cell extracts also showed that LIGIV:XRCC4 may be required for C-NHEJ 
initiation (226, 279). 
The identification of A-NHEJ as a mechanistically and genetically distinct pathway 
has only lent additional complexity to this problem.  Under normal physiological 
conditions, A-NHEJ is virtually undetectable.  In contrast, A-NHEJ processes more than 
half of the DSBs under C-NHEJ defective conditions (159).  This implies that C-NHEJ 
and A-NHEJ might also compete against each other for DNA ends, but that under normal 
conditions, C-NHEJ almost always wins out.  Together, these studies suggest that C-
NHEJ may be able to suppress both HR and A-NHEJ, whereas HR and A-NHEJ 
generally do not influence each other (159). 
This latter point is likely related to the fact that both HR and A-NHEJ require end 
resection as a part of their repair process.  It seems plausible (although certainly not 
proven) that the main distinction between the two pathways (i.e., in deciding which 
pathway to use to repair a DSB) is probably directly related to the degree of resection that 
occurs, with longer resection favoring HR over A-NHEJ and shorter resection favoring 
A-NHEJ over C-NHEJ (280-283).  Again, how or what limits end resection is not known.  
The cell cycle seems to be one of the possible regulators.  HR is used predominantly 
during late S and G2 phases when homologous sequences from a sister chromatid 
become available (283, 284).  C-NHEJ is active in all phases of the cell cycle (21), but it 
plays its most important role generally only during the G1/G0 phases.  In contrast, A-
NHEJ is also active in all phases of the cell cycle, but it is most active in G2 phase and its 
activity is compromised when cells enter the plateau phase of growth (285-287).  Thus, 
one model for how pathway choice gets determined would be if the protein expression 
level and/or post-translational modification of some key DSB repair protein(s) is 
modified as a function of the cell cycle.  Recent studies concerning CtIP are consistent 
with this hypothesis.  End-resection by CtIP is involved in both HR and A-NHEJ during 
S/G2 and G1 phases of cell cycle, respectively.  Moreover, CtIP protein levels are low 
during G1 phase and high during S, G2 and M phases, even though the gene is 
consistently transcribed throughout the cell cycle (288).  This regulation of CtIP at the 
protein level occurs in a kinase-dependent manner.  Importantly, the phosphorylation of 
CtIP on Ser327, which requires cyclin dependent kinase activity, facilitates the 
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interaction with BRCA1 and MRN complex, which subsequently increases the end 
resection activity of CtIP (289-291).  Importantly, A-NHEJ needs smaller amounts of 
resection than HR, so that while cells expressing a CtIP that cannot be phosphorylated at 
Ser327 are defective in HR, A-NHEJ remains unaffected (284). 
In summary, pathway choice is a critical event in the life of a DSB.  The biological 
outcome (e.g., error-free repair, error-prone repair, or chromosomal translocation) for a 
DSB end is utterly different depending upon whether HR, C-NHEJ or A-NHEJ, 
respectively, is chosen to repair it and thus the cell presumably regulates this choice very 
tightly.  It is clear that additional experimentation in this area is required and warranted. 
 
Telomeres 
Unlike bacteria, eukaryotes have linear chromosomes that cause end-replication and 
end-protection problems.  The former issue was vocalized initially by James Watson, 
who described it as the “end-replication problem” (292).  He noted that the end of a 
chromosome being replicated by the lagging strand cannot be synthesized completely, so 
that every replication cycle, a chromosome should shorten, with an attendant loss of 
genetic information.  This end-replication problem has apparently been solved by the 
evolution of the telomere, which is a TG-rich repetitive sequence found at the end of each 
chromosome (293).  This TG-repeat is extended by a dedicated reverse transcriptase, 
telomerase.  Telomerase is minimally composed of two proteins; Tert (telomerase reverse 
transcriptase) and Terc (telomerase RNA component).  In vivo, telomerase is likely 
composed of additional accessory factors (e.g., Dkc1; Dyskeratosis congenita 1, dyskerin; 
(294, 295)), but not all of them have been identified.  In humans, telomerase is 
constitutively active in germ cells and some cancer cells, but almost somatic cells have 
undetectable levels of telomerase activity, which leads to a progressive telomere 
shortening (165, 296).  Biologically in humans, therefore, the telomere acts as a buffering 
region for chromosome end loss and essentially allows for only a limited number of cell 
divisions.  Once a telomere is shortened to a critical point it losses its end protection 
activity (elaborated below) and the cells stop replicating and enter into senescence.  This 
replicative senescence is accelerated without telomerase (296).  Biologically, senescence 
is important because it provides a huge barrier to replicative immortality.  This is a 
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barrier that cells must overcome in order to become cancerous (297).  The simplest way 
to overcome the telomere shortening that triggers senescence is for a cell to (re)express 
telomerase.  Not surprisingly therefore, about 85% of all human cancer cells are 
telomerase positive, making this a popular point for potential clinical therapeutic 
intervention (165, 298).  The approximately 15% of cancer cells that are telomerase 
negative, must still deal with telomere shortening and they do so through a process 
named alternative lengthening of telomere (ALT), which uses HR to extend telomeres 
(299, 300).  In summary, all linear chromosomes face the problem of how to stably 
maintain their ends and telomeres are the universal evolutionary solution. 
The requirement for end-protection arises because linear chromosome ends are 
structurally similar to DNA DSBs.  For example, a human telomere is composed of 
(TTAGGG)n, repeats ranging in length from 2 to 14 kb.  At the extreme end, the 3’ G-
rich strand overhangs the double-stranded portion by 100 to 300 nt (301).  The transition 
between the double-stranded portion of the telomere and the G-rich overhang bears 
structurally similarities to DSBs.  Consequently, unprotected telomeres can provoke cell 
cycle arrest through ATM or ATR activation, chromosome fusion through C-NHEJ, or 
chromosome loss using HR (302-305). 
Cells use 2 mechanisms to obviate these deleterious outcomes.  First, the telomere 
forms a specialized structure: the 3’ G-overhang invades and hybridizes to a duplex part 
of telomere, making a classic displacement (D)-loop (10, 306).  Because this looping is 
telomere-specific, it is referred to as a t-loop (307).  Second, cells have evolved a group 
of six proteins (termed “shelterin”) that bind specifically to the t-loop structure, forming a 
proteinaceous cap on the t-loop.  The formation of the unusual t-loop and the coating of 
this structure by shelterin functionally hide the chromosome end from all DNA damage 
sensors and DSB repair pathways. 
The shelterin complex is composed of six factors; TRF1 and TRF2, POT1 (protection 
of telomeres 1), TPP1 (tripeptidyl peptidase 1), TIN2 (TRF1 interacting nuclear factor 2), 
and Rap1 (repressor/activator protein 1) (107).  TRF1 and TRF2 bind to the double-
stranded telomeric DNA and POT1 binds to the single-stranded DNA.  These proteins are 
held together by the linker proteins, TPP1 and TIN2.  TPP1, in particular, ensures that 
POT1 is connected to the rest of shelterin and facilitates the ssDNA-binding activity of 
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POT1, which protects the telomere from ATR activation (308, 309).  Rap1 is bound to 
TRF2, but the telomeric defects in mouse Rap1 knockout animals are actually quite mild 
(310).  The specific functions of each of the shelterin component have been principally 
studied using mouse knockout mutational analyses.  For example, a deficiency in TRF2 
removes most of the proteinaceous cap from the telomeres and results in ATM activation 
and subsequent cell cycle arrest through up-regulation of p53 (311, 312).  Analogously, 
POT1 competes with RPA for ssDNA binding to the telomeric G-overhang (313).  When 
POT1 is absent, RPA is recruited to the telomere and initiates an ATR-mediated DNA 
damage signaling pathway (314).  In summary, the end protection problem revolves 
around a specific structure (t-loops) and a specific complex of proteins (shelterin) that 
evolved to essentially hid chromosome ends from the DSB repair pathways (307). 
In addition to the shelterin complex, there are other proteins associated with 
telomeres.  Paradoxically — at least superficially — these consist mostly of DNA repair 
and damage signaling proteins.  For example, Ku is recruited to telomeres through its 
interaction with TRF1 and TRF2 in human (112, 139, 141).  Superficially, one might 
think this would facilitate telomere fusions via C-NHEJ, but it appears that at telomeres, 
Ku’s major function is to suppress the aberrant action of HR on the t-loop (117) and thus 
serves a protective role.  DNA-PKcs, which can also be recruited to telomeres, may 
facilitate this aspect of Ku’s protective telomeric role (119).  The recruitment of the MRN 
complex to telomeres in higher eukaryotes was first found in meiotic human fibroblasts 
(48) and later demonstrated to occur via its association with TRF2 (45).  Cells from MRN 
(e.g., NBS1) patients have short telomeres (46, 315).  Like Ku, MRN is now realized to 
play a positive role in telomere maintenance.  In particular, DNA end resection is known 
to be required for the formation of the G-overhang, which, in turn, is critical for t-loop 
formation (47). Additional experimentation has demonstrated that the nuclease activity of 
the MRN complex is needed to generate long G-overhangs and thus the MRN complex is 
required for telomere maintenance (46). 
Despite all the protective systems in place to correctly sequester telomeres and to 
avoid telomere uncapping, occasionally bad things can happen to good telomeres.  When 
such untoward events transpire, the deprotected telomere is recognized as a DSB and it 
initiates canonical checkpoint signaling and becomes a substrate for DSB repair (316-
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318).  For example, in the absence of TRF2, the MRN complex processes telomeric ends 
to such an extent that it activates the ATM:Chk2 signaling pathway (311, 319, 320).  
Subsequently, these unprotected telomeres form TIFs (telomere-dysfunction induced 
foci), which include virtually the same factors found in IRIFs (IR-induced foci) such as 
p53, γH2AX, MDC1, and 53BP1 (320).  Ultimately the TIFs activate the C-NHEJ 
pathway, which results in LIGIV-dependent telomere fusions.  Perhaps the strongest 
argument for the importance of proper telomere maintenance is provided by the disease 
Dyskeratosis congenita.  Patients afflicted with this disorder have profound bone marrow 
failure, cancer predisposition and usually succumb before their third decade of life (295).  
Seven genes (when mutated) have been identified as causing dyskeratosis congenita and 
all of them are involved in some form of telomerase biogenesis (e.g., hTERT) or telomere 
maintenance (e.g., TINF2) (294, 295, 321).  These studies unequivocally underscore the 
importance of proper telomere maintenance. 
 
Recombinant adeno-associated virus (rAAV) 
As noted above, significant amounts of telomere research have been carried out in 
simple model systems such as yeast or in genetically modified mice.  In neither of these 
systems, however, is the biology of human telomere maintenance accurately represented 
(318, 322, 323).  Consequently, our laboratory has tried to develop molecular 
technologies that could be applied to human somatic cells in an effort to generate a 
potentially more applicable model system.  The most important of these technologies is 
the use of rAAV for gene targeting purposes. 
A reliable exogenous gene delivery system is crucial for clinical experiments and for 
use as a therapeutic tool.  Plasmids and retroviruses have been widely used for gene 
delivery, but there is a limit to these vectors as they have the serious drawback that they 
integrate almost randomly into the host cells’ genome (324).  This high random 
integration rate results in a variety of problems.  First, the expression level of an 
exogenous gene cassette can vary depending on the locus where it is integrated (325).  
Second, random integrations can cause transformation by generating deleterious 
mutations (326).  Third, the integrated gene-expression cassette tends to be unstable and 
can be lost over time (327).  Currently, the only way to solve all these problems related to 
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the random integration of gene expression vectors is use the alternative strategy of gene 
targeting, which has none of these attendant disadvantages.  Unfortunately, however, the 
gene targeting frequency in human cells is generally only on the order of one in 106 or 
lower, principally because C-NHEJ (which mediates the random integration) dominates 
over HR (which mediates the gene targeting events) (278, 328).  This all changed, 
however, in 1998 when Russell and colleague reported the surprising observation of one 
in 102 gene targeting efficiency in human cell lines using a rAAV (recombinant AAV) 
vector (329).  Since then, dozens of investigators, our laboratory foremost among them, 
have validated and extended the use of rAAV.  As of today, over 90 different genes have 
been genetically modified at their respective endogenous loci via rAAV gene targeting 
methods (330).  Thus, rAAV has proven itself over the past decade to be a robust tool 
with which to modify the genomes of human cells.  
Adeno-associated virus type 2 (AAV2) is a human parovirus with a 4.7 kb ssDNA 
genome. AAV2 encodes two ORFs, rep and cap, which encode replication and capsid 
proteins, respectively (331).  Wild-type AAV preferentially integrates into the human 
genome at a specific region on chromosome 19, named AAVS1, and stays latent at this 
location.  Products from a helper virus, such as adenovirus or herpes simplex virus, are 
required for a productive replication, which allows AAV to enter into its lytic cycle 
(332).  The site-specificity of its integration and the fact that AAV has no known 
pathological effects made AAV one of the best early vector candidates for gene therapy 
in the clinic (333).  To use AAV as a gene targeting vector, the rep and cap ORFs are 
replaced with human genomic DNA corresponding to the gene of interest.  When rep and 
cap are subsequently provided in trans with some additional helper constructs, active 
virus can be produced that can be used to infect virtually all somatic human cells (334). 
rAAV vectors can be used to make substitutions, insertions, and deletion mutations as 
well as to epitope-tag endogenous loci (335-337).   
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CHAPTER II 
 
 
LIGIV is not essential for the survival 
of human somatic cells 
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C-NHEJ (classic non-homologous end joining) is the predominant DNA DSB 
(double-strand break) repair pathway in human cells.  Seven genes, Ku70, Ku86, DNA-
PKcs, Artemis, LIGIV, XRCC4 and XLF have been identified as key C-NHEJ 
components.  While these proteins are needed for C-NHEJ activity, several of them have 
additional functions.  One prominent example is the telomere maintenance mediated by 
Ku70:Ku86, which is essential for cell survival.  In contrast to Ku70:Ku86, however, 
another C-NHEJ factor, LIGIV, has no known function in telomere maintenance and 
appears to function exclusively in C-NHEJ.  Importantly, a viable LIGIV-deficient 
human B-cell line (NALM-6) has been described.  Together these observations strongly 
suggest that C-NHEJ and LIGIV are dispensable whereas telomere maintenance and 
Ku70:Ku86 are essential for human somatic cell survival.  This hypothesis, however, has 
its detractors.  For example, LIGIV patients have been reported but none of them are 
LIGIV-null, which has been interpreted to mean that LIGIV is essential (at least during 
development).  Moreover, lymphocyte cell lines like NALM-6 are known to depend more 
on HR (homologous recombination) than C-NHEJ for DSB repair and this has been 
interpreted to mean that the viable phenotype of the LIGIV-null NALM-6 cells might be 
a cell line specific phenomenon and not generally applicable to most human cells.  To 
address some of these issues, we inactivated — using rAAV (recombinant adeno-
associated virus) -meditated gene targeting — LIGIV in a fibroblastic human somatic cell 
line (HCT116, a human colorectal cancer cell line) to investigate whether C-NHEJ is an 
essential process or not.  Our LIGIV-null cell line was also viable, confirming that the 
gene and C-NHEJ are not essential.  However, we did observe a strong disequilibrium 
during the second round of gene targeting.  In addition, the cell line displayed a mild 
growth retardation, increased genomic instability, severe defects in DNA end-joining and 
an extreme sensitivity to DNA damaging agents.  All of these observations suggest that 
LIGIV (and by extension, C-NHEJ) is not essential for human somatic cell viability but 
that it does have important roles in maintaining normal cell homeostasis.  
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Introduction 
A DNA DSB is one of the most deleterious lesions that can occur in cells, because 
even a single unrepaired DNA DSB can stop the cell cycle and induce cell death (9, 338).  
To protect themselves from DSBs, cells have developed at least two major DNA DSB 
repair pathways; HR and C-NHEJ (339, 340).  To enact repair, HR uses extensive 
sequence homology, — generally sequences longer than 30 nucleotides (nt) — and 
generates repaired products that are generally “error free”.  In contrast, C-NHEJ requires 
only 0 to 4 nt of homology and is consequently more “error-prone”.  Recently, a third, 
minor pathway, A-NHEJ (alternative-NHEJ) that has features reminiscent of both HR 
and C-NHEJ has been described (286, 341, 342).  A-NHEJ, like HR, requires 
homologous sequences to mediate the repair reaction.  In the case of A-NHEJ, however, 
only 5 to 25 nt of homology (often referred to as “microhomology”) is needed.  
Additionally, because its reaction mechanism always results in accompanying deletions, 
A-NHEJ is therefore also like C-NHEJ in that it is “error prone” (274).  Depending on the 
organism and various parameters (e.g., position in the cell cycle), HR, C-NHEJ and A-
NHEJ are differentially utilized (21, 254, 274, 340, 343, 344).  Lower eukaryotes like 
yeast utilize HR almost exclusively for all DSB repair events regardless of the cell cycle 
state (15, 130, 345).  In contrast, higher eukaryotes such as humans use C-NHEJ more 
often than HR and C-NHEJ is the predominant, if not exclusive, repair mechanism 
utilized during G0/G1 phases (342).  This usage bias is, however, not exclusive.  For 
example, during late S and G2 phases in human cells, HR becomes more active because a 
proximal homology donor becomes available in the form of a sister chromatid (328).  In 
summary, higher eukaryotes have multiple options available to them in terms of the 
pathways that can be used to repair a DSB.  This pathway choice flexibility is probably 
beneficial in certain circumstances and has evolutionarily been selected for.  It is clear, 
however, that since each pathway makes a biologically and functionally distinct product, 
this choice must be very tightly regulated such that the correct product is generated in the 
correct biological context. 
In addition to DSB repair, the C-NHEJ pathway is also required for V(D)J 
recombination, CSR (class switch recombination), and telomere maintenance (119, 346).  
V(D)J recombination is the initial step of antigen receptor maturation that occurs in early 
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B- and T-lymphocytes.  Lymphocyte-specific endonucleases, RAG1 (recombination 
activating gene 1) and RAG2, make DSBs at specific RRSs (recombination signal 
sequences) and generate biochemically and structurally distinct coding or signal ends, 
which are subsequently processed and joined via C-NHEJ (2).  CSR is an exclusively 
deletional recombination reaction that replaces one antibody constant region with 
another, altering the antibody effector function (4).  CSR is initiated by a novel 
recombinase, AID (activation-induced cytidine deaminase), which initially introduces 
uracil:guanine mismatches into the DNA.  These mismatches are recognized either by 
mismatch repair proteins or UNG (uracil-DNA glycosylase) and eventually converted 
into DSBs that can be repaired by either C-NHEJ (104) or A-NHEJ (347-349).  
Telomeres are the ends of linear chromosomes.  They consist of a repetitive tract of DNA 
that assembles into a structure called a t-loop, which is a variation of a classical D-loop 
(350).  The t-loop is also coated by a bevy of proteins that form a proteinaceous cap on 
the DNA and essentially keep the chromosome end invisible to all of the DNA DSB 
pathways.  The core six proteins that bind in a sequence-specific manner to telomeres are 
collectively called  “shelterin” (107, 108).  There are, additionally, a bevy of shelterin-
associated proteins found at telomeres and unexpectedly some of these correspond to C-
NHEJ factors.  For example, the Ku heterodimer, and possibly DNA-PKcs, are part of the 
t-loop structure (120).  Interestingly, telomere protection by Ku complex is essential in 
human cells because Ku loss-of-function mutations provoke cell death triggered by 
telomere dysfunctions (117, 124).  All of the C-NHEJ factors, however, are unlikely to be 
involved in telomere maintenance and there is, for example, little evidence for a role in 
LIGIV, or it’s accessory factors, in telomere maintenance. 
In mammalian cells, there are seven identified and well-researched C-NHEJ 
components: Ku70, Ku86, DNA-PKcs (DNA-dependent protein kinase catalytic subunit), 
Artemis, LIGIV, XRCC4 (X-ray cross complementing group 4), and XLF (XRCC4-like 
factor; also occasionally referred to as Cernunnos).  Ku70 and Ku86 (so named for their 
approximate molecular weights) form a ring-shaped, highly-interdigitated heterodimer 
that binds DSB ends in a sequence-independent manner with extremely high affinity 
(129).  The DNA end-bound Ku heterodimer subsequently recruits DNA-PKcs using a 
protein interaction domain found in the C-terminus of Ku86 (170).  DNA binding induces 
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a large conformational change in DNA-PKcs and stimulates its kinase activity (169).  
Activated DNA-PKcs subsequently phosphorylates itself (where phosphorylation is likely 
inhibitory) and a number of other downstream effectors (where phosphorylation is likely 
activating) (351).  One of DNA-PKcs’s substrates is Artemis, a structure-specific nuclease 
involved in end processing (181, 182, 352).  Additional DNA-PKcs targets may also 
include LIGIV and/or its two accessory factors, XRCC4 and XLF (189, 353, 354).  
XRCC4 functions as a scaffold protein for the ligation complex and it stabilizes LIGIV 
(199).  XLF stimulates the ligation of non-compatible DSB ends by facilitating the re-
adenylation of LIGIV (205, 206, 355). 
Mutation of any of the C-NHEJ components causes many problems.  For example, 
Ku70, Ku86 and DNA-PKcs knock-out mice are viable but they present with severe 
growth defects, severe-combined immune deficiency and profound hypersensitivity to IR 
(ionizing radiation) (160-162).  In humans, the phenotypes are actually more serious.  
There is no known Ku70 or Ku86 patients, a fact that has been correlated with Ku’s 
essential role in telomere maintenance (115, 117, 124, 276) and only one hypomorphic 
DNA-PKcs-deficient patient has been reported (236).  The latter observation suggests 
that, like Ku, DNA-PKcs loss-of-function mutations may not be tolerated in humans.  In 
contrast, Artemis mutant patients with ostensibly null mutations have been described and 
they lack mature B and T lymphocytes, experience radiosensitive severe combined 
immune deficiency (RS-SCID) and are predisposed for leukemia (237).  LIGIV and 
XRCC4 knock-out mice are embryonic lethal and representative MEFs derived from 
these animals show radiation-sensitivity and defects in V(D)J recombination (356).  
Seven LIGIV patients have been reported so far in the literature and four of them 
presented with a “LIGIV syndrome”, which is characterized by severe radiation 
sensitivity, chromosomal instability, unusual facial features, developmental and growth 
delay (239).  The other LIGIV patients displayed only a subset of these features but were 
also afflicted with leukemia and RS-SCID (238).  Importantly, however, all seven LIGIV 
patients described to date had non-null, hypomorphic mutations (230, 239), suggesting 
that the gene, like Ku70, Ku86 and DNA-PKcs is essential. 
Michael Lieber’s group has studied the function of LIGIV for V(D)J recombination 
and IR sensitivity in the human B-lymphoid precursor cell line, NALM-6 (207).  These 
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researchers generated, by classical gene targeting technology, a LIGIV-deficient NALM-
6 cell line, which was — surprisingly — viable.  The viability of the cell line was 
unexpected based upon the reports for LIGIV patients described above.  Moreover, it was 
also unexpected based on mice knockout experiments, since LIGIV-null animals are 
embryonic lethal (209, 210, 356).  One possible explanation for these results is that the 
loss-of-function of LIGIV may be tolerated specifically only in NALM-6 cells, but is not 
generally applicable.  This hypothesis takes into account the fact that lymphoid cells tend 
to use more HR than C-NHEJ (357), so the absence of LIGIV might be less toxic to 
NALM-6 than most of the other cell types.  One way to address this issue would be by 
inactivating LIGIV in a non-B human somatic cell line. 
Accordingly, we report here the inactivation of LIGIV in the fibroblastic human 
colorectal cancer cell line, HCT116, using rAAV (recombinant adeno-associated virus) 
gene targeting methodologies (334).  Two rounds of gene targeting were used to generate 
a LIGIV-null HCT116 cell line, which was viable.  The ability to obtain a viable LIGIV-
null clone is consistent with existence of the LIGIV-null NALM-6 cell line and strongly 
suggests that neither LIGIV nor C-NHEJ is essential in somatic cells.  Importantly, 
however, the LIGIV-null HCT116 cells were not aphenotypic.  First, there was a large 
asymmetry in the second round gene targeting frequency with 15 out of 16 second-round 
targeting events occurring on the already inactive allele, indicating that there is a 
significant disadvantage to being LIGIV-deficient.  In addition, the LIGIV-null HCT116 
cells were extremely sensitive to DNA damaging agents and had defective DNA end-
joining activity.  So, We conclude that LIGIV and C-NHEJ are not essential for human 
somatic cell survival, but they are nonetheless critical for maintaining normal cell 
homeostasis. 
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Materials and Methods 
Cell culture  
HCT116 cells (ATCC) were grown in McCoy’s 5A media (Mediatech) supplemented 
with 10% FBS (fetal calf serum; Cambrex) and 100 U/ml penicillin and 100 U/ml 
streptomycin (Invitrogen).  All cells were grown at 37°C in a humidified incubator with 
5% CO2. 
 
Targeting vector construction  
The targeting vector was constructed as described (334).  The right and left homology 
arms were amplified by PCR using genomic DNA purified from wild-type HCT116 cells 
as the template.  The primers used to make left homology arm of LIGIV targeting vector 
were P2.1 and P2.2 (see below).  The right homology arm was constructed by PCR using 
the primers P2.3 and P2.4 (see below).  As fusion PCR templates, the two arm constructs 
and a 4 kb PvuI-digested fragment of the pNeDaKO-Neo vector (334) were used.  Fusion 
PCR products were amplified by P2.1 and P2.4 primers and then purified by gel-
extraction kit (Qiagen).  The fusion construct was subsequently NotI-digested and then 
cloned into a NotI-digested pAAV-MCS vector. 
 
P2.1 
(5’-ATACATACGCGGCCGCGCAGAAACATGCAGTATTTTCCCCTA-3’) 
P2.2  
(5’-GCTCCAGCTTTTGTTCCCTTTAGCAAAGCGGTGATGAATCTTCTCGT-3’) 
P2.3  
(5’- CGCCCTATAGTGAGTCGTATTACAGATGGAAAAGATGCCCTCAAACT-3’) 
P2.4 
(5’- ATACATACGCGGCCGCTTGTGTTTTCTGCACTATTTCTATTC-3’) 
 
Packaging and isolating virus 
AAV-293 cells (Stratagene) were grown in DMEM media at 37°C in a humidified 
incubator with 5% CO2.  The cells were split into a 10 cm culture dish one day before 
transfection.  pAAV-RC and pAAV-helper plasmid from the AAV Helper-Free system 
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(Stratagene), and the LIGIV targeting vector (8 µg of each) were co-transfected using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol.  Virus was 
harvested 2 days after transfection by collecting in 1 ml DMEM media and then 
performing a freeze and thaw cycle three times with vigorous vortexing in between.  The 
resulting cellular debris was clarified by centrifuging at 13,000 rpm for 2 min, after 
which the virus-containing supernatant was collected and used for a subsequent infection. 
 
rAAV Infection 
HCT116 cells were plated on a 6-well plate one day before infection.  When the cells 
were ~ 60 to 70% confluent, fresh media (1 ml) was added with an adequate amount of 
virus.  After a 2 hr incubation at 37°C, 4 ml of fresh media was added to the virus-
containing media.  Two days after infection, the cells were trypsinized and transferred at 
1000 cells/well on 96-well plates and selection was started using 1 mg/ml G418. 
 
Isolation of genomic DNA and genomic PCR 
Genomic DNA for PCR screening was isolated using a Gentra Puregene Cell Kit 
according to the manufacturer’s instructions (Qiagen).  The DNA was dissolved in a final 
volume of 25 µl, 1µl of which was subsequently used in each PCR reaction.  For 
screening, the RArmF/KO3’R primer set and the P1F/P2R primer set (see below) were 
used for the first and second rounds, respectively.  
 
RArmF (5’-CGCCCTATAGTGAGTCGTATTAC-3’)  
KO3’R (5’- AAAATGAGACATCATTCCACCCCGTGAT-3’)  
P1F (5’- GGGTTGGAGCAAAACAGTTATTAAATGTAG - 3’)  
P2R (5’- CAATTGAGTCTAAAAGGTCGTTTACTTGC - 3’)  
 
Immunoblotting 
LIGIV expression was characterized by first preparing nuclear extracts using a CelLytic 
NuCLEAR Extraction Kit according to the manufacturer’s instructions (Sigma).  Nuclear 
extracts (30 µg) were electrophoresed on a 7.5% SDS-polyacrylamide gel (BioRad) and 
rabbit, anti-human LIGIV antibody (Serotec) was used at a 1:1000 dilution.  To screen 
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for complemented clones, we used whole cell extracts prepared with RIPA buffer 
(Sigma).  LIGIV (Abcam) and HA antibodies (Covance) were used at 1:1000 dilution.  
As a loading control, an actin antibody (SantaCruz) was used at a 1:250 dilution. 
 
Etoposide sensitivity 
Etoposide sensitivity assays were performed as described with a slight modification 
(358).  Three hundreds cells were plated on a 35 mm culture dish ~ 17 to 19 hr prior to 
drug treatment.  Etoposide was dissolved in DMSO (dimethyl sulfoxide) to generate a 10 
mM stock solution.  The cells were treated with etoposide at varying concentrations and 
then incubated for an additional 7 to 10 days.  The cells were subsequently fixed with a 
solution of 10% methanol and 10% acetic acid containing crystal violet.  A colony was 
scored as viable when it consisted of 50 or more cells. 
 
Microhomology assay 
The microhomology assay was performed as described (23).  The pDVG94 plasmid (2.5 
µg) was restriction digested with EcoRV (NEB) and AfeI (NEB), purified and then 
transfected using Lipofectamine 2000 (Invitrogen).  Plasmid DNA was recovered 48 hr 
after transfection using a modified Qiagen mini-preparation protocol (254).  The repaired 
junctions were PCR amplified using FM30 and 5’-radiolabeled DAR5 primers.  The 
resultant radioactive PCR products were restriction digested with BstXI (NEB) and the 
digested PCR products were separated on a 6% TBE polyacrylamide gel.  The gel was 
subsequently dried and exposed to X-ray film for 10~15 min. 
 
DAR5 (28-mer forward primer: 5’-TGCTTCCGGCTCGTATGTTGGTTGGAAT-3’) 
FM30 (26-mer reverse primer: 5’-CTCCATTTTAGCTTCCTTAGCTCCTG-3’) 
 
Complementation 
We constructed a wild-type LIGIV cDNA and LIGIV cDNA with a HA-epitope tag at the 
C-terminal end. We cloned them into pcDNA3.1(+) using BamHI (NEB) and EcoRI 
(NEB).  These constructs were subsequently linearized with PvuI (NEB) and transfected 
into LIGIV-null cells.  48 hr after transfection, the cells were subcultured under limiting 
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dilution into 96-well plates with 1 mg/ml G418.  Colonies were expanded for 4 to 5 
weeks and then complemented clones were identified by immunoblotting as described 
above.  
 
GCR test 
G-banding cytogenetic analyses were performed in the Cytogenetics Core Laboratory at 
the University of Minnesota. 
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Results 
The inactivation of LIGIV in the HCT116 cell line  
We used rAAV gene targeting method to inactivate the LIGIV gene in the HCT116 
colorectal carcinoma cell line (334). This cell line has been used extensively for similar 
gene-targeting studies.  The cell line is immortalized, transformed and defective in the 
MLH1 gene making it mismatch repair defective (359-362).  However, the cell line is 
diploid, has an unusually stable karyotype and is wild type for almost all other DNA 
repair and checkpoint genes (359).  The LIGIV gene is located on chromosome 13 and 
has three exons.  Since the LIGIV coding sequence (CDS) resides only on exon 3, we 
disrupted the first 302 bp of the CDS by replacing it with the neomycin 
phosphotransferase (NEO) gene.  The relevant rAAV targeting vector consisted of two 
~900 bp homology arms (which, on the chromosome, flank the 302 bp region to be 
deleted), and a NEO selection cassette, which was itself flanked by LoxP sites (Fig. 1A). 
HCT116 cells were infected with the rAAVLIGIV vector and in the first round of 
targeting, 177 G418-resistant clones were subsequently screened by PCR using primers 
that were specific to the targeting vector and a unique sequence in the flanking DNA.  
Two correctly targeted clones (#130 and #163) were identified for a relative gene 
targeting efficiency of 1.1%, which is very similar to the frequencies reported for other 
rAAV-mediated gene targeting studies.  To ensure that isolated clones originated from a 
single cell, we subsequently subcloned them.  One of the subclones (#130-26) was 
designated as LIG4+/NEO and then treated transiently with a Cre-recombinase expression 
vector to remove the NEO selection cassette (which is flanked by LoxP sites; Fig. 1A).  A 
G418-sensitive derivative subclone was obtained from this protocol and renamed as 
LIG4+/− or Cre1.  Cre1 cells were then subjected to a second round of gene targeting — 
using the exact same rAAVLIGIV vector that had been used in the first round — to 
inactivate the remaining wild-type allele.  In the second round of gene targeting, we 
screened a total of 673 clones and obtained 16 correctly targeted clones (relative gene 
targeting frequency: 2.4%).  Surprisingly, 15 of these clones were retargeted to the 
already inactivated allele and were therefore still heterozygous.  Only one clone (#312, 
see below) was targeted at the remaining wild-type allele and was designated as 
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LIG4NEO/−.  This clone was subsequently converted into a LIG4−/− cell line by transient 
treatment with the Cre recombinase as described above. 
For the second round of screening, we used a primer set that could distinguish the 
three possible different LIGIV allelic states: a wild-type allele, a NEO-targeted allele and 
the Cre-treated allele with a residual single LoxP site.  These three configurations 
generated 681 bp, 2595 bp and 449 bp PCR products, respectively (Fig. 1B).  Retargeted 
clones, where the targeting construct integrated into the previously inactivated allele, had 
a diagnostic pattern where the 449 bp band from the Cre-treated allele disappeared but 
where the 681 bp band from the wild-type allele was still present (e.g., clones #69 and 
#198, Fig. 1C).  In contrast, randomly-targeted second round clones still retained both the 
449 bp and 681 bp bands in a manner unchanged from the parental Cre1 clone (e.g., 
clone #417 and Cre1, Fig. 1C).  Apart from all these clones was the pattern generated by 
clone #312, which did not produce the 681 bp band from the wild-type allele but did 
generate the 449 bp band originating from the Cre-treated allele, suggesting that it was a 
true null clone (clone #312, Fig. 1C).  In this PCR analysis, only a 2 min extension time 
was used, so the 2595 bp product from the targeted allele was not detected (Fig. 1C).  
Consequently, we further confirmed that the founding LIGIV+/− cell lines, Cre1 and #160, 
have reduced amounts of LIGIV protein and that the LIGIV−/− cell line, #312, expressed 
no LIGIV protein detectable by western blot analysis (Fig. 2).  From these molecular and 
biochemical analyses, we concluded that clone #312 corresponded to a viable LIGIV-null 
cell line and is hereafter referred to as the LIG4−⁄− cell line. 
 
A LIGIV deficiency causes a mild growth defect  
Three thousand cells corresponding to each of the parental (i.e., LIGIV+/+), LIGIV+/− 
(Cre1 or #160) or LIG4−⁄− cell lines were seeded on a 6-well plate on day 0 and the 
growth of cells from day 6 to day 10 was determined.  LIGIV+⁄− cells grew at a rate that 
was slightly, but significantly, reduced from the parental cell line (except on day 10) 
demonstrating that there is a mild haploinsufficiency associated with LIGIV (Fig. 3).  
Moreover, LIGIV−⁄− cells grew slower than either of the two LIGIV+⁄− cells lines, 
especially at earlier time points (Fig. 3).  The growth defect associated with the LIGIV-
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null cell line, however, in contrast to the growth defect reported for DNA-PKcs (363), 
another key C-NHEJ gene, was quite mild. 
 
A LIGIV deficiency induces genomic instability  
One of the deleterious consequences of unrepaired DNA DSBs is genomic instability, 
which predisposes cells to cancer (364).  Because LIGIV is essential for C-NHEJ 
activity, we expected that LIGIV−⁄− cells might be genomically unstable, and tested this 
by measuring karyotypic abnormalities using standard G-banding of metaphase 
chromosomes (Table 1).  The background rate for finding detectable GCRs (gross 
chromosomal rearrangements/abnormalities) is 10% or lower for the parental cell line 
(115, 363).  Twenty metaphases from three independent LIGIV heterozygous clones were 
analyzed: #163-7 and #130-26 are two LIGIV+⁄− subclones obtained from the first round 
of targeting while #69 is one of the second-round retargeted LIGIV+⁄NEO clones (Fig. 1C).  
Collectively, the LIGIV+⁄− cells showed an average of 10% GCRs (range of 0% to 20%), 
which was almost the same as that of the parental cell (Table 1), suggesting that there is 
no haploinsufficiency for genomic instability, in spite of the slower cell growth.  In 
contrast, the LIGIV−⁄− cell line had a 30% GCR rate suggesting that LIGIV is a 
suppressor of genomic instability (Table 1). 
 
LIGIV−⁄− cells are extremely sensitive to DNA damaging agents 
The very first LIGIV patient described in the literature developed leukemia, but she 
actually died from an extreme adverse response to the radiation treatment for this cancer 
and not from the leukemia itself (238).  To experimentally determine if this effect could 
be recapitulated in our somatic cell model, we carried out colony forming assays in the 
presence or absence of etoposide, a topoisomerase II inhibitor and a strong radiomimetic 
drug (365) (Fig. 4).  Positive control cell lines included the parental, wild-type cell line 
and clone #1, which was a randomly targeted clone from the first round of gene targeting 
and it therefore retained the LIGIV+/+ genotype.  As negative controls we used a clone, 
#70-32, which has a Ku86+⁄− genotype and is known to be etoposide-sensitive (366).  
Compared to the wild-type and randomly targeted clone, the LIGIV+⁄− clone showed a 
mild sensitivity comparable to that of the Ku86+⁄− cell line (Fig. 4).  In stark contrast, the 
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LIGIV−⁄− cell line was extremely sensitive to even low concentrations of etoposide (Fig. 
4).  This result strongly suggests that LIGIV is required for the repair of etoposide-
induced DNA DSBs. 
 
LIG4−⁄− cells show an increased use of microhomology for DNA end joining 
The A-NHEJ DNA DSB repair pathway is generally only detectable when C-NHEJ is 
deficient.  Indeed, microhomology-mediated end joining (the hallmark repair signature of 
A-NHEJ) is increased in the 180BR cell line, which was derived from a LIGIV patient 
(244).  To see if these attributes could be extended to our cell line, we tested the DNA 
end joining activity of LIGIV−⁄− cells using a reporter substrate, pDVG94, that can 
differentiate C-NHEJ and A-NHEJ products (254).  Digestion of pDVG94 with EcoRV 
and AfeI restriction enzymes generates a blunt-ended linear substrate that has 6 bp repeats 
of homologous sequence (ATCAGC) at both ends (Fig. 5A).  When this substrate is 
transfected into mammalian cells it can be joined by either C-NHEJ or A-NHEJ, but only 
when it is repaired by A-NHEJ will a novel BstXI restriction recognition site be generated 
(Fig. 5A).  Consequently, this linear substrate was transfected into cells and recovered 48 
hr later.  Repaired junctions were amplified by PCR with radiolabeled primers, and the 
resulting 180 bp radiolabeled PCR products were digested with BstXI.  The amount of 
180 bp uncut product represents the repair carried out by C-NHEJ whereas the 120 bp 
BstXI-digested product corresponds to repair by A-NHEJ.  Wild-type cells had less than 
1% A-NHEJ activity (Fig. 5B, lane 2), consistent with previous analyses (254).  In 
contrast, more than 99% of the repair in LIGIV−⁄− cells was A-NHEJ-mediated (lane 4).  
Based upon these results we concluded that LIGIV is the major C-NHEJ pathway ligase 
and in the absence of LIGIV cells use the A-NHEJ pathway for DSB repair. 
 
Complementation experiments using the re-expression of a wild-type LIGIV cDNA  
To confirm that the phenotype we observed in LIG4−⁄− cells was due to the absence of 
LIGIV, we attempted to rescue the LIG4−⁄− cells using the expression of a LIGIV cDNA 
(Fig. 6).  A wild-type LIGIV cDNA was cloned into the pcDNA3.1(+) mammalian 
expression vector with or without an HA epitope tag.  These constructs were transfected 
into the LIG4−⁄− cells and G418-resistant colonies were screened by immunoblot analysis 
	   48	  
for the expression of LIGIV as described in the Materials and Methods section.  Four 
clones, two each for each of the cDNAs, were used for further characterization.  Clones 
#14 and #57 expressed untagged wild-type LIGIV while clones #17 and #52 were 
complemented with the HA epitope-tagged wild-type LIGIV.  Clones #14 and #52 
showed higher levels of expression than clones #57 and #17, respectively (Fig. 6).  First, 
we tested the DNA end joining activity of the complemented clones.  All four clones 
showed a significant shift towards the wild-type profile (Fig. 5B, lanes 6, 8, 10 and 12).  
The clones with the lower level of LIGIV expression (clone #57 and #17; Fig. 6) also 
showed the lower degree of repair complementation (Figure 5B, lane 8 and 10).  We also 
tested the etoposide sensitivity of the complemented clones.  Again, two of the clones 
(clones #14 and #52) showed better (albeit not wild-type levels) of complementation than 
clone #57 and #17, respectivly (Fig. 7).  The ability to complement the repair and 
etoposide-sensitivity defects of our LIGIV-null cell line by the re-expression of LIGIV 
strongly suggests that the phenotypes of this cell line are due specifically to the loss-of-
function of LIGIV. 
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Discussion 
In this study, we generated a viable LIGIV−⁄− HCT116 cell line using rAAV-mediated 
gene targeting methodology.  The inactivation of LIGIV in two independent human cell 
lines, NALM-6 (207) and HCT116 {this study}, demonstrates that LIGIV is not essential 
for human somatic cell viability.  With this said, it is important to note that multiple 
independent studies using rAAV-mediated gene knockout strategies have demonstrated 
that there is no allelic preference in gene targeting (367-370).  However, in the second 
round of LIGIV gene targeting, we observed a large bias toward retargeting at the 
already-inactivated locus compared to targeting of the wild-type locus, with 15 of the 
former events and only one of the latter.  This disequilibrium in the gene targeting 
frequency is usually indicative of genes that provide a significant growth disadvantage 
when absent.  This is the case for DNA-PKcs (363) and PARP-1 {M. Mueller & E. A. 
Hendrickson, unpublished data} where highly skewed second round gene targeting 
frequencies (1 out of 17 and 2 out of 32 correctly targeted clones for DNA-PKcs and 
PARP-1, respectively) were observed.  Not surprisingly, the resulting DNA-PKcs-null and 
PARP-1-null cell lines showed very severe proliferation defects with cell doubling times 
on the order of ~40 hr {(363); M. Mueller & E. A. Hendrickson, unpublished data}.  In 
contrast, the LIGIV-null cell line reported here, while it does display growth defects (Fig. 
3), still doubles at a fairly robust rate.  The discrepancies in these studies may be related 
to genomic stability.  The loss of both alleles of DNA-PKcs for example, results in a cell 
line with a very high rate of GCRs in which 75% of all metaphases show at least one 
gross karyotypic abnormality (363).  This level of genomic instability is certainly 
deleterious and likely explains the large deficits in proliferation of the DNA-PKcs-null 
cells.  LIGIV-null cells, on the other hand, had a much lower (albeit elevated) frequency 
of GCRs (30%; Table 1).  From these considerations we conclude that while LIGIV is 
unequivocally non-essential for human somatic cells, it nonetheless provides important 
cellular functions such that cells without LIGIV are at a distinct disadvantage for growth 
and survival in comparison to LIGIV-proficient cells. 
 
C-NHEJ is not essential for human cell viability 
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We have demonstrated that LIGIV is not essential for human somatic cell viability.  
Since LIGIV is absolutely required for C-NHEJ, it would be logical to extrapolate our 
results to conclude that C-NHEJ is also non-essential in human somatic cells.  Confusing 
this interpretation, however, is the observation that two other major C-NHEJ components, 
Ku70 and Ku86, are essential in human somatic cells (115, 117, 276).  We believe this 
discrepancy is due to the fact that LIGIV likely functions exclusively in C-NHEJ, 
whereas Ku has additional (essential) roles in telomere maintenance (139, 371).  Unlike 
LIGIV, Ku70 and Ku86 are physically associated with telomeres (112, 113, 119), and 
once either Ku subunit is depleted, the telomeres shorten and then fuse (119).  Previous 
research from our laboratory showed that a Ku86 deficiency causes massive telomere 
loss, sister chromatid fusion and t-circle formation, which eventually induces cell death 
within a week (117).  To investigate whether LIGIV is involved in telomere fusion under 
Ku86 deficient conditions, we have generated a Ku86 and LIGIV doubly-null cell line 
{Y. Wang and E. A. Hendrickson, unpublished data}.  This doubly-null cell line still 
displays telomere fusions {Y. Wang and E. A. Hendrickson, unpublished data}, implying 
that only Ku86, but not LIGIV nor C-NHEJ, is involved in telomere maintenance in 
human cell.  Consistent with these observations are the recent results demonstrating that 
the functional inactivation of the two LIGIV accessory factors, XLF {F. Fattah and E. A. 
Hendrickson, manuscript in preparation} and XRCC4 {B. Ruis and E. A. Hendrickson, 
manuscript in preparation} result in viable cell lines.  Thus, the preponderance of data 
suggests that not only is LIGIV not essential in human somatic cells, but that C-NHEJ is 
non-essential as well.  
 
LIGIV is nonetheless probably essential for early development 
To date, only seven LIGIV-defective patients have been reported in a world-wide 
population of seven billion (230, 240, 243).  This paucity of patients is analogous to the 
gene targeting disequilibrium we observed and suggests strongly that there is a profound 
selective disadvantage to having reduced levels of, or being totally without, LIGIV.  Four 
of the LIGIV-defective patients presented with a “LIGIV syndrome”, which is associated 
with chromosomal instability, pancytopaenia, developmental and growth delay and 
dysmorphic facial features (239).  Two other patients had leukemia (i.e., cancer 
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predisposition) (238, 241) and the last patient presented as a T-B-NK+ RS-SCID (243).  
The LIGIV mutations in all of these patients have been characterized at least at the DNA 
level.  One patient had a mutation in the putative nuclear localization signal (NLS), so 
that the protein, which was otherwise presumably functional, was mislocalized in the 
cytoplasm.  Other patients had unique kinds of homozygous or compound heterozygous 
hypomorphic mutations, which did not completely abolish, but significantly reduced, 
enzyme function (242), and the severity of the clinical features was correlated with the 
level of residual LIGIV activity (241).  In summary, even though LIGIV is dispensable 
for human somatic cell survival, the absence of unequivocally LIGIV-null patient 
suggests that there is an essential role for LIGIV somewhere during early development.  
This stage may correspond to neural development because two of the main clinical 
features of LIGIV patients are microcephaly and neurological abnormalities (239).  This 
view is consistent with work carried out in mice.  LIGIV is essential in the mouse and the 
mice succumbed very early in development not to any obvious defect in C-NHEJ, but due 
to massive neuronal cell death (209, 210).  The extraordinary requirement for LIGIV 
during neural development is not obvious.  The brain does, however, occupy only 2% of 
the total body weight, but consumes 20% of the cellular oxygen (372-374).  Perhaps this 
high oxidative stress causes more DNA DSBs in brain tissue compared to other 
tissues/organs, which would clearly be detrimental to cells without functional LIGIV.  
This speculation is at least consistent with the extreme sensitivity of LIGIV-null cell to 
DNA damaging agents (Fig. 4), where cells encountering high levels of DNA DSBs may 
resemble cells required for early neuronal development subjected to high oxidative stress.  
In summary, we believe that the data are compelling that LIGIV is likely essential for the 
development of an organism, but dispensable for the survival of single cells. 
 
Ku, and not LIGIV, is the main regulator of repair pathway choice 
The viability of LIGIV-null cells suggests that other DNA DSB pathways (i.e., HR 
and A-NHEJ) are sufficient to deal with the endogenous DNA DSB damage that arises in 
normal cells.  This observation, however, begs the question of how a normal cell that 
suffers a DNA DSB decides which DSB repair pathway to use to enact repair.  This issue 
is quite important since the repaired products these pathways generate are distinctly 
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different.  Numerous recent studies have suggested that this regulatory activity resides 
with Ku (19, 27, 254).  C-NHEJ, the major DNA DSB pathway, is usually depicted as a 
sequential event with the first protein in the reaction mechanism, Ku, essentially acting to 
commit the DSB to C-NHEJ while simultaneously suppressing the access of HR and A-
NHEJ factors to the DSB (254).  Our work is consistent with that view.  Thus, in a recent 
study from our laboratory our LIGIV-null cell line was shown to have lost virtually all of 
its end joining activity (254).  That study and our work here demonstrate that the residual 
end joining activity that remains in LIGIV-null cells corresponds almost exclusively to 
A-NHEJ (Fig. 5).  The phenotype of LIGIV-null cells stands in stark contrast to that of 
Ku-reduced cells, which — while having no detectable C-NHEJ activity — actually have 
elevated levels of HR (158, 227, 249) and A-NHEJ (244, 254, 347).  Nonetheless, it may 
be possible that LIGIV retains a subtle role for pathway choice regulation although that is 
not obvious from our studies.  Thus, LIGIV:XRCC4 has been reported to be required for 
C-NHEJ initiation by facilitating polymerase and nuclease activity in HeLa cell extract 
(226, 227).  Moreover, in yeast, Dnl4 and Lif1, yeast orthologs of LIGIV and XRCC1, 
are required to stabilize NHEJ complexes and suppress HR by inhibiting resection (227).  
Combined, these results still leave the possibility that initiation and/or stabilization of C-
NHEJ by LIGIV may be required to suppress A-NHEJ, although that was not so evident 
in our studies.  
Interestingly, it could also be argued that LIGIV has a small role in suppressing HR.  
Thus, the first round of gene targeting for LIGIV was 1.1% whereas the second round 
gene targeting frequency was 2.4%, suggesting that reduced LIGIV levels enhance HR.  
Moreover, in additional gene targeting studies, we have shown that the targeting 
frequency at the Ku70 locus in LIGIV-null cells is 2-fold elevated compared to wild-type 
cells (Supplementary Table 1; F. Fattah and E. Hendrickson, unpublished data).  
Similarly, the targeting frequency at the RAD54B locus is increased 2-fold in LIGIV-null 
cells (Supplementary Table 1; unpublished data).  Together, these studies show 
conclusively that in the absence of LIGIV, gene targeting — clearly an HR-mediated 
reaction — is slightly enhanced.  Nonetheless, this enhancement is nowhere near the 
improved gene targeting frequencies reported for Ku-reduced human cell lines (276). In 
summary, our data are consistent with a mechanism where the bulk of the pathway choice 
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regulation resides within the purview of Ku, but that the presence or absence of LIGIV 
may influence these processes as well. 
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Figure 1. The targeting strategy and primers used for the LIGIV knockout. (A) The black 
rectangle represents the first 302 bp of LIGIV coding sequence, which was replaced by 
the NEO gene using rAAV-mediated gene targeting. The gray rectangles represents the 
~900 bp of homology arms flanking the targeting region. The black triangles represent 
LoxP sites. (B) Primers used for the second round of screening. The P1F/P2R primer set 
gives different-sized PCR products depending on the allelic states of the LIGIV gene; 
681 bp for the wild-type allele, 2595 bp for the NEO-targeted allele, and 449 bp for a cre-
treated allele. Under the PCR condition we used here with short extension time, the 2595 
bp product was not generated. (C) PCR screening. #130-26 is one of the LIGIV+/NEO 
subclones. Cre1 is a G418-sensitive LIGIV heterozygous cell generated by Cre-
recombination of #130-26. Cre1 was used for the second round of targeting. Cell lines 
#69 and #198 are retargeted clones from the second round of gene targeting. Clone #312 
is LIGIV−⁄− and #417 is an example of a LIGIV+/− clone that suffered a random 
integration during the 2nd round of gene targeting. 
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Figure 2. Inactivation of the LIGIV gene is confirmed at the protein level. Western blot 
analysis confirms that clone #312 is LIGIV−⁄− cell. Cre1 is a G418-sensitive LIGIV 
heterozygous cell and clone #160 is a LIGIV+/− clone that suffered a random integration 
during the 2nd round of gene targeting. 
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Figure 2. Immunoblotting analysis of LIGIV targeted clones
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Figure 3. The LIGIV−⁄− cell line has a mild growth defect. On day 0, three thousand cells 
were seeded into 6-well plates and the cells were counted from day 6 to day 10. Cre1 and 
#160 are LIGIV+/− clones. The data shown here represent the average of six counts that 
came from four independent sets of duplicates excluding the maximum and minimum 
values.  
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Figure 3.  LIGIV deficiency causes mild growth retardation
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Figure 4. LIGIV−⁄− cells are extremely sensitive to DNA damaging agents. On day 0, 
three hundred cells were subcultured into 6-well plates with different concentrations of 
etoposide. 10 to 14 days later, the cells were fixed and stained with crystal violet. The 
number of colonies that survive at different concentrations of etoposide was normalized 
by the survivability of untreated cells, which was set as 1. Clone #1 is one of the first-
round random integrates, so it still has wild-type LIGIV alleles. Clone 70-32 is an 
etoposide-sensitive Ku86+/− HCT116 cell line. Each value represents the average of two 
independent experiments. 
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Figure 4. LIGIV null cell displays extreme sensitivity against etoposide
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Figure 5. LIGIV−⁄− cells use microhomology for DSB repair. (A) After EcoRV and AfeI 
restriction enzyme digestion, the reporter substrate, pDVG94, becomes a blunt-ended 
linear plasmid with 6 bp direct repeats at both ends. Repair of the plasmid via C-NHEJ 
retains part of both repeats, whereas A-NHEJ generates only a single repeat, which can 
be subsequently cleaved by BstXI. Repaired junctions can then be amplified by PCR 
using radiolabeled primers and the 180 bp PCR product is subjected to BstXI digestion. 
The 180 bp uncut product represents repair via C-NHEJ whereas the 120 bp digested 
product represents A-NHEJ-mediated repair. (B) In LIGIV−⁄− cells, virtually almost all of 
the repair is mediated by A-NHEJ (lane 4). After complementation (lanes 6,8,10, and 12), 
the ratio between the 180 bp versus 120 bp products becomes more similar to that of 
wild-type (lane 2), indicating the restoration of functional C-NHEJ activity in the 
complemented cells.  
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Figure 6. LIGIV−⁄− complementation. Clones #14 and #57 are complemented with an 
untagged wild-type LIGIV cDNA. Clone #17 and #52 are complemented with a HA-
tagged wild-type LIGIV. In the LIGIV immunoblots, there is a non-specific band right 
above the authentic LIGIV band. Both a short exposure and a long exposure of the same 
blot are presented. Clones #14 and #52 express more LIGIV protein than clones #57 and 
#17, respectively. The same samples were blotted with a HA-antibody as well. Actin has 
used as a loading control.  
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Figure 6. Immunoblot result of LIGIV complemented clones
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Figure 7. Complemented clones are more resistant to etoposide than LIGIV−⁄− cells. The 
etoposide sensitivity test was performed exactly as described in Figure 4. 
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Figure 7. LIGIV complementation resuces extreme etoposide-sensitivity of LIGIV null cell
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Table&1.&Summary&of&GCR&frequency&in&LIGIV&clones&
Designation Genotype
LIGIV
GCRsMetaphases
LIGIV
LIGIV
Frequency&(%)
LIGIV
#69
#163I7
#312
#130I26
20
20
20
20
0
4
6
2
0.0
20.0
30.0
10.0

LIGIVwtHCT116 143 14 9.8+/+
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Supplementary Figure 1. G-band karyotype. The red arrows show instances of observed 
aberrant chromosomal abnormalities. (A) LIGIV+/− #163-7. (B) LIGIV+/− #130-26. (C) 
LIGIV−⁄− #312. 
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Supplementary Table 1. Gene targeting rate in LIG4 deficient cell lines
Targeted
Genes
Cell Lines
LIG4 Rad54B Ku70
wtHCT116
LIG4+/-
LIG4-/-
1.13
2.16
1st : 8.82
2nd : 13.19
3rd : 4.74
1st : 0.69
2nd : 4.12
0.73
2.20
*n.a.
*n.a.
*n.a.
*n.a. = not availalbe
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CHAPTER III 
 
 
LIGIII is an essential gene for the survival of human 
somatic cells 
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C-NHEJ (classic non-homologous end joining) is the primary DNA DSB (double-
strand break) repair pathway in higher eukaryotes.  Recently, evidence has been 
accumulated for the existence of a novel, albeit minor, end joining repair pathway.  This 
pathway can normally be detected only under C-NHEJ deficient condition and is called 
A-NHEJ (alternative-NHEJ).  Currently, the molecular mechanism of A-NHEJ is very 
obscure.  Nonetheless, several proteins have been implicated in the A-NHEJ pathway 
including LIGIII:XRCC1, PARP1, MRN, CtIP, and Histone H1.  Among these genes, a 
dependency on LIGIII is one of the most prominent features of A-NHEJ.  To 
experimentally test the requirement for LIGIII in A-NHEJ we constructed a LIGIII 
conditionally null human cell line using rAAV (recombinant adeno-associated virus) – 
mediated gene targeting methodology.  Our data demonstrate that, similar to studies 
recently described in the mouse and chicken cell line, human LIGIII is required for 
mitochondrial function and this defines its essential activity for cell viability.  
Disappointingly, however, DNA repair activity in the nucleus appeared utterly unaffected 
by the deficiency in LIGIII.  Moreover, A-NHEJ was predicted to be the primary 
mediator of rAAV random integration events, but the same rAAV-mediated gene 
targeting rate was observed in LIGIII-null cells as in wild-type cells.  In conclusion, we 
have shown that human LIGIII has an essential function in mitochondria maintenance, 
but we find that it is dispensable for most types of nuclear DSB repair.  
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Introduction 
A DNA DSB is one of the main challenges that undermine genomic integrity (2).  In 
order to avoid the destructive and pathological outcomes that result from unrepaired 
DNA DSBs, it is crucial to have efficient DSB repair pathways.  In most organisms, there 
are two major DSB repair pathways, HR (homologous recombination) and C-NHEJ (10, 
18).  HR is preferentially used in lower organisms, however, in mammalian cells — and 
particularly in human cells — the majority of DSBs are repaired via the C-NHEJ pathway 
where Ku70:Ku86 and LIGIV:XRCC4 are the major players.  In C-NHEJ, DSB ends are 
bound by Ku70:Ku86 heterodimer, which subsequently recruits DNA-PKcs, the catalytic 
subunit of the DNA-PK holoenzyme (131, 132).  A structure-specific nuclease, Artemis, 
cleans up DSB ends that aren’t flush or overlapping, and these polished broken ends are 
then covalently rejoined by a ligation complex, composed of LIGIV, XRCC4, and XLF 
(190, 204, 237).  
Recently, it has become apparent that there is a minor end-joining pathway present in 
higher eukaryotes that is generally only detectable in the absence of C-NHEJ.  It has 
interchangeably been referred to as MMEJ (micro-homology-mediated end joining), B-
NHEJ (backup-NHEJ) and A-NHEJ, but for the purposes of consistency, we will restrict 
ourselves to the use of just the latter name.  The first description of A-NHEJ came from 
an analysis of the chicken DT40 cell line (159).  In chicken cells (as well as in all 
mammalian cells) DSB repair is always biphasic, with fast (< 30’) and slow (4 to 24 hr) 
components.  When mutations were made in DT40 C-NHEJ genes, the fast component of 
DSB repair completely disappeared, but the slow component did not.  The authors went 
on to show that the slow component was not due to HR and thus they surmised that it 
must be some sort of novel end joining, aka A-NHEJ (159).  Confirmation of the 
existence of A-NHEJ came during an analysis of the 180BR cell line, a primary human 
fibroblast cell line containing inactivating mutations in LIGIV (244).  Interestingly, even 
without functional LIGIV, the ligase known to be essential for C-NHEJ, 180BR cell were 
still able to repair some DSBs (244); again implying the existence of an alternative end 
joining pathway. 
The mechanism of A-NHEJ was initially (and actually, for the large part still is) 
obscure.  It is presumed that some other end-binding factor besides Ku is required to bind 
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onto the ends and funnel the DSBs into the A-NHEJ pathway.  Then, because 
microhomology appears to be used at high frequency to mediate the repair event, some 
end resection (perhaps extensively so) is required.  Alignment activities to bring the 
microhomologies into register are probably needed, followed by the action of a flap-like 
nuclease to trim non-base paired regions and finally a ligation complex to covalently link 
the ends back together.  Because the pathway uses microhomology to mediate the repair 
event, deletions (perhaps extensive ones) always accompany the repair event as does loss 
of one of the blocks of microhomology (274, 375). 
With interest in A-NHEJ sparked, several laboratories made dedicated genetic and 
biochemical attempts to identify the factors associated with the pathway.  In particular, a 
brute force nuclear extract fractionation protocol identified LIGIII, heretofore known 
only for its role in BER (base excision repair), as the ligase required for A-NHEJ (194).  
Using guilt by association as a scientific rationale, PARP1 and XRCC1, two proteins 
known to interact with LIGIII during BER, were subsequently identified as also being 
involved in A-NHEJ (27, 376).  PARP1 is presumed to compete with Ku for binding to 
broken DNA ends thereby dictating pathway choice whereas XRCC1 appears to act as a 
chaperone or stability function for LIGIII (247, 248, 377).  Additional factors have also 
been implicated in A-NHEJ.  A recent report suggests that histone H1 may act as an 
alignment factor  — an important activity given the role of microhomology needed to 
mediate the repair event — during A-NHEJ (250).  CtIP and the MRN complex — 
factors known to be involved in the end resection events required for HR — have, not 
surprisingly, (given that most of the junctions repaired by A-NHEJ possess 5 to 25 nt of 
microhomology) also been implicated in the end resection steps of A-NHEJ (22, 43, 44, 
252). 
If the gene factors that are needed for A-NHEJ are still not completely defined and 
the A-NHEJ reaction mechanism is still somewhat nebulous, it is probably fair to say that 
the biological role(s) of A-NHEJ is even more poorly understood.  Interest in A-NHEJ 
was originally piqued, when it was demonstrated to provide a back-up mechanism for 
CSR (class switch recombination).  CSR is a lymphoid-restricted, quasi site-specific 
recombination that is required for the isotype switching of antibodies; a process needed 
for the primary antibody that can successfully engage other effector functions (4).  CSR, 
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like V(D)J recombination, was long considered to be an exclusively C-NHEJ-dependent 
process.  Later work, however, demonstrated that significant amounts of CSR could still 
be detected even when C-NHEJ had been ablated and this activity was then shown to be 
due to A-NHEJ (347-349).  Most of the current interest in A-NHEJ, however, stems from 
its implicated use in the chromosomal translocations that are present in cancer cells.  
Sequencing of human cancer genomes has shown that most of these chromosomal 
translocations have extensive microhomology at their breakpoint junctions, which 
strongly implicates A-NHEJ in their genesis (378-380).  This hypothesis has gained 
support from a recent report from the Jasin group, where LIGIII conditionally-null mice 
cells showed decreased translocation frequencies and reduced microhomology usage 
(269, 272).  Finally, our laboratory has demonstrated that a reduction in Ku70 levels 
increased the rAAV-mediated gene-targeting rate (276).  Surprisingly, however, the 
random rAAV integration rate did not change, which implied that these events may be 
mediated instead by A-NHEJ (276, 378). 
Unlike the HR and C-NHEJ pathways, which are evolutionarily conserved from 
bacteria to man, the LIGIII-dependent A-NHEJ pathway appears to have evolved quite 
recently and has only been detected in Xenopus laevis and mammals (190).  This makes 
the experimental analysis of A-NHEJ somewhat difficult since the commonly used model 
systems (e.g., yeast) are not directly relevant.  Additionally, some of the accepted A-
NHEJ factors are multifunctional and/or essential.  For example, PARP1 is known to 
interact with and PARylate proteins involved in DNA repair, transcription, DNA 
methylation, and the regulation of chromatin structure and histone modification to control 
physiological and pathological outcomes (381).  Similarly, MRN and CtIP are major 
components in the end processing required for HR and MRN complex at least also 
functions as a damage sensor and a signal transducer during DSB repair in general (43, 
49, 54, 84).  In addition, before it was recognized as a crucial A-NHEJ component, the 
LIGIII:XRCC1 complex had been studied extensively for its roles in single-strand break 
repair, short patch base excision repair and nucleotide excision repair (190, 247, 382).  
This multifunctionality certainly makes biochemical and genetic analyses difficult.  
Compounding this issue is that fact that functional inactivation of either LIGIII or 
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XRCC1 in the mouse results in early embryonic lethality (265, 266, 269).  Similarly, 
histone H1 is an essential component of general chromatin (383). 
Despite these daunting experimental hurdles, some features of the A-NHEJ pathway 
have slowly come into focus.  First, A-NHEJ-mediated repair events appear to require 5 
to 25 nt of microhomology, which is clearly distinguishable from HR or C-NHEJ, where 
either extensive (50 to hundreds of nt) homology or no homology are required, 
respectively.  Second, the repaired products always have associated deletions.  End 
resection is almost certainly required to find the microhomology near the break site, and 
once annealing and repair occur, the flap structures are likely degraded, resulting in 
deletions.  The third, and the most distinct feature, is A-NHEJ’s LIGIII-dependency.  
There are three ligases in mammals; LIGI, LIGIII, and LIGIV.  LIG1 is required for 
Okazaki fragment ligation during DNA replication, and LIGIV functions exclusively in 
C-NHEJ.  In contrast, and although experimental proof is still incomplete, LIGIII appears 
to be the only ligase utilized by the A-NHEJ pathway.  
Unlike other ligases, LIGIII is molecularly heterogeneous (261, 262).  Alternative 
splicing generates an ubiquitously expressed alpha form and a germ cell-specific beta 
form.  Only the mitotic alpha form has a C-terminal BRCT domain, which permits 
interaction with its binding partner, XRCC1 (245, 247, 263).  In addition to alternative 
splicing, alternative translation initiation generates mitochondrial and nuclear forms of 
LIGIII, which either contain or lack a MLS (mitochondria leading sequence), 
respectively (262).  This heterogeneity of LIGIII molecular isoforms implies diverse 
functional roles for LIGIII.  One experimental approach to unraveling the complexity of 
LIGIII is to generate a LIGIII-deficient model system.  This has already been 
accomplished in the mouse.  LIGIII-null mice were early embryonic lethal (266, 269).  
Recently, a LIGIII conditionally-null mouse was described that showed significant 
mitochondrial function deficits, but little in the way of DNA repair phenotypes (269).  In 
contrast, to date there have been neither human LIGIII patients nor LIGIII-deficient 
human cell systems described. 
In this study, we have conditionally inactivated the LIGIII gene in the HCT116 
human colorectal carcinoma cell line to generate an A-NHEJ-defective human model 
system.  Based on the previous mice studies, we anticipated that LIGIII would be an 
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essential gene due to its mitochondrial function (269, 271).  Indeed, we were able to 
confirm this hypothesis and demonstrate that the loss of LIGIII from human cells results 
in death due to mitochondrial dysfunction.  To investigate LIGIII’s nuclear A-NHEJ 
activity, we also constructed a cell line that does not express LIGIII in the nucleus but is 
kept alive by complementation with a mitochondrial-only form of LIGIII.  A nuclear 
LIGIII deficiency caused mild growth retardation, but disappointingly did not affect the 
overall repair activity nor sensitivity against DNA damaging agents of the cells.  Perhaps 
in keeping with this finding, we were also able to demonstrate that LIGIII-dependent A-
NHEJ does not mediate rAAV random gene integrations.  
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Materials and Methods 
Construction of LIGIII targeting vectors 
Conditional and regular knockout LIGIII targeting vectors were constructed utilizing the 
system described, with a few modifications (334).  For the conditional knockout vector, 
the left and right homology arms, the latter of which contained the loxP-flanked exon 4 
fragments, were generated by PCR.  The primer sets used to make these fragments were: 
Exon4_KpnF1/XhoR1 was used to generate the LoxP-flanked exon 4 fragment.  For the 
left homology arm, Exon4_LARM_F1 and LARM_SacR1 primers were used.  For the 
right homology arm, Exon4_RARM_XhoF1 and R1 primers were used.  The relevant 
homology arms and a neomycin-resistance gene cassette were assembled together as a 
fusion PCR product, which was then cloned into the pAAV-MCS vector.  A regular 
knockout targeting vector was generated in a similar way, but it did not include the loxP-
flanked exon 4 sequences.  To select for productively infected cells, the rAAV-infected 
cells were incubated in 1 mg/ml G418-containing media for approximately 2 weeks.  At 
this time, genomic DNA was purified from all G418-resistant clones and PCR was used 
to screen for the subset of those in which correct targeting had taken place.  Targeted 
clones were screened with Exon4_SC_F2 and NeoR2 primers, and retargeted clones were 
confirmed by LIG3_LArm_F3 and LIG3_RArm_R2 primers.  
 
Exon4_KpnF1: 
5’-CCGGTACCGTAGAGATGGGGTCTTTCTTTGTTGC-3’ 
Exon4_XhoR1:  
5’-CGCTCGAGATAACTTCGTATAATGTATGCTATACGAAGTTATCCA 
GGAGAGACAGAGGGGGCAAG-3’ *Bold Italic indicates the LoxP sequence 
Exon4_LARM_F1: 
5’-ACATAAGCGGCCGCAGAGCACTTTGGCATCTGTCTTC-3’ 
Exon4_LARM_SacR1: 
5’-GGCGGCCCGCGGAAAAAATTAAAAAATTAGCTGG-3’ 
Exon4_RARM_XhoF1: 
5’-CGCTCGAGGGCTTTTATTCTGGACTCTTTTTTTC-3’                 
Exon4_RARM_R1: 
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5’-ACATAAGCGGCCGCTGGAGTAGGCAAGAGACTCATAC-3’    
Exon4_SC_F2: 
5’-ATGAGCATCCTGAATAGGCCTTTCCTCCGG-3’ 
NeoR2: 
5’-AAAGCGCCTCCCCTACCCGGTAGGGCG-3’ 
LIG3_LArm_F3: 
5’-TGCCACCATGTCCAGCTAA-3’ 
LIG3_RArm_R2: 
5’-GAGTCCAGAATAAAAGCC-3’ 
 
LIGIII complementation 
To construct the mitochondrial-only LIGIII cDNA, the second and third ATGs in the 
ORF (open reading frame) of the LIGIII cDNA were mutated to ATC, to ensure that the 
nuclear form of LIGIII could not be expressed.  This mitochondrial-only LIGIII cDNA 
was cloned into the pcDNA3.1(+) vector with a C-terminal HA epitope tag.  For the 
nuclear-only LIGIII, the N-terminal ORF that encodes the MLS was deleted and a 
FLAG-epitope tag was added to the C-terminus.  This modified, nuclear-only LIGIII 
cDNA was cloned into a modified pcDNA3.1(+), where the standard neomycin-
resistance gene had been replaced with a puromycin-resistance gene.  Complementation 
constructs were linearized by PvuI (NEB) and transfected with Lipofectamine 2000 
(Invitrogen).  For selection, 1 mg/ml G418 and 2 µg/ml puromycin, respectively, were 
used. 
 
Immunoblotting  
Whole cell extracts were prepared with RIPA buffer and 30 µg of protein was 
electrophoresed on 4% to 20% SDS (sodium dodecyl sulfate)-polyacrylamide gel 
(BioRad) and rabbit, anti-human DNA LigIII antibody (GeneTex) was used at a 1:1000 
dilution.  Both the HA antibody (Covance) and FLAG antibody (Sigma) were also used 
at a 1:1000 dilution.  The actin antibody (SantaCruz), which was used for the loading 
controls, was diluted 1:250. 
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IHC (Immunohistochemistry) 
Cells were plated on multi-chamber slides (Thermo Fisher Scientific) a day before 
analysis and subsequently fixed with 4% (v/v) paraformaldehyde in PBS for 10 min.  
Slides were incubated in antigen retrieval buffer (100 mM Tris, 5% (v/v) urea, pH 9.5) at 
95°C for 10 min.  Permeabilization was done with 0.1% Triton X-100.  The LIGIII 
antibody (GeneTex) was used at a 1:1000 dilution and the Alexa Fluor 488 goat, anti-
mouse IgG antibody (Invitrogen) was used to visualize LIGIII.  DAPI (0.2 µg/ml) was 
used to stain the nucleus. 
 
Etoposide, MMS (methyl methane sulfonate) and CPT (camptothecin) sensitivity 
We performed an etoposide sensitivity assay as described with slight modifications (358).  
The cells were plated on a 6-well cell culture dish approximately 17 to 19 hr prior to drug 
treatment.  Etoposide was dissolved in DMSO (dimethyl sulfoxide) to give a 10 mM 
stock solution.  The cells were then incubated in etoposide-containing medium for 7 to 10 
days, fixed and stained with crystal violet.  For the MMS sensitivity test, cells were 
incubated in MMS-containing media for 1 hr and then maintained in drug-free media for 
7 to 10 days.  CPT was dissolved in DMSO to give a 10 mM stock solution.  Cells were 
incubated in CPT-containing media for 24 hr and then switched to drug-free media for 7 
to 10 days, or until visible colonies (> 50 cells) had formed. 
 
DNA end joining assay 
A DNA end joining assay was performed as described (23).  Cells were subcultured into 
6-well cell culture dishes a day before transfection.   pDVG94 plasmid (2.5 µg) digested 
with EcoRV (NEB) and AfeI (NEB) was transfected using Lipofectamine 2000 
(Invitrogen).  Plasmid DNA was recovered using a modified Qiagen mini-preparation 
protocol at 48 hr after transfection.  Repaired DNA junctions were PCR amplified using 
FM30 and 5’-radiolabeled DAR5 primers.  PCR products were then digested with BstXI 
(NEB).  Digested PCR products were separated by electrophorese on a 6% TBE 
polyacrylamide gel.  The gel was then dried and exposed to film. 
 
DAR5 (28-mer forward primer): 
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5’-TGCTTCCGGCTCGTATGTTGGTTGGAAT-3’ 
FM30 (26-mer reverse primer): 
5’-CTCCATTTTAGCTTCCTTAGCTCCTG-3’ 
 
rAAV gene targeting 
pAAV-HPRT-Puro, pAAV-helper, and pAAV-RC vectors were transfected into 70% 
confluent AAV-293 cells in 10 cm cell culture dishes and infectious rAAV-HPRT-Puro 
virus was harvested 3 days later by freeze/thawing (334).  The virus was subsequently 
purified using a rAAV virus purification kit (VIRAPUR) and the viral titer was 
quantitated by qPCR.  A day before infection, cells were split into 2 X 105 cells/well in 6-
well cell culture dishes in duplicate.  Before adding virus, the exact number of cells was 
determined by counting one of the duplicate wells, and then virus at a MOI of 1 X 104 
was added to the other well.  2 days after infection, 1% of the cells were plated into a 10 
cm culture dish without any drug selection and used to determine plating efficiency.  The 
remaining cells were plated into 10 cm culture dishes with 2 µg/ml puromycin.  This 
media was replaced 5 days later with puromycin-containing media supplemented with 5 
µg/ml of 6-thioguanine (6TG) except for one plate, which was used to quantitate the 
random integration frequency (i.e., those clones that were just G418 positive).  When the 
cells had formed visible colonies (> 50 cells) at approximately 10 to 14 days later, the 
plates were fixed and stained with crystal violet.  
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Results 
Generation of LIG3-conditional null HCT116 cell line 
To generate a HCT116 cell line that is conditionally-null for LIGIII expression, an 
rAAV gene-targeting methodology was adopted (334), similar to the targeting strategy 
that had been successfully used to generate a Ku86 conditionally-null HCT116 cell line 
(117).  The conditional targeting vector contained three LoxP sites flanking the 
neomycin-resistant gene (NEO) and exon 4 of LIGIII, respectively (Fig. 1A).  Eight 
correctly targeted first round clones (LIGIIINEO/+; Fig. 1B) from 210 G418-resistant 
clones were identified (relative gene targeting: 3.8%).  One of these clones was 
transiently treated with pGK-Cre to remove the NEO selection cassette (Fig. 1C).  The 
resulting LIG3flox/+ cell line was subjected to a second round of gene targeting using a 
regular knockout vector, where exon 4 was designed to be replaced by the NEO gene 
(Fig. 1C).  Ten second round, correctly-targeted cell lines were identified from 711 
G418-resistant clones (relative gene targeting: 1.4%).  Additional analysis (data not 
shown) demonstrated that 9 of the clones were re-targeted (and therefore biologically 
uninteresting) whereas one clone was correctly targeted to the second allele (i.e., 
LIGIIIflox/NEO; Fig. 1D), which was subsequently infected with an AdCre virus to remove 
the NEO gene.  The resulting LIG3flox/- cell line (Fig. 1E) was viable and when needed, 
Cre recombinase could be re-introduced to generate LIG3-/- cells (Fig. 1F). 
PCR analyses were used to molecularly confirm the genetic designation of the cell 
lines.  A 670 bp PCR product represents the wild-type LIGIII exon 4 whereas a 746 bp 
product should be generated when the floxed (flanked by two loxP sites) exon 4 DNA is 
used as a substrate.  As expected, PCR of the parental wild-type LIGIII+/+ cell line 
generated only the 670 bp band, whereas PCR of the LIG3flox/+ cell line produced both 
the wild type (670 bp) and the floxed allele (746 bp) bands (Fig. 2A).  In contrast, LIGIII 
conditionally null cell lines — with or without the NEO gene cassette — generated only 
the 746 bp PCR product corresponding to the floxed allele (Fig. 2A). 
To assess the conditionality of the cell lines, LIGIII+/+ and LIGIIIflox/- cells were 
infected with increasing amount of AdCre virus, and 5 days later genomic DNA was 
purified and analyzed by PCR (Fig. 2B) and whole cell extracts were prepared and 
analyzed by immunoblotting (Fig. 2C).  As the amount of Cre recombinase increased, the 
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PCR signal from the genomic floxed allele (764 bp) decreased until the signal was 
undetectable (Fig. 2B).  Similarly, at the protein level, the increasing presence of Cre 
completely ablated detectable LIGIII protein expression (Fig. 2C).  In stark contrast, Cre 
expression in the parental wild-type LIGIII+/+ cells had no effect on formation of the exon 
4-derived PCR product (670 bp) (Fig 2B) nor was any effect on LIGIII protein expression 
(Fig. 2C).  From these experiments, we concluded that we had successfully constructed a 
LIG3flox/- (i.e., conditionally null) cell line. 
 
The mitochondrial form of LIGIII is essential for human somatic cell viability 
To assess the essential nature of LIGIII, we initially infected the LIGIIIflox/NEO cell 
line with AdCre and then isolated 22 individual G418-sensitive colonies by limiting 
dilution.  Theoretically, two possible cell lines could have been recovered: LIGIIIflox/-, 
and LIGIII-/-.  Interestingly, all 22 recovered clones had a LIGIIIflox/- genotype and none 
were LIGIII-/-.  This extreme asymmetry in the recovery of Cre-treated survivors 
suggested emphatically that the LIGIII-/- cell line was not viable (data not shown). 
Because the mitochondrial form of LIGIII is essential in mice (269, 271), we tested 
whether this activity was conserved in human LIGIII.  To this end, we complemented the 
LIGIIIflox/- cells with a modified LIGIII cDNA that could be expressed only in the 
mitochondria (mL3), and generated a stable LIGflox/-:mL3 cell line.  The mL3 expression 
construct was made by mutating the second and third LIGIII ATGs to ATCs (Fig. 3A).  
The nuclear form of LIGIII is normally translated from the second ATG, and without the 
second ATG only the longer mitochondrial-specific version of the protein should be 
made (262).  We mutated the third ATG simply as a precaution to ensure that no N-
terminally truncated nuclear protein could be expressed.  Importantly, after infecting 
LIG3flox/-:mL3 cells with AdCre virus, we isolated by limiting dilution single cell clones, 
and 25 out of 43 of the isolated clones were genotypically LIG3-null (LIG3-/-:mL3) cells — 
a result that was opposite of what we had obtained when we tried to establish LIGIII-null 
cells in the absence of mL3 expression (described above).  A mitochondrial exclusive 
expression pattern of mL3 was verified by IHC (immuno-histochemistry).  Cells were 
first incubated with a primary antibody directed against LIGIII and then a green-
fluorescent secondary antibody was used for visualization.  DAPI staining was used to 
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visualize the nuclei.  In the parental wild-type HCT116 LIGIII+/+ cells, LIGIII protein 
was expressed ubiquitously (Fig. 3B).  In LIG3-/-:mL3 cells, however, fluorescent signal 
was detected exclusively in the cytoplasm (Fig. 3B).  From these experiments we 
concluded that it is solely the mitochondrial form of LIGIII that is essential for human 
somatic cell viability whereas the nuclear form of LIGIII is apparently dispensable for 
survival. 
 
Complementation of LIGIII-/-:mL3 with a nuclear LIGIII cDNA 
With a viable LIGIII-null cell line in hand (i.e., LIG3-/-:mL3 cells) we were equipped to 
investigate the phenotypes resulting from the loss of nuclear LIGIII expression.  Before 
beginning these analyses, however, we augmented our reagents with a derivative cell line 
that re-expressed a nuclear-specific LIGIII cDNA.  This expression construct was 
generated by deleting the N-terminal MLS coding sequence from the wild-type cDNA 
and by adding a C-terminal FLAG epitope-tag to generate the nuclear-only LIGIII 
cDNA, nL3 (Fig. 3A). We used this construct to isolate a stable LIG3-/-:mL3:nL3 cell line 
that exhibited a strong LIGIII IHC signal from the nucleus in addition to pan-cytoplasmic 
staining (Fig. 3B). 
 
A LIGIII deficiency causes a growth defect 
The growth rate of LIGIII-deficient cells was determined.  Three thousand cells were 
seeded on day 0 into each well of a 6-well tissue culture dish and the number of cells in 
each well were counted on days 4 to 8 (Fig. 4).  LIGIIIflox/- cells showed a slight 
haploinsufficiency for growth, which was exacerbated in the LIG3-/-:mL3 cell line.  From 
these experiments we concluded that the absence of nuclear LIGIII expression results in 
proliferation defects.  
 
LIGIII-null cells are not sensitive to DNA damaging agents 
Given that LIGIII has been implicated in both (single-strand break) and DSB repair 
pathways (191, 194), we used colony-forming assays to examine the sensitivity of 
LIGIII-null cells to a variety of DNA damaging agents.  Etoposide is a topoisomerase II 
inhibitor and a powerful radiomimetic that induces DNA DSBs (365). As a positive 
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control, a LIGIV-/- cell line (Chapter 2) was included.  As expected, LIGIV-/- cells were 
exquisitely sensitive to etoposide, even at the lowest concentration (Fig. 5A).  In contrast, 
LIG3flox/-, LIG3-/-:mL3 and LIG3-/-:mL3:nL3 did not show any increased sensitivity to 
etoposide compared to the wild-type parental cells (Fig. 5A).  Similarly, the LIGIII-
deficient cell lines were not hypersensitive to MMS (methyl methanesulfonate) (Fig. 5B) 
nor CPT (camptothecin) (Fig. 5C).  MMS is an alkylating agent that induces SSBs and at 
high doses can cause DSBs (384).  CPT is a topoisomerase I inhibitor that can cause 
DNA SSBs, DSBs and replication fork stalling.  In conclusion, and somewhat 
surprisingly, the absence of LIGIII (and presumably the A-NHEJ DSB repair pathway) 
did not result in a frank hypersensitivity to DNA damage agents. 
 
The absence of LIGIII does not affect the overall DNA end joining activity of human 
cells 
The DNA end-joining activity of LIGIII-null cells was measured using an extra-
chromosomal reporter assay system: the pEGFP-Pem1-Ad2 construct (27, 194, 254, 343).  
In this assay, end joining is measured by the reconstitution of GFP expression (Fig. 6). 
The reporter plasmid consists of the GFP gene, which is interrupted by a 2.4 kb intron 
derived from the rat Pem1 gene.  An exon (Ad2) derived from adenovirus serotype 2 has 
been introduced into the middle of the intron and is flanked by HindIII and I-SceI 
restriction enzyme recognition sites (Fig. 6A).  Without modification, the GFP gene is not 
expressed because the Ad2 exon is incorporated into GFP mRNA (Fig. 6C).  Pre-
digestion of the plasmid with HindIII- or I-SceI removes the Ad2 exon and generates a 
linear plasmid with compatible (i.e., ends that can be joined by simple ligation) or 
incompatible (i.e., ends that require some sort of processing before they are rejoined) 
ends, respectively (Fig. 6B).  Productive end joining of the linear plasmid after it is 
transfected into the experimental cell line can be quantitated using FACS (fluorescent 
activated cell sorting) analysis of GFP expression (Fig. 6C).  Un-digested or partially 
digested plasmids normally retain the Ad2 exon and therefore cannot express functional 
GFP protein. 
When the pEGFP-Pem1-Ad2 plasmid was transfected into the parental wild-type cell 
line approximately 35% of the DNA was productively end joined regardless of whether it 
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had been digested by either HindIII- or I-SceI-digested (Fig. 6D).  As expected, LIGIV-
null cells were profoundly impaired in this DNA end-joining activity and showed only a 
few percent of activity in comparison to wild type.  This observation confirms that LIGIV 
(and presumably C-NHEJ) is required for most of the end-joining activity detectable in 
human somatic cells (254).  In contrast, LIGIIIflox/- and LIGIII-/-:mL3 cell lines had DNA 
end-joining activities similar to wild-type cells (Fig. 6D).  Thus, partial or complete 
deficiencies in LIGIII do not appear to affect the overall DNA end joining activity of 
human somatic cells. 
 
Microhomology-mediated end joining is still detectable in human somatic cells 
lacking LIGIII expression  
To extend these observations, we next attempted to specifically quantitate 
microhomology-mediated end-joining.  To this end, a reporter substrate, pDVG94, that is 
biased towards detecting microhomology-mediated end-joining events (23, 254, 385) was 
used in vivo to measure the end-joining activity of LIGIII-deficient cells.  EcoRV and 
AfeI digestion of pDVG94 generates a blunt-ended, linear, double-stranded substrate with 
6 bp direct repeats at both ends (Fig. 7A).  Repair of this substrate by C-NHEJ generally 
generates a product that retains at least some of either repeat, whereas microhomology-
mediated end-joining (A-NHEJ) produces a unique product that contains only a single 
repeat, and which now forms the recognition sequence for the BstXI restriction enzyme.  
The linearized pDVG94 plasmid was introduced into the relevant cell lines and then 24 hr 
later the DNA was recovered from the cells and repaired junctions were amplified by 
PCR with radiolabeled primers (Fig. 7A).  The resulting ~180 bp PCR products were then 
digested with BstXI and subjected to agarose gel electrophoresis.  BstXI-resistant DNA 
corresponds to C-NHEJ-mediated repair events whereas a 120 bp product is diagnostic of 
A-NHEJ/microhomology-mediated end-joining (23, 254, 385).  As expected, and as has 
been previously reported (254), wild-type cells generated predominately the 180 bp 
product, consistent with most of the end-joining in human somatic cells resulting from C-
NHEJ.  Similarly, and again as expected (Chapter 2), a LIGIV-null cell line showed 
highly elevated levels of the 120 bp product indicative of a reliance on A-NHEJ.  
Surprisingly, in either LIGIIIflox/- or two independent LIGIII-/-:mL3 cell lines the amount of 
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the 120 bp product was unchanged in comparison to wild-type cells (Fig. 7B) indicating 
that LIGIII-deficient cells are still able to carry out microhomology-mediated end-
joining. 
 
A LIGIII deficiency does not affect the overall rAAV gene-targeting rate 
AAV infections in humans result in no known pathogenesis and this feature (amongst 
others) has made rAAV gene targeting technology one of the more promising candidates 
for therapeutic use (327, 329, 331).  Nonetheless, random viral integration events are 
clearly not desired and thus increasing the correct gene targeting frequency is one of the 
most sought-after advances for rAAV-mediated gene targeting technology.  Previous 
studies from our laboratory had indicated that neither HR nor C-NHEJ were likely 
responsible for rAAV random integrations (276).  In addition, sequencing results from 
other laboratories had indicated that many, if not all, rAAV random integration events 
were mediated by microhomology usage.  Together, these observations led to the 
hypothesis that rAAV random integrations are mediated by A-NHEJ, and that perhaps by 
disrupting A-NHEJ (e.g., by functionally inactivating LIGIII) the correct rAAV-mediated 
gene-targeting rate could be improved.  
To experimentally test this hypothesis, we performed gene targeting in a LIGIII-null 
cell line at the HPRT (hypoxanthine phosphoribosyltransferase) locus using an rAAV 
gene targeting vector designed to disrupt exon 3 of HPRT.  HPRT is an X-chromosome 
linked gene and the enzyme encoded by HPRT plays a central role in the generation of 
purine nucleotides through the purine salvage pathway (386).  Cells expressing a wild-
type HPRT gene are poisoned by the toxic nucleoside analog 6-TG (6-thioguanine), 
whereas cells with a defective HPRT gene can survive in the presence of 6-TG.  Because 
HCT116 was derived from a male patient, it contains only a single X-chromosome and 
therefore after only a single round of gene targeting, 6-TG selection could be used to 
isolate the correctly targeted clones.  Interestingly, LIGIII-null cells showed a 2-fold 
increase in the frequency of correct targeting (Fig. 8B).  Unexpectedly (and 
unfortunately) the frequency of random integration events was not reduced in LIGIII-null 
cells, but was actually enhanced (Fig. 8A).  Overall, there was no statistical difference in 
the targeting rate between wild-type and LIGIII-null cell lines (Fig. 8C).  These data 
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demonstrate that while LIGIII is a general suppressor of rAAV integrations, it does not 
preferentially affect random versus correct targeting events. 
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Discussion 
LIGIII has an essential mitochondrial function 
In this study we generated a viable human somatic cell line that lacks the expression 
of nuclear LIGIII.  Somewhat paradoxically, we nonetheless conclude that LIGIII is an 
essential gene.  This conclusion is based on the presumed requirement for isoforms of 
LIGIII in mitochondrial maintenance.  Thus, no live null cells could be isolated after an 
AdCre infection of the LIGIIIflox/NEO cell line.  In contrast, after complementing the 
LIG3flox/- cell line with a LIGIII cDNA that encoded a mitochondrial-specific isoform of 
LIGIII (mL3), we easily isolated LIGIII-null (LIGIII-/-:mL3) cells.  Therefore, we conclude 
that in human somatic cells, LIGIII is dispensable in the nucleus but essential in 
mitochondria.  This conclusion is consistent with a recent report describing a similar 
conditionally-null knockout strategy of LIGIII in the mouse (269). 
What the essential activity of LIGIII in the mitochondria may be, is currently unclear.  
One obvious function would be a requirement for LIGIII in Okazaki fragment maturation 
during mitochondrial DNA replication.  LIGI mediates Okazaki fragment maturation in 
the nucleus (192, 387, 388), but since LIGI lacks a MLS and it is not detected in 
mitochondria, it is clear that some other ligase must perform this function in 
mitochondria.  Similarly, since LIGIV also lacks a MLS, is non-essential (Chapter 2) and 
appears to be involved exclusively in C-NHEJ it is also a poor candidate.  In contrast, the 
mitochondrial-specific isoform of LIGIII should be able to mediate the ligation of 
Okazkai fragments, which are very similar to the intermediates that LIGIII is known to 
ligate together during BER (247, 389).  Curiously, there does not appear to be a specific 
requirement for LIGIII in the mitochondria — i.e., its essential nature is due perforce to 
the fact that it is the only ligase expressed in the mitochondria.  In a very revealing 
experiment, a chimeric expression construct consisting of the MLS of LIGIII fused to the 
coding region of LIGI functionally rescued the mitochondrial defects of LIGIII-null mice 
(269).  Thus, while there is a requirement for ligase activity in the mitochondria of 
mammals, there does not appear to be a requirement for a specific ligase. 
Other explanations are also possible.  Thus, for example, mitochondria are the sites of 
oxidative phosphorylation and this process generates a lot of ROS (reactive oxygen 
species) and/or free radicals (390, 391).  ROS, in turn, are very potent generators of DNA 
	   91	  
DSBs (392, 393), which, if they accrued to a high enough level, would certainly have 
deleterious consequences on the mtDNA (mitochondrial DNA) in terms of gene 
expression and DNA replication.  It is therefore fairly easy to envision that a dedicated 
DSB repair system must be in place to keep mtDNA intact.  Again, it is unclear whether 
LIGIII would assume this role by default since it is the only ligase localized to 
mitochondria and/or whether ROS-induced damage generates structures that can only be 
ligated by LIGIII.  
 
rAAV random integrations are not mediated by LIGIII/A-NHEJ 
The mechanism of gene targeting is intimately linked to DNA DSB repair pathways.  
Correct targeting events require HR and the random integrations of the targeting vector 
are presumably facilitated by DNA DSB end-joining pathways (i.e., C-NHEJ, A-NHEJ or 
both).  In published work from our laboratory, reductions in Ku did not significantly 
impact the frequency of random integrations of rAAV vectors when they were used for 
gene targeting (276).  Similar observations have been made for LIGIV- (chapter 2), XLF- 
(F. Fattah et al., manuscript in preparation) and XRCC4- (B. Ruis and E. A. Hendrickson, 
unpublished data) deficient cells suggesting very strongly that C-NHEJ is not required for 
this process.  Thus, we anticipated that impairing the A-NHEJ DSB repair pathway 
should greatly reduce rAAV random integrations and increase the overall gene targeting 
rate.  Surprisingly, no such effect was observed (Fig. 8B) and in fact, the random rAAV 
integration frequency was actually somewhat elevated, demonstrating that A-NHEJ is 
normally a suppressor of these events.  This result is perplexing.  One possibility is that 
there is genetic redundancy such that in C-NHEJ-defective cell lines, random integration 
events are carried out by A-NHEJ and in A-NHEJ-defective cells they are carried out by 
C-NHEJ.  We are currently trying to construct a LIGIII-:LIGIV-doubly-null cell line (i.e., 
defective for both A- and C-NHEJ pathways, respectively) to experimentally address this 
possibility (although see below for issues related to this construction).  A potentially 
more interesting possibility is if there exists yet another — hitherto — unidentified end-
joining pathway.  This hypothesis is actually supported by our results analyzing the DNA 
repair capacity of LIGIII-null cells (see below).  If this model is correct than the LIGIII-
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:LIGIV-doubly-null cell line (assuming it is viable) may still be proficient for random 
rAAV integration events. 
Finally, it is worth noting that previous work has shown that defects in any of the C-
NHEJ genes do not improve the frequency of rAAV-mediated correct targeting events.  
The only exceptions to this are cells defective in either Ku subunit, where significantly 
elevated levels of rAAV-mediated gene targeting occur (276).  These experimental 
results have been interpreted to mean that Ku is the master regulator of DSB repair 
pathway choice and can essentially determine the ultimate chromosomal location of an 
incoming piece of dsDNA.  This model would predict that the status of LIGIII is 
irrelevant to this process.  In contrast, we observed that the correct gene targeting 
frequency mediated by rAAV was elevated ~3-fold in LIGIII-null cells (Fig. 8A).  This 
increase in gene targeting is not nearly as large as that seen in Ku-defective cells (276, 
277, 369), which would be consistent with Ku being the major regulator of the gene 
targeting process.  Nonetheless, this increase also suggests strongly that Ku can’t be the 
sole regulator and it warrants more investigation into how LIGIII mechanistically impacts 
this process. 
 
The existence of a LIGIII-independent MMEJ pathway 
We utilized a reporter construct, pDVG94, to measure MMEJ activity (Fig. 7).  In 
order to generate a 120 bp BstXI-dependent restriction product from this plasmid a unique 
repair event is required: both ends of the blunt-ended plasmid must be resected and 6 nt 
long complementary strands must be precisely annealed and ligated without the loss or 
addition of a single nucleotide (Fig. 7A).  This repair product can be detected only at very 
low levels (a few percent of the total) in wild-type cells (Fig. 7B) and has been widely 
interpreted as being produced by A-NHEJ (23, 254).  When cells are mutated genes 
required for C-NHEJ, this 120 bp fragment becomes virtually the sole repair product 
(Fig. 7B; Chapter 2; (254)).  All of these observations led to the prediction that the 
ablation of A-NHEJ should block the formation of this repair product.  Our data show 
unequivocally that this does not happen.  Thus, the appearance of the 120 bp product was 
completely unaffected (and perhaps even slightly elevated) by the absence of nuclear 
LIGIII (Fig. 7B).  This was, once again, an unexpected and perplexing result.  One 
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possibility is that our cell line is leaky and does in fact still express some LIGIII in the 
nucleus.  While we cannot rule out this possibility, we do not believe that this is a likely 
explanation.  First, we mutated not only the normally-used ATG for the nuclear form of 
LIGIII, but a downstream ATG as well to ensure that not even truncated forms of the 
protein would be expressed (Fig. 3A).  In addition, the mitochondrial-exclusive 
expression pattern of the LIGIIImL3 construct was confirmed by IHC (Fig. 3B).  Finally, it 
is hard to reconcile the slow growth phenotype of LIGIII-null cells (Fig. 4) with the 
possibility that enough LIGIIImL3 was expressed to enable A-NHEJ.  Still it should be 
pointed out that if LIGIIImL3 protein did leak into nucleus, even at undetectable levels, 
this could likely have had functional relevance since it has been demonstrated that even 
low levels of LIGIII are sufficient for effective A-NHEJ (394).  Finally, it should be 
noted that this explanation is also relevant to the lack of an effect that was observed by 
the loss-of-function of LIGIII on gene targeting described earlier. 
An alternative attractive possibility is that there is another end-joining pathway, 
discrete from C-NHEJ and A-NHEJ.  This hypothesis, which we elaborated above as a 
possible explanation for the absence of an anticipated effect on gene targeting, would 
explain the continued production of the 120 bp product even in the absence of LIGIII 
(Fig. 7B).  A more complicated explanation could be if the C-NHEJ and A-NHEJ 
pathways mechanistically overlap.  Thus, these results could be explained if the C-NHEJ 
pathway has the capacity to produce low levels of the 120 bp product irrespective of A-
NHEJ.  This model predicts that A-NHEJ is essentially inactive in the presence of 
functional C-NHEJ — as has indeed been argued by numerous investigators (23-25, 27, 
159, 244, 249, 347, 395).  In this scenario, the inactivation of LIGIII would have no 
effect on the production of the low levels of the 120 bp product as long as C-NHEJ is 
active; a result that is consistent with our data (Fig. 7B).  Again, one genetic approach to 
answering this question would be to try and construct a LIGIII-:LIGIV-doubly mutant 
cell line and measure the residual end-joining activity. 
 
A deficiency in both C-NHEJ and A-NHEJ induces synthetic lethality 
One of the reasons that made it hard to identify any A-NHEJ defects in our LIGIII-
null cells was because the majority of repair events were mediated by C-NHEJ.  As noted 
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above, we have begun genetic experiments to try and address these issues.  These 
complicated doubly mutant genetic experiments, do require, however, a lot of time.  In an 
attempt to obtain a more expeditious, albeit less rigorous, answer we tried to suppress C-
NHEJ by transient siRNA knockdowns.  Specifically, we knocked-down the expression 
of DNA-PK complex subunits in the LIGIII-null background.  Unfortunately, however, 
knockdown of either Ku70 or DNA-PKcs in LIGIII-null cells induced a serious 
proliferation defect that was ultimately accompanied by high levels of apoptotic cells 
(data not shown).  The high cell mortality made it technically impossible to characterize 
the cells any further.  Importantly, the efficient knockdown of Ku70 to a level that was 
less than 5% of wild-type (254, 276), and the complete ablation of DNA-PKcs expression 
by targeted knockout (363) did not by themselves cause significant apoptosis in contrast 
to what was observed in the LIGIII-null background.  Although preliminary, these 
experiments at least suggest that the deficiency of both C-NHEJ and A-NHEJ in human 
somatic cells may not be tolerated.  Future genetic experiments are directed at addressing 
this issue. 
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Figure 1. Targeting strategy and primer sets used for the screening. (A) A cartoon of part 
of the LIGIII genomic locus. The rectangles represent exons and lines in between are 
introns. The conditional knockout vector has three loxP sites (triangle) that flanks a NEO 
cassette and exon 4. (B) G418-resistant clones were selected and among them, correctly 
targeted clones were identified by PCR. LIGIIINEO/+ clones were treated with pGK-Cre to 
remove the NEO gene prior to the second round of targeting. (C) A G418-sensitive 
LIGIIIflox/+ clone was targeted with an exon 4 knockout vector. (D) A correctly targeted 
clone, LIGIIIflox/NEO, was treated with AdCre to derive a G418-sensitive LIGIIIflox/- clone, 
depicted in (E). (F) AdCre treatment of LIGIIIflox/- clone results in LIGIII-/- cells, which 
were used for characterization.   
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Figure 2. AdCre infection removes both LIGIII DNA and protein in LIGIIIflox/- cell. (A) 
PCR test of LIGIIIflox/- cell. We used the primer set that gives different sized PCR 
products from loxP-floxed allele (746 bp) and wild-type allele (670 bp). With the same 
primer set, NEO gene will give over 3 kb band and loxP-only allele will give smaller than 
200 bp product, but they are not shown in this figure. (B) LoxP-floxed allele was 
disappeared after AdCre infection. With increasing amount of AdCre virus, 746 bp of 
loxP-floxed allele is gone in LIGIIIflox/- clone. (C) Western blot shows the loss of LIGIII 
protein. Protein samples were parallel to the DNA samples in (B). Increasing amount of 
AdCre virus is correlated with decreasing amount of LIGIII protein.  
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Figure 2 (B) PCR characterization of the DNA LIGIII conditional null clone after AdCre infection 
Figure 2 (C) Western blot analysis of the DNA LIGIII conditional null clone after AdCre infection 
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Figure 3. Complementation with mitochondria-only LIGIII cDNA rescues the lethality 
of LIGIII-/- cells. (A) Constructs used for complementation. To make a mitochondrial-
only LIGIII (mL3), the second and third ATGs were mutated to ATC. For the nuclear-
only LIGIII (nL3) construction, the N-terminal MLS sequence was deleted. mL3 and nL3 
were modified with C-terminal HA- and FLAG- epitope tags, respectively.  (B) Nuclear 
and mitochondrial localization of LIGIII complemented clones. In wild-type HCT116, 
LIGIII is expressed ubiquitously. In contrast, LIGIII-/-:mL3 cells showed a mitochondrial-
exclusive expression pattern. In LIGIII-/-:mL3:nL3 cells, mL3 is detected in the cytoplasm 
and nL3 is over-expressed in the nucleus.   
 
 
 
 
 
 
 
 
 
 
 
 
 
	   100	  
 
 
 
 
 
 
 
 
 
Figure 3. Complementation with a mitochondrial-exclusive form of LIGIII rescues the cell lethality
ATG ATC ATC
HA
ATG
FLAG
ATG
nL3-FLAG
A.
mL3-HA MLS
B.
LIGIII DAPI Merge
wtHCT116
LIGIII-/-:mL3
LIGIII-/-:mL3:nL3
	   101	  
Figure 4. Growth defects of human somatic cells with reduced or no LIGIII. Three 
thousand cells were plated on day 0 and their growth was assessed by counting trypan 
blue excluding cells at the indicated days. The average of two independent experiments, 
each done in triplicate, is shown.    
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Figure 4.  LIGIII deficiency causes growth retardation
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Figure 5. LIGIII deficient cells are not sensitive to DNA damaging agents. (A) Etoposide 
sensitivity test. Three hundred cells were plated a day before etoposide treatment. Clone 
#35 is LIGIII-/-:mL3 cell, and clone #34 is LIGIII-/-:mL3:nL3 cell. Survival was normalized by 
setting the value from no etoposide treatment as 1. As a positive control, a LIGIV-/- cell 
line, which is known to be extremely sensitive to etoposide, was used. The plotted values 
are the average of three independent experiments. (B and C) MMS and CPT sensitivity 
tests, respectively, were performed in a similar way to the etoposide sensitivity test, 
except for the drug-treatment time: cells were incubated in MMS-containing media for 1 
hr, and CPT-containing media for 24 hr. 
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Figure 6. A LIGIII deficiency does not affect end-joining activity. (A) A cartoon of the 
pEGFP-Pem1-Ad2 repair substrate used for analysis of NHEJ activity. Expression of the 
GFP cassette is driven by the CMV promoter and terminated by the SV40 polyA 
sequence. The GFP coding sequence is interrupted by a 2.4 kb intron containing an 
adenovirus exon (Ad), which is flanked by HindIII and I-SceI restriction enzyme 
recognition sites. Splice donor (SD) and splice acceptor (SA) sites are shown. (B) HindIII 
digestion generates compatible ends with 4 nt overhangs, whereas I-SceI digestion 
produces ends, that require some processing before they can be rejoined. (C) Due to the 
presence of the Ad-exon into the middle of the Pem1 intron, the Ad exon is efficiently 
spliced into the middle of the GFP ORF, inactivating the GFP activity and thus making 
the starting substrate GFP negative. Both sides of the Ad exon have HindIII/I-SceI 
restriction sites. Cleavage with either of these endonucleases removes the Ad exon and 
upon successful intracellular plasmid circularization GFP expression is restored and can 
be quantitated by flow cytometry. (D) The impact of LIGIII deficiency on end joining. 
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Figure 6. A LIGIII deficiency has no effect on the overall DNA end-joining ability of human somatic cells
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Figure 7. LIGIII-null cells have normal microhomology-mediated end-joining activity. 
(A) After EcoRV and AfeI restriction enzyme digestion, the reporter substrate, pDVG94, 
becomes a blunt-ended linear plasmid with 6 bp direct repeats at both ends. Repair via C-
NHEJ generally retains at least part of either repeats, whereas A-NHEJ generates only a 
single repeat and a novel restriction enzyme site which can be cleaved by BstXI. Repaired 
junctions were amplified by PCR using radiolabeled primers and the 180 bp PCR product 
was subjected to BstXI digestion. The 180 bp uncut product represents repair via C-NHEJ 
whereas the 120 bp digested product represents A-NHEJ mediated repair. (B) Both 
LIGIII-het and LIGIII-null cells have similar microhomology end-joining activity to the 
wild-type control.  
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Figure 8. A LIGIII deficiency does not affect the rAAV-mediated gene targeting rate at 
the HPRT locus. (A) rAAV random integration frequency. The random integration 
frequency was determined as the number of Puro-resistant clones normalized by plating 
efficiency. (B) rAAV gene targeting frequency. The gene targeting frequency was 
determined as the number of both Puro- and 6TG-resistant clones normalized by plating 
efficiency. (C) The rAAV gene targeting rate represents the ratio of the correct targeting 
events versus the total viral integration events. LIGIII-null cells show both higher random 
integration and gene targeting frequencies, but overall, the LIGIII-null cells did not show 
any difference in gene targeting rate compared to wild-type cell.  
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Figure 8. A LIGIII deficiency has no effect on the overall rAAV gene targeting rate
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CHAPTER IV 
 
 
A deficiency in Rad54B rescues the telomere defects and 
leads to the prolonged survival of Ku86-null cells 
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All eukaryotes maintain their DNA in the form of linear chromosomes.  Linear 
chromosomes — or more precisely, the ends of linear chromosomes — however, have 
attendant problems including issues about how they are replicated and how they can be 
distinguished from interchromosomal DSBs (double-strand breaks).  To solve these 
problems, all eukaryotic cells have evolved a repetitive DNA structure, termed a 
“telomere” that resides at the ends of each chromosome.  In human cells, a telomere 
consists of 4 to 14 kb of a hexameric (TTAGGG)n repeat that ends with 200 to 300 nt of a 
3’-G-rich, single-stranded overhang.  This overhang can invade the neighboring duplex 
telomeric DNA to form a lariat-like, D-loop structure that is referred to as a t-loop.  A set 
of dedicated telomere-specific binding proteins — collectively called “shelterin” — bind 
to the t-loop.  The combination of the unusual structure and the proteinaceous cap formed 
by shelterin appear to protect the ends of chromsomes from random nuclease activity and 
from recognition by DNA DSB repair machineries.  Because one of the main roles of 
telomeres is to sequester chromosomal ends away from DNA DSB repair factors it came 
as a large surprise when several damage signaling and DNA repair proteins were shown 
not only to be physically associated with telomeres, but to be required for their proper 
maintenance.  Among these, Ku86 was one of the most unexpected components, because 
it is the essential DNA end-binding factor for C-NHEJ (classic non-homologous end 
joining), the main DNA DSB repair pathway.  Nonetheless, the loss-of-function of Ku86 
results in cell lethality not because of a defect in C-NHEJ (although that certainly 
happens) but due to the telomere defects, including telomere loss, sister chromatid 
fusions, and the loss of the t-loop in the form of a circle (i.e., “t-circle” formation).  The 
formation of t-circles has been experimentally observed in several other situations and it 
has been generally inferred that this happens because of the aberrant action of HR 
(homologous recombination) on t-loops.  To experimentally test this hypothesis, we 
generated a Ku86:Rad54B (RAD54B plays an essential role in HR) doubly-null human 
cell line.  Ku86:Rad54B doubly-null cells displayed a greatly attenuated lethality and 
significantly reduced amounts of t-circle formation.  Thus, our results demonstrate that in 
human somatic cells the t-circle formation mediated by the loss-of-function of Ku86 is 
largely a RAD54B- (and by extrapolation, HR-) dependent process. 
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Introduction 
Most cells encounter almost constant challenges to their genomic stability in the form 
of DNA damage and were it not for equally robust DNA repair activities, all cells would 
rapidly succomb to the accumulated damage (396).  One of the most difficult challenges 
a cell faces is how to deal with a DNA DSB.  Importantly, the genomic instability caused 
by DNA DSBs results in insertions, deletions, and — probably most pathologically — 
translocations, which are known to predispose cells to a cancerous fate (273).  DNA 
DSBs can arise from different sources (2).  There are endogenous sources, such as V(D)J 
recombination, a site-specific recombination reaction required for the development of the 
immune system (167), stalled replication forks, and ROS (reactive oxygen species) that is 
the byproduct of oxidative phosphorylation in mitochondria.  Cells can also suffer DSBs 
due to exogenous sources.  The most clinically relevant of these is exposure to IR 
(ionizing radiation), which is often used as a therapeutic modality in the treatment of 
cancer (397).  Although the absolute number of DSBs per cell on a daily basis is likely to 
be fairly low (398), their potential to generate pathological outcomes means that each and 
every DSB needs to be properly repaired as studies in yeast have demonstrated that even 
a single unrepaired DSB can be a lethal event (338). 
Not surprisingly, all living organisms have evolved robust mechanisms to efficiently 
repair DSBs.  In mammals there are least three genetically distinct DNA DSB repair 
pathways: HR (homologous recombination), C-NHEJ (classic non-homologous end 
joining) and A-NHEJ (alternative NHEJ) (340).  HR requires significant end resection 
and it uses extensive sequence homology, which results in essentially error-free repair 
products (10).  In contrast, C-NHEJ does not necessarily require any end resection and 
very frequently results in error-prone repair with associated deletions and/or insertions 
(18).  A-NHEJ appears mechanistically to be somewhat of a hybrid between the other 
two pathways; requiring some, but not necessarily significant amounts of, resection and 
the use of small, but not extensive, blocks of homology, which result in a repaired 
product in which a deletion has always occurred (286).  In human cells, the C-NHEJ 
pathway appears to the highly preferred pathway of DNA DSB repair (2).   C-NHEJ is 
highly researched and the mechanism is well understood.  There are seven major C-NHEJ 
factors and almost all of these genes are evolutionarily conserved from bacteria to 
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humans.  Somewhat confusingly, however, loss-of-function mutations in any of these 
factors can lead to different phenotypes in different organisms.  The best example of this 
concerns mutations of either Ku subunit, Ku70 or Ku86.  In all organisms — with one 
glaring exception — in which either one of these genes has been functionally inactivated, 
the resulting cells or animals are viable, albeit with varying hypersensitivities to DNA 
damaging agents and immune deficits.  For example, Ku70- and Ku86-null mice, while 
presenting with IR-hypersensitivity and immune deficits are nonetheless viable (160, 
161).  In striking contrast, neither null, nor even heterozygous, human Ku70- or Ku86-
mutant patients has ever been reported.  Moreover, inactivation of either Ku70 or Ku86 in 
human somatic cell lines resulted in death (124).  This species-specific difference was 
very puzzling until our laboratory demonstrated that the lethality of the human Ku86 
deficiency was caused by telomere dysfunction (117). 
Telomeres, the repetitive DNA sequence found at the ends of all linear chromosomes 
seemed to have evolved with the emergence of eukaryotes, where linear chromosome 
replaced the circular chromosome of prokaryotes.  The transition from circular to linear 
chromosomes solved some old problems concerning chromosome segregation, but 
simultaneously created some new problems related to chromosome synthesis and stability 
(105).  Because the DNA replication of the lagging chromosomal strand occurs by 
Okazaki fragment synthesis, the logistics of this process requires that a chromosome end 
will be shortened each cell cycle, resulting, ultimately, in the loss of genetic information.  
The other problem associated with linear chromosome ends is end-protection.  Linear 
chromosome ends are structurally very similar to DNA DSBs and the “repair” of 
chromosome ends will cause chromosome fusion and, ultimately, other types of genetic 
instability.  Telomeres solve both of these problems.  Human telomeres consist of 4 to 14 
kb of hexameric (TTAGGG)n repeats that terminate with a 200 to 300 nt single-stranded, 
G-rich overhang (298).  The G-rich overhang is performs two quite important functions.  
First, it is the substrate for a dedicated reverse transcriptase complex, termed telomerase, 
than can extend chromosome ends when they shorten (399).  Second, it invades and 
hybridizes to the duplex part of telomere forming a classic, lariat-shaped D-loop, termed 
a t-loop.  The somewhat bizarre t-loop structure in turn acts as a binding site for a six-
protein complex, called shelterin.  The unusual structure of telomeres and the 
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proteinaceous cap formed by the shelterin complex essentially makes the chromosomal 
ends invisible to the cellular DNA DSB repair pathways and thus imparts stability to 
them.  Very paradoxically, some of the same DNA repair and damage signaling proteins 
that can fuse short or uncapped telomeres are required for normal telomere and t-loop 
maintenance (302).  This is best exemplified by Ku86, one half of the potent DNA end-
binding factor, Ku, used by C-NHEJ (112, 113, 119, 142, 371).   Short and/or uncapped 
telomeres will be fused by C-NHEJ in a Ku-dependent fashion, resulting in either cell 
death or cellular transformation.  Remarkably, however, human Ku is also required for 
the maintenance of normal telomeres.  Human cells lacking Ku86 die due to telomere 
dysfunction, including massive telomere loss, sister chromatid fusions, and the 
conversion of the t-looped structure into a circles (aka a “t-circle”) (117).  The formation 
of t-circular DNA has been reported in a variety of conditions in which telomere 
dysfunction has been induced (117, 400) and the general consensus is that t-circle 
formation results from the aberrant action of HR on the t-loop.  Since Ku deficient cells 
are known to result in an upregulation of HR (276, 369, 401-405), one hypothesis is that 
the elevated HR levels in Ku-deficient cells leads indirectly to the t-circle formation. 
To experimentally investigate this hypothesis, we devised a scheme to analyze 
telomere function in HR and Ku86 doubly-deficient cell.  To this end, we deleted the 
Rad54B (radiation sensitive 54B) gene to inactivate HR.  Rad54B is a member of the 
Rad52 epistasis group, which encodes the core factors of HR (67, 81).  Rad54B was first 
identified as a novel member of the SNF2/SWI2 ATP-dependent chromatin remodeling 
family and a homolog of Rad54, which is a DNA-dependent ATPase that functions as a 
chromatin remodeling factor during HR (81).  Rad54B has been previously inactivated in 
a human cell line and the resulting viable cell line did not have any appreciable growth 
defects or sensitivities to DNA damaging agents.  Importantly, however, HR activity 
appeared to be completely abrogated based on gene targeting experiments where the 
targeting frequency dropped from 7 to 15% to undetectable (83).  Thus, we functionally 
inactivated the Rad54B gene in the existing Ku86 conditionally-null HCT116 cell line 
(117).  Impressively, the deficiency in Rad54B suppressed the formation of t-circles and 
greatly extended the lifespan of cells converted to the Ku86-null phenotype.  Based on 
these observations, we conclude that RAD54B (and by logical extension, HR) does 
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indeed mediate the telomere dysfunction caused by Ku86 loss-of-function mutations in 
human cells. 
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Materials and Methods 
 
Rad54B targeting vector construction and screening 
The pAAV-Neo-Rad54B targeting vector was generated as described (334).  The 661 
bp of DNa needed for the left homology arm was made by PCR using the E3-LARM-
NotI-F1 and E3-LARM-SacII-R1 primers.  The 1620 bp of right homology arm DNA 
was made by PCR using the E3-RARM-KpnI-F1 and E3-RARM-NotI-R3 primers.  
Primer sets #1 and #2 were subsequently used for screening for correctly targeted clones.  
Primer set #1 consisted of Rad54B-E3-CreS-F1 and Rad54B-E3-CreS-R1.  Primer set #2 
consisted of Rad54B-E3-LARM-SC-F4 and NeoR2. 
 
E3-LARM-NotI-F1: 
5’-ACATAAGCGGCCGCTTTAAGTATTGATTTTAGTATTGAGAAATTTAAC-3’  
E3-LARM-SacII-R1: 
5’-GGCGGCCCGCGGCTAAAAGAAACAAATATATATTTAAATCAGAACTC-3’ 
E3-RARM-KpnI-F1:  
5’-CCGGTACCGACTGCTTTTTATTGATAAGGTTTATGCTTGACC-3’ 
E3-RARM-NotI-R3: 
5’-ACATAAGCGGCCGCGGTGATGGGGAAAATGACATATGTTATTTAACTGG-3’ 
Rad54B-E3-CreS-F1: 
5’-GAGTTCTGATTTAAATATATATTTGTTTCTTTTAG-3’ 
Rad54B-E3-CreS-R1: 
5’-CAAGCATAAACCTTATCAATAAAAAGC-3’ 
Rad54B-E3-LARM-SC-F4: 
5’-CCAACATAGTGAGATTACCATTATCTCACC-3’ 
NeoR2: 
5’-AAAGCGCCTCCCCTACCCGGTAGGGCG-3’ 
 
Cre recombination of the Ku86 conditionally-null cell lines 
Ku86-null HCT116 cells were generated when needed as described with a slight 
modification (117).  Ku86flox/- cells were plated in 6-well plates at 5 X 104 cells/well and 
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16 to18 hr later, 5 X 108 viral particles were added in 2 ml media.  After infection (24 hr), 
the virus-containing media was replaced with 2 ml of fresh media. 
 
Use of an inducible Cre system 
A PiggyBac transposon system (406) was used with slight modification.  Cells were 
subcultured into 6-well plates a day before transfection.  A vector expressing the 
PiggyBac-transposase (2 µg) and another vector containing the PiggyBac-CreERt2-
transposon lacking a GFP (green fluorescent protein) marker (2 µg) were transfected 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol.  After 
transfection (2 days), the cells were subclutured into a 96-well plate using 2 µg/ml 
puromycin in the media for selection.  Clones stably expressing CreER were 
subsequently identified by immunoblotting using an antibody directed against Cre (data 
not shown).  For the CreEr induction, a 1 mM 4-OHT (tamoxifen) stock solution, which 
was dissolved in ethanol, was diluted 1000 fold. 
 
Immunoblotting 
Whole cell extract was prepared using RIPA buffer (Sigma) and proteins were 
subjected to electrophoresis on a 4 to 20% gradient gel (Bio-Rad).  Ku86 (SantaCruz) and 
actin (SantaCruz) antibodies were used at 1:500 and 1:250 dilutions, respectively.  A Cre-
antibody (Abcam) was used at 1 µg/ml and a Rad54B antibody (gift of R. Kanaar) was 
used at a 1:1000 dilution.  UV-irradiated HeLa cell lysate (40 µg; SantaCruz) was used as 
a positive control. 
 
Growth rate 
On day 0, 5 X 104 cells were plated in 6 cm culture dishes.  Starting at day 1, cells 
were, where required, incubated in 5 nM of 4-OHT-containing media.  At later time 
points, cells were harvested and counted using a Countess cell counter (Invitrogen). 
 
Neutral-neutral, 2D-gel electrophoresis 
Neutral-neutral, 2D-gel electrophoresis was performed as described (117). 
 
	   119	  
T-FISH  
T-FISH (telomere-FISH) was performed with metaphase-arrested cells using a 
protein-nucleic acid telomere-specific probe {Cy3 conjugated to (T2AG3)3}, according to 
the protocol provided by the manufacturer (DAKO) and previous studies (115, 117). 
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Results 
 
Construction of a Rad54B gene targeting vector 
The HCT116 cell line has three copies of the Rad54B gene because a portion of one 
chromosome 8 — which is where the Rad54B gene resides — is duplicated (83).  This 
required three rounds of gene targeting and screening (Sup. Fig. 1).  Exon 3 was chosen 
for deletion because its removal produces an out-of-frame mutation.  The homology arms 
for this vector were asymmetric, with only 661 bp in the left homology arm whereas the 
right homology arm was considerably longer at 1620 bp (Fig. 1A).  The length of the 
homology arms, which are normally of equal length (276, 334, 363), were adjusted in this 
way to accommodate extensive repetitive sequences present upstream of exon 3.  In 
general, we try to avoid including repetitive sequences in the homology arms when at all 
possible, but at the same time we try to maximize the total length of homology arms, 
because a longer total homology in the arms increases the efficiency of rAAV gene 
targeting (407).  
For screening, we used two different sets (#1 and #2) of primers (Fig. 1A).  Primer set 
#1 anneals to a region outside of exon 3 and generates different-sized PCR products for 
the wild-type allele and the loxP-only allele, which are 237 bp and 146 bp, respectively.  
Correctly targeted clones were subsequently treated with the Cre recombinase to excise 
the NEO selection cassette, so that the same targeting vector could be used for the 
following round of gene targeting.  A loxP-only allele was generated by this Cre 
recombination reaction and was detected by the generation of a 146 bp product using 
primer set #1.  Primer set #2 uses a forward primer that anneals upstream of exon 3 and a 
reverse primer that anneals to the NEO selection cassette.  This generates a diagnostic 
768 bp PCR product only from correctly targeted clones.  PCR analyses following a third 
round of gene targeting using primer set #2 (Fig. 1B) and #1 (Fig. 1C), respectively 
confirmed the isolation of the desired RAD54B-null clones.  In these experiments, 
genomic DNA generated from Rad54B+/Neo/- cells was used as a positive control for PCR.  
Clone #63 corresponded to a retargeted clone because the 237 bp PCR product produced 
from the wild-type allele was still present (Fig. 1C).  In contrast, clones #84, #91, and 
#103 were Rad54B−⁄−⁄− clones, because they were correctly targeted (Fig. 1B) and they no 
longer had any exon 3 sequences (Fig. 1C). 
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Ku86 and Rad54B protein expression was then verified by immunoblot analysis. 
HeLa cell extract was used as a positive control (Fig. 2A).  Parental (wtHCT116) cell 
extract was also used a positive control, which was important since this genetic 
background contained a cross-reacting, non-specific band that migrated near the position 
of authentic RAD54B (Fig. 2A).  Rad54B-/-/- HCT116 cell extract was used as a negative 
control.  Consistent with the PCR analyses ((Fig. 1C) clone #63 (a re-targeted clone) still 
expressed RAD54B protein (Fig. 2A) whereas the putative Ku86flox/-:RAD54B-null 
clones #9, #91 and #103 did not express detectable Rad54B protein (Fig. 2A).  Ku86 
protein levels were also assessed in these clones along with the parental (WT) and 
Ku86flox/- HCT116 control cell lines.  All of the cell lines were infected with AdCre and 
the levels of Ku86 expression were determined by immunoblot analysis at day 5.  Ku86 
protein expression in wild-type cells did not change even after AdCre infection (Fig. 2B).  
However, all the Ku86flox/-:Rad54B clones and the Ku86flox/- clone expressed almost no 
Ku86 protein after AdCre infection, confirming that their Ku86 alleles were conditionally 
null (Fig. 2B).  From these analyses, we concluded that we had successfully generated 
viable Ku86flox/−: Rad54B−⁄−⁄− cell lines. 
 
A Rad54B deficiency in a LIGIV-null background causes synthetic lethality 
Initially we tried to functionally inactivate the Rad54B gene in LIG4-/- as well as 
Ku86flox/- cells.  The single LIGIV-/- mutant cell line is viable ((207); Chapter 2) and it is 
essentially devoid of C-NHEJ activity ((254); Chapter 2).  The single Rad54B-/-/- mutant 
cell line is also viable (see above) and completely defective in HR (83).  Because each 
single mutant was viable, we hoped that the LIGIV-/-:Rad54B-/-/- doubly mutant cell line 
would also survive and serve as “A-NHEJ-only” system.  Unfortunately, the 
simultaneous absence of LIGIV and Rad54B in HCT116 cells caused a synthetic 
lethality.  We reached this conclusion based upon gene targeting data.  Thus, the first and 
second rounds of RAD54B targeting in the LIGIV-/- cell line targeting occurred with a 
8.8% and 13.2% correct targeting efficiency, respectively (Table 1A).  An asymmetry in 
the targeting frequency was already noted, however, during the second round of targeting 
as 8 out of 12 clones were retargeted at the previously inactivated allele (Table 1A).   
This asymmetry was greatly exacerbated during the third round of targeting.  The overall 
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targeting rate dropped to only 4.7 %, and 10 out of 11 correctly targeted clones were 
shown to be retargeting events (Table 1B).  Moreover, even though one clone was 
Rad54B-/-/- based on PCR analysis, it proliferated very poorly and then stopped growing 
altogether after a month, which made it impossible to characterize further (Table 1A). 
These results stand in stark contrast to the data we obtained for inactivating RAD54B 
in the Ku86flox/- background.  In these experiments, the gene targeting frequency remained 
constant at ~5% and there was no re-targeting bias observed in the second and third 
rounds (Table 1B).  Together, these data strongly suggest that a combined LIGIV and 
Rad54B deficiency triggers a synthetic lethality and imply that the A-NHEJ pathway is 
not sufficient to sustain human cell survival.  On the other hand, cells expressing only 
50% the parental levels of Ku86 are decidedly still viable even with a RAD54B 
deficiency.  Thus, human cells can apparently survive on A-NHEJ, as long as they have 
some C-NHEJ function. 
 
Introduction of a 4-OHT-inducible Cre-recombinase system 
Visual observation of Ku86flox/-:Rad54B-/-/- cells following an AdCre infection 
suggested that many of the cells were still alive at times when all of the Ku86flox/- cells 
were dead or dying (data not shown).  This suggested that the Rad54B deficiency might 
rescue the lethality of the Ku86 loss-of-function.  Attempts to isolate viable Ku86-/-
:Rad54B-/-/- cells, however, 2 to 3 weeks after AdCre infection yielded only cells with a 
Ku86flox/-:Rad54B-/-/- genotype, resulting — presumably — from cells where Cre 
recombination did not occur.  The inability to isolate stable Ku86-/-:Rad54B-/-/- cells 
suggested that a Rad54B deficiency simply delayed the death of Ku86-/- cells.  Using 
AdCre methodologies to pursue this hypothesis, however, was fraught with several 
technical difficulties.  First, AdCre infections turn out empirically to be “tricky”, where 
the precise amount of AdCre is required to yield low toxicity and effective 
recombination.  Small errors on either side of the optimal concentration yield either very 
high toxicity or too low of a conversion rate of the flox to the null allele, respectively.  
Second, even though adenovirus can be quite an effective system at optimal doses, it is 
never 100% efficient.  Empirically, in AdCre-treated cultures, the unrecombined cells 
eventually overgrow the null cells and repopulate the culture.  To solve these technical 
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problems, we introduced a 4-hydroxyl tamoxifen (4-OHT)-inducible Cre-recombinase 
into our cells using a PiggyBac transposon delivery system.  Two vectors are required for 
this system.  The first vector is capable of transiently expressing the PiggyBac 
transposase in trans (Fig. 3A).  The other vector contains the Cre-recombinase linked to 
the estrogen receptor at its C-terminus (CreER) and a puromycin selection marker, which 
are flanked by 5’- and 3’-PiggyBac terminal repeats (Fig. 3A).  These two constructs 
were co-transfected into the relevant cell lines and puromycin-resistant clones were 
isolated and characterized for CreER expression by Western blotting (data not shown).  
Clones (e.g., #1 and #19, below) expressing CreER were designated as “CreER”. 
The induction efficiency of this system was first determined.  Ku86flox/- and Ku86flox/-
:CreER cell lines were treated with 4-OHT or the vehicle, EtOH.  Clones #1 and #19 were 
two independent clones of Ku86flox/-:CreER , both of which expressed robust levels of CreER 
protein.  The viability of Ku86flox/- cells was affected by neither EtOH nor 4-OHT (Fig. 
3B).  In contrast, the Ku86flox/-:CreER cells were completely killed when Cre expression was 
induced by 4-OHT, but not by EtOH (Fig. 3B).  These encouraging results demonstrated 
that the system is specifically responsive to 4-OHT and not leaky.  Moreover, unlike the 
adenovirus infections, which by themselves can be quite toxic, the 4-OHT treatment itself 
did not have any detectable toxicity (Fig. 3B).  Next, we checked the toxicity of the Cre 
recombinase expression.  We treated WTCreER cell and Ku86flox/-:CreER cells with increasing 
concentrations of 4-OHT.  After 7 days of 4-OHT treatment, the Ku86flox/-:CreER cells had 
all succumbed whereas no defects in the proliferation of the WTCreER cells was detected, 
indicating that overexpression of Cre recombinase in the nucleus is not inherently toxic to 
cells. 
 
The absence of Rad54B increases the survivability of Ku86-null cells 
With the CreER system in hand, we set out to determine how a Rad54B deficiency 
affects the lethality of Ku86-null cells.  Relevant clones stably expressing CreER were 
treated with 4-OHT for 12 days.  The viability of WTCreER cells was essentially unaffected 
by a 4-OHT treatment (Fig. 3D).  In contrast, 4-OHT exposure killed almost all of the 
Ku86flox/-:CreER cells (Fig. 3D).  Intriguingly, the viability of Ku86flox/-:CreER:Rad54B-/-/- 
clones, while poor, was nonetheless clearly higher than Ku86flox/-:CreER treated cells (Fig. 
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3D).  The absence of Ku86 protein in the Ku86flox/-:CreER and Ku86flox/-:CreER:Rad54B-/-/- cells 
after 4-OHT treatment was confirmed by immunoblot analyses (Fig. 3E).  These results 
demonstrate that a deficiency in Rad54B partially rescues the lethality induced by the 
absence of Ku86.  This conclusion was verified by measuring the growth rate (Fig. 4). 
Although the rescue was slight compared to wild-type cells (Fig. 4A), it was significantly 
better than the survival of the Ku86-null cells (Fig. 4B). 
 
A Rad54B deficiency suppresses the t-circle formation that occurs in Ku86-null cells 
Telomeric DNA, when aberrantly acted upon by HR, can be lost in the form of t-
circles.  To test whether the enhanced survival associated with the absence of RAD54B 
(and by extrapolation, HR; (83)) in Ku86-null cells correlated with diminished t-circle 
formation we performed neutral/neutral 2D gel electrophoresis using Ku86-/-Rad54B-/-/- 
and control cells.  As a positive control, asynchronously growing WI-38 VA13 cells were 
analyzed.  VA13 is an ALT (alternative lengthening of telomeres) cell line that is known 
to constitutively express t-circular DNA (117, 306, 408).  Indeed, a retarded arc on the 
2D gels was observed (Fig. 5A) as had been reported (117).  Moreover, genomic DNA 
purified from Ku86-/- cells 5 days after 4-OHT treatment showed a well-defined t-circular 
arc.  In contrast, the Ku86-/-Rad54B-/-/- cell line did not contain t-circles (Fig. 5C). These 
experiments demonstrated that t-circle formation in Ku86-/- cells requires RAD54B and, 
likely, the entire HR pathway.  
	   125	  
Discussion 
A Rad54B loss-of-function partially rescues the lethality of Ku86-null cells 
In this study, we generated a Ku86flox/-:Rad54B-/-/- cell line and found that the lethal 
phenotype of Ku86-null human cells can be partially rescued in the absence of 
RAD54B/HR activity.  Human Ku86-null HCT116 cells die because of severe telomere 
dysfunction, including the production of t-circular DNA (117).  In contrast, human 
Rad54B-null HCT116 cells are viable (with normal proliferation), but they contain no 
functional HR activity, based on the observation that they are incapable of performing 
gene targeting (83).  We observed that when we combined the absence of RAD54B with 
the Ku86-null genotype that this delayed the death of the Ku86-null cells (Fig. 3).  In 
addition to the extended survival, Ku86-/-:Rad54B-/-/- cells showed significantly reduced 
amounts of t-circles compared to the single mutant Ku86-/- cells (Fig. 5).  These results 
are consistent with models where 1) t-circles are formed by HR and 2) where Ku86 acts 
as a potent suppressor of HR at telomeres. 
 The original description of aberrant t-circle formation was observed in a study where 
TRF2ΔB, which lacked its N-terminal basic (“B”) domain, was over-expressed in mouse 
cells (306).  The authors of this study concluded that TRF2 could act as a suppressor of t-
circle formation, presumably by suppressing the action of HR on t-loops.  The 
mechanism of this suppression, however, was not clear.  Our laboratory subsequently 
showed that the t-circle formation could be phenocopied by the inactivation of Ku86 
(117).  We came to a similar interpretation as the previous group; but again, the 
mechanism by which Ku86 might mediate the HR suppression was not clear.  Our current 
work and additional work from other laboratories clarifies some, albeit not all, of these 
points.  First, it is now known that Ku and TRF2 proteins directly interact (112, 141).  A 
simple interpretation of this data is that TRF2 may simply act as the sequence-specific 
binding factor that is needed to physically localize Ku to telomeres.  This model is 
consistent with the fact that TRF2ΔB is known to retain all of its DNA binding activity.  
The regions of TRF2 and Ku that are needed for interaction are not yet defined, but we 
propose that Ku either interacts directly with the “B” domain or that the “B” is needed for 
TRF2’s interaction with Ku.  In other words, our model predicts that the t-circle 
formation observed in TRF2ΔB cells is due to the absence of Ku at the telomeres and not 
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directly due to the expression of TRF2ΔB.  We regard Ku as a much likelier candidate 
than TRF2 for the actual protein that suppresses HR, because this is a function that Ku is 
known to possess at non-telomeric sequences.  Thus, Ku-reduced cells have highly 
elevated levels of correct gene targeting at a bevy of different chromosomal loci (276).  If 
Ku can suppress HR at intragenic locations it seems likely that it can also do so at the end 
of chromosomes.  Needless to say, our work has yet to elucidate precisely how Ku 
mediates this suppression of HR, but we favor a model in which Ku physically interacts 
with, and inhibits, a key HR factor.  That t-circle formation requires HR activity now 
seems irrefutable; at least in some species or cell types.  Earlier researchers transiently 
knocked down the expression of XRCC3 or NBS1, factors implicated in HR (408), and 
demonstrated that t-circle formation induced by TRF2ΔB  overexpression (306) or in 
ALT cells (400) was concomitantly reduced.  Our “cleaner” loss-of-function genetic 
experiments lend great support to this earlier work and strongly implicate HR as the 
culprit in t-circle formation.  Nonetheless, it needs to be noted that there are reports of 
HR-independent t-circle formation.  Thus, there are reports in WRN (Werner’s 
Syndrome) patient cells and in some plants that t-circle formation can proceed in a 
XRCC3 or NBS1-independent fashion (409, 410).  These processes clearly need to 
investigated in more depth, but at face value one might conclude that there exist two 
pathways for t-circle formation: one HR-dependent and one HR-independent.  If this is 
the case, then our data strongly suggest that the t-circle formation induced by the loss of 
Ku86 expression utilizes the HR-dependent pathway.  Viewed in this light, it will be 
interesting to make double mutants with Ku86flox/- and either XRCC3 or NBS1.  Our 
prediction would be that removal of either of these factors would also suppress the 
lethality of Ku86-null cell lines. 
 
The mechanism of the prolonged survival of Ku86-/-:Rad54B-/-/- cells 
The loss of Ku86 function results in t-circle formation and eventual cell death (117).  
The inactivation of RAD54B in this genetic background ablates t-circle formation (Fig. 
5) and prolongs the cell’s survival (Fig. 3).  While provocative, this observation 
nonetheless begs the obvious question.  That is, doubly mutant cells do not form t-circles 
and although they have an extended lifespan, they ultimately succomb.  Thus, if the cells 
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are not dying due to t-circle formation, they must be dying due to some other defect.  
Some of our most recent preliminary data suggests that the doubly mutant cells may still 
be dying due to telomere dysfunction; just not t-circle formation.  Experiments to 
characterize the G-strand overhang indicate that the G-overhang is greatly hyperextended 
in the doubly mutant cell line (data not shown).  This observation is consistent with an 
earlier published report from our laboratory (115) demonstrating that Ku86+/- cell lines 
have elongated G-overhangs.  These data suggest that Ku may actually have two 
functions at telomeres: suppressing HR and t-circle formation and suppressing the action 
of nucleases and the resulting G-overhang hyperresection.  In cells proficient for HR, the 
loss of suppression on HR in Ku mutants predominates and that results in a deadly 
increase in t-circle formation.  In cells defective for HR (i.e., RAD54B-null cells), 
however, the loss of suppression on end resection predominates and the cells die due to 
hyperextended G-overhangs.  We are currently trying to use technologies that will allow 
us to quantitate single-stranded telomeric DNA.  In the future, these experiments could 
also be addressed genetically by looking for enhanced survival in cells defective in the 
nuclease thought to be involved in telomeric end resection such as ExoI or Dna2 (411). 
 
A deficiency in both C-NHEJ and HR is not compatible with cell survival 
The lethal phenotype of Ku86-/- cells is delayed, but not completely rescued in the 
absence of Rad54B.  Similarly, we also demonstrated that while LIGIV-null and 
RAD54B-null single mutant cell lines were viable, the double LIGIV-null:RAD54B-null 
cell line died (Table 1A).  Thus, although cells are capable of surviving without HR or C-
NHEJ, they are apparently not capable of surviving without both pathways.  Another way 
to look at this, is that A-NHEJ by itself is apparently not sufficient for cell survival.  
Given the mutagenic nature of A-NHEJ, this should perhaps not be such a great surprise.  
Nonetheless, it will be very interesting to determine if HR (e.g., a LIGIII-null:LIGIV-null 
cell line) or C-NHEJ (e.g., a LIGIII-null:RAD54B-null cell line) by themselves are 
capable of sustaining human somatic cells. 
 
The phenotype of Ku86-deficiency is species-specific 
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The functional inactivation of genes in mice often fails to phenocopy what actually 
transpires in human cells, and telomere biology is perhaps one of the best examples of 
this.  Ku86-null mice are completely defective for V(D)J recombination and show growth 
defects, but they are still alive (161, 412).  In contrast, LIGIV-null mice are early 
embryonic lethal (209, 210, 356). Surprisingly, the embryonic lethality of LIGIV-
deficient mice can be rescued by the loss of Ku86 expression (413).  Ku70 and LIGIV 
doubly-null mice also have a less severe phenotype than LIGIV-null singly mutant mice 
(160).  These studies are at least consistent with Ku playing a role in suppressing HR 
(276, 369, 401-405) and A-NHEJ (24, 159, 254).  Presumably, the loss of Ku elevates the 
expression of HR and A-NHEJ enough to compensate somewhat for the loss of C-NHEJ 
due to the absence of LIGIV.  In contrast to all of this work, however, Ku70 (276) and 
Ku86 (115, 117, 124) are essential for human somatic cell viability whereas LIG4-null 
human cells are viable. Moreover, the lethality of Ku86-deficient human cell comes from 
telomere defect, which is not rescued by a LIGIV deletion (data not shown).  Ku86-/-
:LIG4-/- cells die with a cell death phenotype that is indistinguishable from that of Ku86-/- 
cells (data not shown).  These opposing phenotypes demonstrate that care should be taken 
in extrapolating results obtained in model systems to humans. 
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Figure 1. The Rad54B targeting strategy. (A) To generate a Rad54B knockout, exon 3 
was replaced by a NEO cassette using rAAV gene targeting methods. The targeting 
vector had 661 bp of a left homology arm (LA) and 1620 bp of a right homology arm 
(RA). Two primer sets, #1 and #2, were used to identify the wild-type, targeted and loxP-
only alleles. (B) The PCR products generated by primer set #2. Genomic DNA from a 
Rad54B+/NEO/- clone was used as a positive control for PCR. Clones #63, #84, #91, #103 
are from the third round of gene targeting. (C) The PCR products generated by primer set 
#1. Clones #84, #91 and #103 produ ed only the 146 bp band, demonstrating the absence 
of any remaining exon 3 (237 bp) sequences.  
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Figure 2. The production of Ku86-/-:Rad54B-/-/- cells was confirmed by immunoblotting. 
(A) The loss of Rad54B protein. Whole cell extracts were prepared from HeLa, 
wtHCT116, Rad54B-/-/- HCT116, and Ku86flox/-:Rad54B+/-/- third round targeted clones. 
Clones #9, #91 and #103 are Rad54B-/-/-. #63 is a retargeted clone, which still has one 
conditional Rad54B allele. Actin was used as a loading control. (B) Loss of Ku86 protein 
after AdCre virus infection. Ku86flox/-:Rad54B-/-/- cells (5 × 104) were plated a day before 
they were either left uninfected (-) or infected (+) with AdCre at the MOI of 1 × 104. 
After infection (5 days), cells were harvested and whole cell extracts were prepared for 
immunoblot anaysis. Untreated wtHCT116 and Ku86flox/- cell lysates were included as 
controls.  
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FIgure 2. Western blot analysis confirms the construction of a Ku86:Rad54B doubly-null cell line
Actin
Rad54B
Non-specific
He
La
wt
HC
T1
16
#9 #63 #91 #103Ra
d5
4B
-/-
/-
Actin
Ku86
WT Ku
86
flo
x/-
: AdCre+-
WT Ku86flox/- #9 #63 #91 #103
Ku86        : Rad54B clonesflox/-
+- +- +- +- +-
A.
B.
	   133	  
Figure 3. A 4-OHT-inducible CreER system was established in WT (wild-type), 
Ku86flox/- and Ku86flox/-:Rad54B-/-/- clones. (A) Cells were co-transfected with two 
constructs. One construct transiently expresses the PiggyBac transposase. In the other 
construct, the coding sequence of the cre recombinase fused with the estrogen receptor 
(CreER) and the puromycin-resistance gene are flanked by PiggyBac terminal repeats 
(black boxes). (B) The 4-OHT-inducible system efficiently causes the excision of Ku86 
and results in cell death. Ku86flox/-:CreER cells were treated with 4-OHT or vehicle (EtOH) 
for 2 weeks. Cells treated with 4-OHT died whereas those treated with EtOH did not. (C) 
WTCreER cell and Ku86flox/-:CreER cells were treated with increased amounts of 4-OHT for 
7 days. Only the Ku86flox/- cells died. (D) Delayed death of Ku86-/-:Rad54B-/-/- cells. All 
the indicated cells express CreER and they were treated with 4-OHT or EtOH for 12 
days. Clones #103-1, #103-18 and #91-19, #91-37 are sub-clones of #103 and #91 cells, 
respectively. (E) Ku86 protein is not expressed in 4-OHT-treated Ku86flox/- cells. The 
indicated cell lines were treated with 5 nM of 4-OHT on day 0 and the Ku86 protein level 
was checked on days 0, 5 and 12. 15 µg of whole cell extracts were used for this 
immunoblot analysis. On day 5, there was no detectable Ku86 protein in any of the 
clones except WTCreER. On day 12, most of Ku86-deficient cells were dead, so 15 µg of 
whole cell extracts could not be collected.    
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Figure 3. A 4-OHT-inducible CreERt2 system for use with the Ku86:Rad54B clones
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Figure 4. A Rad54B deficiency delays the cell death caused by the loss of function of 
Ku86. Five thousands cells were plated on day 0. Starting day 1, the cells were incubated 
in 5 nM of 4-OHT-containing media. All the cell lines utilized in this analysis express 
CreER. Ku86-19 and #91-19, #91-37 are sub-clones of Ku86flox/-:CreER and Ku86flox/-
:CreER:Rad54B-/-/-#91, respectively.  
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Figure 4. A Rad54B deficiency attenuates the lethality of Ku86 loss of function
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Figure 5. A significant reduction of t-circle formation in Ku86-/-:Rad54B-/-/- cells 
compared to Ku86-/- cells. Neutral/neutral 2D-gel electrophoresis was used to detect t-
circle formation. (A) A diagram showing the different arced migrations and the 
corresponding DNA structures. (B) Uninfected ALT WI-38 VA13 cells (C) AdCre-
infected Ku86flox/- cells (D) AdCre-infected Ku86flox/-:Rad54B-/-/- #91 cells. 
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Figure 5. Neutral/neutral 2D-gel electrohporesis confirms reduced t-circle formation 
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Supplementary Figure 1. The targeting strategy and primer sets used for three rounds of 
Rad54B gene targeting. Primer sets #1 and #2, described in Figure 1A, were used for 
each round of screening. (A) The parental HCT116 cell line has three copies of the 
Rad54B gene and we targeted exon 3. (B) After the first round of targeting, correctly 
targeted clones produce a new PCR product using primer set #2. (C) Subsequent AdCre 
infection excises the NEO selection cassette from the Rad54BNEO/+/+ cell line. The 
excision of the NEO cassette was first verified by G418-sensitivity and the G418-
sensitive clones were subjected to PCR with primer set #1, and correct clones were 
confirmed by the absence of a PCR product from primer set #2 and the presence of new 
smaller product using primer set #1. Since the primer set #1 anneals outside of exon 3, 
the loxP-only allele produces a PCR product that is smaller than that produced from the 
intact exon 3. (D) The same targeting vector was used for the second round of gene 
targeting. All correctly targeted clones produced a PCR product using primer set #2. If 
the targeting vector integrated into the already inactivated allele, then the small PCR 
product using primer set #1 would disappear. Thus, clones that generated both small and 
large PCR products from primer set #1 were Rad54BNEO/+/−. (E) Rad54BNEO/+/− cells were 
infected with AdCre again and G418-sensitive clones (i.e., Rad54B+/-/-) were isolated and 
then subjected to a last round of targeting. (F) Rad54BNEO/−/− clones were confirmed by 
the presence of a PCR product using primer set #2 and the absence of the small, wild-
type allele PCR product using primer set #1. (G) A final treatment with AdCre resulted in 
the desired genotype, Rad54B-/-/-. 	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Supplementary Figure 1. Targeting procedure for triploid Rad54B gene
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CHAPTER V 
 
 
Conclusions and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   143	  
Conclusions 
We successfully inactivated the LIGIV gene in the human somatic cell line, HCT116.  
Prior to my work, it had been suggested that Ku86 has roles in both C-NHEJ and 
telomere maintenance, whereas LIGIV functions exclusively in C-NHEJ.  Because Ku86-
null cells died (117, 124) and LIGIV-null cells were viable (207), it had been proposed 
that telomere maintenance was the essential function whereas C-NHEJ activity was 
dispensable.  While this argument is superficially compelling, the fact that different cell 
lines had been used to generate the relevant data was scientifically off-putting.  Thus, all 
of the Ku86-null work had been carried out in the HCT116 colorectal carcinoma cell line 
while the LIGIV-null work had been carried out in the EBV-immortalized B-cell line, 
NALM-6.  These differences were compounded by the fact that the NALM-6 cell line 
was preferentially known to use HR (357) and by the glaring world-wide absence of 
LIGIV-null patients.  To address these issues, we decided to make a LIGIV knockout 
mutation in the same genetic background as the Ku86 mutations had been made; namely, 
the HCT116 cell line.  So, we utilized rAAV-mediated gene targeting methodologies to 
functionally inactivate the LIGIV gene in HCT116 cells to verify or discredit our 
hypothesis.  Disequilibrium during the second round of gene targeting and extreme 
sensitivity of LIGIV-null cells to DNA damaging agents vividly demonstrated the 
disadvantage of being LIGIV deficient.  Nonetheless, we successfully generated a viable 
LIGIV-null cell line.  Although our data do not address why LIGIV-null patients have not 
been identified, they do show unequivocally that human somatic cells do not require 
LIGIV. 
In a related project, we demonstrated that the functional inactivation of LIGIII results 
in cell death.  While theoretically provocative, the practical limitations of performing 
biochemical assays with dead cells were daunting.  To obviate this biological obstacle, 
we next successfully generated a viable nuclear LIGIII-null HCT116 cell line using 
mitochondrial-specific complementation.  Although a demonstration that LIGIII is 
needed for mitochondrial maintenance was important, we were inherently more interested 
in LIGIII’s nuclear roles.  Unfortunately, the absence of LIGIII from the nucleus was 
phenotypically unnoticeable (with one exception to be described below).  Perhaps most 
disappointing was the absence of an effect on rAAV-mediated gene targeting, where 
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work from several groups (327, 378), including ours (276), had strongly implicated 
LIGIII.  Although much of the data generated using the conditionally-null LIGIII cell line 
was negative, the construction of the cell line was important in and of its own right since 
it is the first human cell line ever described with the loss-of-function of a key candidate 
A-NHEJ pathway gene. 
Finally, we constructed a Ku86flox/-:Rad54B-/-/- cell line.  Ku86-null cells were known 
to die due to telomere defects including massive telomere loss, sister chromatid fusions 
and t-circle formation (117).  Work from our laboratory and other laboratories had 
circumstantially implicated aberrant HR activity as being responsible for the t-circle 
formation.  To scientifically address this issue, we attempted to functionally inactivate the 
HR pathway in the conditionally-null Ku86 cell line.  To this end, we inactivated the 
Rad54B gene, because Rad54B-/-/- cells were known to be HR defective based upon their 
inability to undergo further gene targeting (83).  In a rare instance of experimental results 
corresponding to theoretical predictions, we observed that Ku86-/-:Rad54B-/-/- cells show 
significantly reduced t-circle formation compared to Ku86-/- cells.  In addition, Ku86-/-
:Rad54B-/-/- cells survived longer.  Both of these observations suggested that a Rad54B 
deficiency can partially rescue the pathologies associated with Ku86-null cells.  More 
specifically, our data are the first good genetic data implicating HR in the genesis of t-
circles. 
 
Future Directions 
rAAV-mediated gene targeting is a magic bullet for investigators working with 
human somatic cell lines. 
In the course of my thesis work, I utilized rAAV-mediated gene targeting technology 
to functionally inactivate three genes (LIGIV, LIGIII and RAD54B) that are required for 
each of the three major DNA DSB repair pathways (C-NHEJ, A-NHEJ and HR, 
respectively).  The utility of having cell lines specifically defective in a particular DNA 
DSB repair pathway is evident from 1) the data presented in this thesis, 2) the fact that 
these cell lines have already found there way into published works (117, 276, 363), and 
from their application in commercial endeavors (unpublished observations).  Moreover, 
we have also already demonstrated our ability to establish second-generation cell lines, 
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which contain genetic alterations at two different loci (e.g., Ku86flox/-:Rad54B-/-/- cells).  
The rAAV methodology has been designed to be “scarless”, i.e., such that no drug 
selection markers are left in the chromosome after the targeting event.  Because of this 
feature, the methodology can, in principle, be limitlessly applied to a single cell line — 
making as many genomic alterations as the investigator wishes.  This ability, once the 
sole purview of bacterial or yeast geneticists, has greatly enhanced the attractiveness and 
utility of human somatic cells as a valid model system.  In addition, it should be noted 
that we have confined ourselves to mostly making gross alterations (“knockouts”) of the 
human genome.  The existing rAAV methodology is, however, much more refined and 
established vectors and protocols already exist for the use of rAAV to make: 1) 
conditional alleles, 2) knock-in mutations and inserting epitope tags at the 3) N- and 4) C-
termini of chromosomal genes (117, 330).  This powerful methodology makes the 
investigator the limiting factor for answering most biological questions.  There is no 
reason (and indeed many of these experiments are already ongoing in our laboratory) that 
the cell lines that I have generated during my thesis work, can not be further modified to 
address a myriad of questions in DNA repair, DNA replication, DNA recombination and 
telomere maintenance. 
 
Introducing an inducible-CreER systems an improvement to study conditionally-
null cell lines 
Our laboratory has already generated two conditionally-null cell lines (Ku86flox/- and 
LIG3flox/-) to study essential genes {(117); and chapter 3} and is in the process of making 
many more.  All of these constructions utilize the technology of Cre:LoxP site-specific 
recombination (414).  At some step — and often at many steps — the expression of the 
Cre recombinase is required to mediate the appropriate recombination event.  In the past, 
our laboratory has used plasmids, adenoviruses, lentiviruses and hit-and-run/suicidal gene 
expression constructs to express Cre.  Unfortunately, all of these methods have associated 
problems including high toxicity, or too low or too high of an efficiency.  These problems 
have varied in their severity from mildly irritating to so severe that the desired 
experiment could not be accomplished.  Here, for the first time, I made use of the 4-OHT 
inducible Cre recombinase system following its introduction by PiggyBac-mediated 
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transposition.  This system shows almost no toxicity and it is easy to control (Chapter 5), 
making it a major improvement to the existing technologies.  We predict that introducing 
the inducible CreER system into the LIGIIIflox/- and future conditionally-null cell lines 
will solve a lot of attendant technical problems and will become a generally valuable tool 
to the field to study essential genes. 
 
Future uses of the conditionally-null LIGIII cell line: 1) generation of an A-NHEJ 
chromosomal translocation reporter system 
Perhaps the single biggest surprise (and disappointment) of my thesis work was the 
lack of phenotypes associated with the loss-of-function of nuclear LIGIII (Chapter 4).  
Significant amounts of circumstantial evidence had suggested that LIGIII was required 
for rAAV-mediated integrations and for micro-homology mediated end-joining.  Alas, no 
defects in either of those processes were observed.  Nonetheless, we remain convinced 
that the construction of the LIGIII conditionally-null cell line will prove itself useful.  
First, based on the sequencing of chromosomal translocations in human cancer cell lines, 
it had been inferred that LIGIII/A-NHEJ might be involved in their genesis, since the 
junctions often contained microhomology.  That hypothesis gained significant support 
from analyses of chromosomal translocations in conditionally-null LIGIII MEFs (272).  
We think we can extend these observations (which have a direct impact on the initiation 
of tumorigenesis) in our cell line.  Thus, we propose to introduce I-SceI restriction sites at 
two specific chromosomal locations using rAAV-mediated gene targeting technology.  I-
SceI is a restriction enzyme whose recognition sequence is not normally found in the 
human genome (415).  Once this cell line is established, I-SceI can be transiently 
expressed and chromosomal translocations can be detected by FISH using whole 
chromosome painting techniques (380, 416, 417).  A more complicated variation of this 
experiment would be to imbed two halves of a selectable marker (e.g., GFP, LacZ, NEO, 
etc.) adjacent to the I-SceI sites (416, 417).  In this scenario, the selectable marker is 
reconstituted only when I-SceI–induced chromosomal translocations occur (272, 380).  
Other methodologies could also be used.  For example, a pair of zinc-finger nucleases 
could be used to induce DSBs at two specific loci.  If chromosomal translocations 
happened, they could be identified and isolated using PCR approaches where one of the 
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primers hybridizes adjacent to one of the zinc-finger nuclease binding sites and another 
primer hybridizes next to the other site.  Similar approaches have been described using 
mouse cell lines (272).  Using one of these approaches we think we could use our cell 
line to study the impact of the presence and absence of LIGIII expression on 
chromosomal translocations in human cells. 
 
Future uses of the conditionally-null LIGIII cell line: 2) is LIGIII required to bypass 
the crisis induced by gradual telomere loss? 
Although it was not the focus of my thesis work, one of the tangential issues I was 
interested in was to study the mechanism of telomere fusions in Ku86-deficient cells.  We 
have described extensively our work looking at t-circle formation associated with the loss 
of Ku86 expression (Chapter 5).  One of the other features of the Ku86 loss-of-function 
mutation is that it induces sister telomere fusions (117).  This feature was in fact the 
motivation for generating the Ku86flox/-:LIGIV-/- cell line.  These cells, however, showed 
no impairment in sister chromatid fusions in comparison to the Ku86flox/- cell line (data 
not shown) demonstrating a lack of involvement of LIGIV in this process.  This 
observation, in turn, was one of the most relevant rationales for generating the LIGIIIflox/- 
cell line (Chapter 4).  Indeed, the construction of a Ku86flox/-:LIGIIIflox/- cell line, with 
which we intend to study sister:sister chromatid fusion is almost completed (data not 
shown).  In the interim, however, we decided to see if we could extend the utility of our 
mutant cell lines.  Thus, the loss of telomeres mediated by Ku86 loss-of-function, while 
intellectually interesting, is nonetheless not very relevant to normal cells.  In normal cells, 
the relevant telomere loss is the slow, gradual reduction of the telomere due to cellular 
proliferation, which, if left unchecked can lead to the progression of malignancy (418).  
Therefore we initiated collaboration with the laboratory of Duncan Baird to analyze the 
impact of our loss-of-function mutant cell lines on gradual telomere loss.  To this end, Dr. 
Baird’s laboratory established stable derivatives of our wild-type HCT116, LIGIV-/- and 
LIGIII-/- cells using a DN-hTERT construct that reduces telomerase activity.  Dr. Baird’s 
laboratory had shown that the expression of the DN-hTERT construct in other human cell 
lines over the course of several months resulted in a gradual telomere shortening that 
ultimately led to telomere fusions and a “crisis”-like state (419).  In our cell lines, 
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telomere shortening occurred and telomere fusions could be detected as the cells entered 
a crisis-like state (data not shown).  These results implied that neither LIGIV nor LIGIII 
functions in the pathway of telomere fusions resulting from gradual telomere shortening.  
Subsequently, however, we made a startling preliminary observation.  After entering 
crisis, eleven of eleven independent wild-type subclones and four of four independent 
LIGIV-/- subclones recovered and multiple survivor clones grew out.  In striking contrast, 
none of eleven independent LIG3-/- sub-clones yielded a single survivor.  These 
preliminary data were supported by knockdown experiments in other human cell lines 
where it was observed that a reduction in LIGIV had no effect on telomere fusions or 
survival whereas LIGIII knockdown cells yielded chromosome fusions, but not survivors 
(data not shown).  These studies, albeit preliminary and having been performed only 
once, indicate the presence of a LIGIII-dependent event that is required for human cells 
to survive the crisis induced by gradual telomere shortening. 
To further characterize this phenomenon, we will sequence the telomeric fusion 
junctions produced from each cell line in the hope that the molecular signatures at the 
repaired junctions will give us some insight into whether certain junctions accumulate or 
are absent in the LIGIII-null cells.  Additional genetic experiments are also planned.  A 
complementation experiment where a nuclear LIGIII expression construct has been 
introduced into the LIGIII conditionally-null cell line is already underway.  Additional 
preliminary data from Dr. Baird’s laboratory has implicated p53 in this phenomenon.  
Thus, we plan to knockout the p53 gene in the LIGIII-/-:mL3 cell line to determine whether 
the failure of LIGIII-/- cells to survive crisis is mediated by p53.  Since virtually all 
human cancer cells are postulated to arise only after surviving crisis, we feel that these 
experiments have the possibility to have important clinical ramifications. 
 
Future uses of the conditionally-null LIGIII cell line: 3) structure:function analyses 
of LIGIII 
An additional mundane, albeit important, use for the conditionally-null LIGIII cell 
line would be to use it as a tool in classic structure:function (aka, “wreck and check”) 
experiments.  Thus, LIGIII contains several readily-identifiable domains: a zinc-finger 
domain, a BRCT domain, etc. but the functional significance of these domains remains 
	   149	  
poorly understood since there has been no experimental system available to dissect their 
function.  Our conditionally-null LIGIII cell line fills that scientific void.  Thus, 
(assuming we ultimately have a phenotype or biological endpoint that we can 
quantitatively measure) wild-type nuclear LIGIII expression constructs containing 
mutations in these domains can be expressed in the cells and their impact assessed.  
While not hypothesis-driven per se, this practical approach to assessing a gene’s 
function(s) has historically proven to be very useful.  In the same vein, we can use the 
LIGIV- and RAD54B-null cell lines for an identical purpose. 
 
Interactions between the HR, C-NHEJ and A-NHEJ pathways 
1) Pathway choice mechanism 
The initial end resection process of A-NHEJ is similar to that of HR.  Unlike HR, 
however, there is no evidence that A-NHEJ requires EXO1 and DNA2, the nucleases 
required for the several kilobases of end resection that occur in HR (54, 90).  This 
suggests that the degree of resection may differentiate between whether a DSB is repaired 
via HR or A-NHEJ.  A-NHEJ is most active in G2 phase and its activity is compromised 
when cells enter the plateau phase of growth, which was demonstrated in mouse MEF 
and hamster CHO cell lines (285-287).  Thus, the cell cycle dependent regulation of 
nucleases might be one way in which pathway choice is determined (45, 288, 290).  To 
understand if pathway choice is mediated by end resection, it will be necessary to 
generate cell lines deficient in the nucleases involved in early steps of DSB repair, 
including Mre11, CtIP, Exo1 and Dna2 (22, 34, 37, 54, 87-90).  An analysis of the 
relative activities of HR and A-NHEJ in these cell lines should ensure a better 
understanding of repair pathway choice mechanisms. 
We could enhance these studies with the use of modified repair substrates to 
determine how the degree of end resection influences repair pathway choice.  In a C-
NHEJ-deficient condition, repair substrates with microhomology positioned at different 
intervals from a predetermined DSB could be used to test how much resection is required 
for A-NHEJ.  
 
2) Inactivation of other A-NHEJ components 
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The LIGIII-/- HCT116 cell line we have described herein (Chapter 3) is the only 
available A-NHEJ-deficient human cell line.  Inactivation of other A-NHEJ components 
will be necessary to understand the A-NHEJ pathway in human cells.  Our laboratory has 
already produced a complete series — encompassing seven different genes — of C-
NHEJ-deficient cell lines using rAAV-mediated gene targeting as a proof of principle 
that this is a viable way to approach this problem.  Thus, one of the future goals of the 
laboratory is to make knockout cell lines corresponding to the other genes that have been 
implicated in A-NHEJ: MRN, PARP-1, XRCC1, CtIP and histone H1 (27, 44, 248, 250, 
252, 420).  Indeed, we have already made a PARP-1-/- cell line (M. Mueller and E. A. 
Hendrickson, unpublished) and other constructions are ongoing. 
 
3) What is the minimum DSB repair activity required for cell survival?  
We have already observed that combined C-NHEJ:A-NHEJ or HR:C-NHEJ 
deficiencies, respectively, cause cell death.  In particular, it is interesting that the 
deficiency of C-NHEJ and A-NHEJ results in synthetic lethality, because it suggests that 
A-NHEJ and C-NHEJ are not completely redundant, but that A-NHEJ probably has its 
own (albeit unknown), distinct functions.  This non-redundancy was hinted at previously, 
when it was shown that LIGI and LIGIII, but not LIGIV, were required for MMEJ (421).  
Inactivation of other A-NHEJ components should help us assess the unique function of 
A-NHEJ.  Finally, it will be also interesting to characterize the viability of HR and A-
NHEJ deficient cell lines, because it should help us determine whether HR and A-NHEJ 
are redundant for certain tasks, as well as addressing what the minimum DNA DSB 
repair activity is that is required for cell survival. 
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